Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
36100.0 | 2017-08-24 00:00:00 UTC | Kite Pharma at New 52-Week High: What's Driving the Stock? | ACAD | https://www.nasdaq.com/articles/kite-pharma-at-new-52-week-high%3A-whats-driving-the-stock-2017-08-24 | nan | nan | Kite Pharma, Inc.'sKITE shares hit a new 52-week high of $143.00 on Thursday before eventually closing at $138.17.
Shares of the company have risen sharply so far this year as its CAR-T therapy axicabtagene ciloleucel (previously KTE-C19) is nearing an FDA approval. In fact, Kite Pharma's year-to-date share price movement shows that the stock has substantially outperformed the industry , having skyrocketed 209.7% during the period, while the industry has gained 6.9%.
Kite Pharma has been riding on the back of an impressive progress made by axicabtagene ciloleucel. The candidate is currently under priority review in the United States for treating aggressive non-Hodgkin lymphoma (NHL) with an FDA decision expected on Nov 29. The Biologics License Application (BLA) filing was based on data from a phase I-II study, ZUMA-1.
We believe that the solid efficacy profile demonstrated by the pivotal ZUMA-1 trial should support the candidate's approval this year. At the second-quarter conference call, the company announced that the FDA has informed that an Advisory Committee meeting will not be required to review the company's BLA for axicabtagene ciloleucel. The candidate is expected to be approved of and launched in the United States this year.
In July, a regulatory application was also filed in the EU for the given indication with sanction and unveiling also expected next year.
Immuno-oncology is one of the most actively pursued areas of research today. There are several other companies working to bring about innovative immuno-oncology treatments to the market.
Juno Therapeutics Inc. JUNO and Novartis AG NVS are also developing JCAR017 and CTL019, respectively, utilizing the CAR-T cell technology. Though the efficacy profile of all the three candidates is comparable, axicabtagene ciloleucel is likely set to hit the market first.
Other studies revolving around axicabtagene ciloleucel are also advancing fast.
Apart from axicabtagene ciloleucel, Kite Pharma is developing additional CAR-based candidates including KITE-585 and KITE-718.
Phase I study on the first of the four TCR/CAR-T candidates - KITE-718 in solid tumors, including non-small cell lung cancer, bladder cancer plus head and neck cancer - was initiated in the second quarter. KITE-718, a TCR cell therapy candidate, targets cancer antigens MAGE A3 and MAGE A6 in a solid tumor.
Kite Pharma has also recently filed an investigational new drug (IND) application for CAR-T candidate, KITE-585, targeting BCMA antigen for multiple myeloma. Phase I studies are expected to be initiated in the second half of the year.
Kite Pharma, Inc. Price
Kite Pharma, Inc. Price | Kite Pharma, Inc. Quote
Zacks Rank & Stocks to Consider
Kite Pharma currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36101.0 | 2017-08-18 00:00:00 UTC | Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer | ACAD | https://www.nasdaq.com/articles/jazz-pharmaceuticals-arm-announces-%24500m-senior-notes-offer-2017-08-18 | nan | nan | Jazz Pharmaceuticals Public Limited CompanyJAZZ announced that its wholly owned subsidiary, Jazz Investments I Limited, intends to offer exchangeable Senior Notes, due 2024, for an aggregate principal amount of $500 million in a private offering to qualified institutional buyers.
Notably, the notes will be exchangeable for cash, ordinary shares or a combination of both to certain circumstances.
Jazz's shares have significantly outperformed the industry so far this year. The stock has surged 33.9% compared with the industry's 3% decrease during the same period.
The net proceeds from the offering are expected to be used by Jazz to fully or partially repay a portion of its outstanding $500 million debt under its revolving credit facility. Also, the company plans to use the remaining net proceeds, if any, for general corporate purposes, including potential business development activities.
The company already completed a private placement of another $575.0 million principal amount of exchangeable notes due 2021 in August 2014, bearing an annual interest of 1.87%.
Significantly, Jazz has been very active on the acquisition front. Deals include the company's buyout of biopharma company, Gentium, which added Defitelio (treatment of severe hepatic VOD) to its portfolio. With the Celator merger in May last year, Jazz has added Vyxeos to its pipeline.
The company completed the rolling NDA submission for Vyxeos to the FDA in March for treatment of acute myeloid leukemia (AML). Later in May, the FDA accepted Vyxeos NDA under priority review. Hence, Jazz expects this Celator takeover to be earnings accretive from 2018.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC Price | Jazz Pharmaceuticals PLC Quote
Zacks Rank & Stocks to Consider
Jazz currently carries a Zacks Rank #2 (Buy). Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Summit's loss estimates narrowed from $2.59 to 32 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 25.55%. Its share price soared 48.4% so far this year.
Aduro Biotech's loss per share estimates narrowed from $1.46 to $1.32 for 2017 and from $1.54 to $1.24 for 2018 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. The company came up with a positive earnings surprise in two of the trailing four quarters with an average beat of 3.52%.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really take off.
See Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
Summit Therapeutics PLC (SMMT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report To read this article on Zacks.com click here. Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. | Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36102.0 | 2017-08-17 00:00:00 UTC | FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa | ACAD | https://www.nasdaq.com/articles/fda-accepts-portolas-ptla-bla-resubmission-for-andexxa-2017-08-17 | nan | nan | Portola Pharmaceuticals, Inc.PTLA recently announced that the FDA has accepted its resubmitted biologics license application (BLA) for the reversal agent for Factor Xa inhibitors, AndexXa (Andexanet Alfa). A decision from the U.S. regulatory body is expected on Feb 2, 2018.
AndexXa has been developed for patients treated with a direct or indirect Factor Xa inhibitor, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Notably, AndexXa is also under review in the EU with marketing application filed in the third quarter of 2016.
Portola's shares have significantly outperformed the industry so far this year. The stock has soared 143.8% compared with the broader industry's decrease of 1.9%.
The resubmission includes additional information requested by the FDA in a complete response letter (CRL) issued to Portola in August last year. In the letter, the FDA had requested for information related to product manufacturing. It had also asked for more data to support the inclusion of direct Factor Xa inhibitor Lixiana (edoxaban) and indirect Factor Xa inhibitor Lovenox (enoxaparin) on the product label.
We remind investors that the BLA was based on positive data from two phase III ANNEXA studies that evaluated the safety and efficacy of AndexXa in reversing the anticoagulant activity of the Factor Xa inhibitors, Xarelto (rivaroxaban) of Johnson and Johnson, Inc. JNJ and Eliquis (apixaban) of Bristol-Myers Squibb Company BMY , in older healthy volunteers. Significantly, AndexXa enjoys an Orphan Drug Status in the United States.
Per the company's press release, more than 90,000 U.S. patients treated with oral Factor Xa inhibitors in 2016 were admitted to hospital due to excessive bleeding. It has also been estimated that more than 150,000 patients taking the injectable Factor Xa inhibitor Lovenox in the United States could benefit from an antidote each year.
With no currently approved antidote for Factor Xa inhibitors yet, there is a high unmet need for the same in the market.
Going ahead, we expect investors' focus to remain on further details of AndexXa's regulatory aspect.
Portola Pharmaceuticals, Inc. Price
Portola Pharmaceuticals, Inc. Price | Portola Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Portola currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. The company came up with a positive earnings surprise in two of the trailing four quarters with an average beat of 3.52%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. | A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36103.0 | 2017-08-15 00:00:00 UTC | What You See, and What You Get: The Neurology of Perception | ACAD | https://www.nasdaq.com/articles/what-you-see-and-what-you-get-neurology-perception-2017-08-15 | nan | nan | (
(1: 00 ) - Neuroscience: The 4 Theaters Of The Brain
(5: 00 ) - Investors Train Their Brains to Trade: Assumption and Perception
(10: 00 ) - Neurology Is The New Oncology: The Boom In Brain Sciences
(14: 00 ) - Biotech Companies With Breakthrough Research
(21: 00 ) - Appreciating Differences: The Story Of A Misdiagnosis
(34: 00 ) - Episode Roundup: Podcast@Zacks.com
Welcome back to Mind Over Money. I'm Kevin Cook, your field-guide and story-teller for the fascinating arena of behavioral economics. Today's episode is all about your brain, from three different angles.
First, I want to share with you a lesson I used to teach beginning and intermediate traders about their perception and their assumptions.
Second, I'm going to talk about some of the exciting biotechnology companies doing breakthrough research in neurological and neurodegenerative diseases like Parkinson's, multiple sclerosis, and Alzheimer's.
And last, I am going to tell you a story about a young woman who led a torturous first third of her life with a neurological condition that went undiagnosed, and where no drugs would have helped anyway.
That story comes from a terrific book I'm reading by Dr. John Ratey, a clinical professor of psychiatry at Harvard Medical School...
A User's Guide to the Brain: Perception, Attention, and the Four Theaters of the Brain
Ratey's Four Theaters is a description that really appeals to me based on my reading of other neuroscience books over ten years ago. Back then I concluded that behavior and identity are a complex dance created by several sometimes-competing forces-- what I call your "multi-mind."
And this ties into something I realized in the early 2000's when I was training traders. First, the reason short-term trading is so hard is because our brains evolved for very different challenges than those of watching our money fluctuate up and down wildly on a screen full of red and green arrows.
So I say "your brain wasn't made to trade" because we are barely equipped to manage probability and risk in long-term planning, let alone minute by minute. We naturally do the wrong things like keep losing positions and take profits too quickly, the two-ingredient recipe for trading failure.
This is why over 95% of those who try short-term trading in stocks, currencies, or commodities -- especially with leverage -- will fail and lose most, if not all, of their money. Even though the odds are better than Vegas, we stack them against ourselves with unconscious cognitive biases and bad habits of emotional decision making.
To hear a powerful analogy I use to teach traders about their biases and their "multi-mind," be sure to listen to my full podcast attached to this article.
Meet Tony Coles of Yumanity
Doing some preliminary research for this podcast, I found a great article by Matthew Herper writing for Forbes in February of 2015. Matt says "I cover science and medicine, and believe this is biology's century." I couldn't agree more.
That's why I love running a new portfolio here at Zacks called Healthcare Innovators where I get to focus on the megatrends of science and medicine.
Matt's story "The Coming Boom In Brain Medicines" starts out with a great introduction to a scientist you should know...
TONY COLES COULD have had any job he wanted in the drug industry. In five years at the helm of cancer drug developer Onyx Pharmaceuticals he increased its market cap eightfold by purchasing an experimental blood cancer drug for $800 million, developing it into a big seller and flipping the whole company to Amgen for $10.4 billion in October 2013. He personally made $60 million on the deal. Biotech watchers expected him to start another cancer company or even command a drug giant like Merck or Pfizer.
Instead, Coles, 54, is using his own money to build a Cambridge, Mass.-based startup called Yumanity that is using yeast, the microbes that help make bread and beer, to study how misfolded proteins in the brain cause Alzheimer's, Lou Gehrig's disease and Parkinson's, and to create drugs based on that knowledge. There's already interest from Big Pharma. Coles says he chose to attack brain diseases, not tumors, because the need is so dire and the science is so fresh.
"We've got 50 million people around the world who have these diseases, costing $650 billion a year, and lots of families like mine that have been affected," says Coles. "I had a grandmother who died of the complications of Alzheimer's disease. I think about my own health as well."
(end of excerpt from Matthew Herper's Forbes article)
The New Next-Frontier in Biotechnology
In my Healthcare Innovators portfolio, I am very focused on the frontiers of cancer research. Especially exciting is the field of "immuno-oncology" where researchers are learning to harness a patient's own immune system to fight his or her cancer. The research and the treatments are costly, but the rewards could be enormous -- and life-saving.
A second disease-fighting frontier I follow is that of "gene editing" where the science is allowing a person's genome to be altered and possibly cure inherited ailments.
But the new frontier I have very limited experience with as a healthcare investor is the neurological and neurodegenerative diseases. One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD).
And I currently own Sarepta Therapeutics (SRPT) for the successful launch of their drug for the treatment of Duchenne muscular dystrophy.
Alfred Sandrock, the Chief Medical Officer of Biogen (BIIB) has said that "neurology is the new oncology." And I find it thrilling that this $60 billion company with 12-month trailing sales of $11.7 billion, is so engaged in the new next-frontier in biotech.
In the podcast, I describe other companies involved on this frontier like Alkermes (ALKS) and Neurocrine Biosciences (NBIX).
I also own Sangamo Therapeutics (SGMO) primarily for their "zinc finger" gene-editing technology. But it doesn't hurt that they have early-stage programs in Huntington's disease and Alzheimer's in their R&D pipeline too.
Appreciating Differences, Appreciating Health
I close the podcast with a 10-minute story that Ratey shares of a woman named Rickie, who was actually the subject of the 1990 book of the same name by Frederic Flach, a psychiatric researcher at Cornell University.
It's an incredible story ofpersonal tragedy and eventual triumph that you must hear.
My goal is not just to help you learn about the brain and perception but also to encourage you to recognize others who may seem very "different" than you and why that might be.
And also to appreciate your own health, to the degree you have it. That's one I often take for granted myself.
Disclosure: I own shares of SRPT and SGMO for the Zacks Healthcare Innovators portfolio.
Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators portfolio.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes PLC (ALKS): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. First, the reason short-term trading is so hard is because our brains evolved for very different challenges than those of watching our money fluctuate up and down wildly on a screen full of red and green arrows. | Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). ( (1: 00 ) - Neuroscience: The 4 Theaters Of The Brain (5: 00 ) - Investors Train Their Brains to Trade: Assumption and Perception (10: 00 ) - Neurology Is The New Oncology: The Boom In Brain Sciences (14: 00 ) - Biotech Companies With Breakthrough Research (21: 00 ) - Appreciating Differences: The Story Of A Misdiagnosis (34: 00 ) - Episode Roundup: Podcast@Zacks.com Welcome back to Mind Over Money. | Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). ( (1: 00 ) - Neuroscience: The 4 Theaters Of The Brain (5: 00 ) - Investors Train Their Brains to Trade: Assumption and Perception (10: 00 ) - Neurology Is The New Oncology: The Boom In Brain Sciences (14: 00 ) - Biotech Companies With Breakthrough Research (21: 00 ) - Appreciating Differences: The Story Of A Misdiagnosis (34: 00 ) - Episode Roundup: Podcast@Zacks.com Welcome back to Mind Over Money. | One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ( (1: 00 ) - Neuroscience: The 4 Theaters Of The Brain (5: 00 ) - Investors Train Their Brains to Trade: Assumption and Perception (10: 00 ) - Neurology Is The New Oncology: The Boom In Brain Sciences (14: 00 ) - Biotech Companies With Breakthrough Research (21: 00 ) - Appreciating Differences: The Story Of A Misdiagnosis (34: 00 ) - Episode Roundup: Podcast@Zacks.com Welcome back to Mind Over Money. |
36104.0 | 2017-08-14 00:00:00 UTC | Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern | ACAD | https://www.nasdaq.com/articles/gerons-gern-imetelstat-progressing-well-setbacks-concern-2017-08-14 | nan | nan | We issued an updated research report on Menlo Park, CA-based Geron CorporationGERN on Aug 11.
Geron is developing anti-cancer therapies based on telomerase inhibitors. The company currently has one candidate in its pipeline, imetelstat. It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis (MF) and myelodysplastic syndromes (MDS). Geron has a collaboration with Johnson & Johnson's (JNJ) subsidiary Janssen for imetelstat.
Geron has no approved product in its portfolio and its top line solely comprises license fees and royalties.
Imetelstat is being evaluated for myelofibrosis (MF) in a phase II IMbark study and for myelodysplastic syndromes (MDS) in a phase II/III IMerge study.
Geron announced in Apr 2017 that Janssen has completed the second internal data review of the two studies. Janssen said that the benefit/risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication. Owing to the favorable update, both trials are continuing unmodified.
If Janssen decides to proceed to Part 2 of IMerge (a larger, 170 patient, phase III study), patient enrollment is expected to begin in the fourth quarter of this year. Moreover, Geron announced in July that Part 1 of IMerge will be expanded to enroll additional patients in a refined MDS population to confirm the clinical benefit and safety observed from the current result.
Meanwhile, the results from IMbark study suggested that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications. Janssen is expected to evaluate maturing data from the IMbark study next year, including an assessment of overall survival.
Geron's shares have underperformed the industry so far this year. Shares of Geron rose 0.5% during the period compared with the industry's gain of 6.2%.
However, we are concerned about Geron's dependence on a single pipeline candidate. Geron has faced setbacks as imetelstat was placed under clinical hold in 2014. It also faced unfavorable findings in internal reviews of initial data from IMbark and IMerge studies. Any further setback may have significant negative impact on the company's stock.
Geron Corporation Price and Consensus
Geron Corporation Price and Consensus | Geron Corporation Quote
Zacks Rank & Stocks to Consider
Geron carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. The company came up with a positive earnings surprise in two of the four trailing quarters with an average beat of 3.25%. The stock is up 8.2% so far this year.
Aduro Biotech's loss per share estimates narrowed from $1.46 to $1.36 for 2017 and $1.54 to $1.26 for 2018 over the last 30 days. The company delivered a positive surprise in two of the four trailing quarters with an average beat of 2.53%.
Enzo Biochem's loss estimates narrowed from 12 cents to 7 cents for 2017 and 11 cents to 3 cents for 2018 over the last 60 days. The company came up with a positive earnings surprise in the four trailing quarters with an average beat of 55.83%. The stock is up 59.3% so far this year.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Geron Corporation (GERN): Free Stock Analysis Report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. Click to get this free report Geron Corporation (GERN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . Click to get this free report Geron Corporation (GERN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. | Click to get this free report Geron Corporation (GERN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. Click to get this free report Geron Corporation (GERN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36105.0 | 2017-08-14 00:00:00 UTC | Analysts Forecast 10% Gains Ahead For VXF | ACAD | https://www.nasdaq.com/articles/analysts-forecast-10-gains-ahead-vxf-2017-08-14 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (Symbol: VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $110.66 per unit.
With VXF trading at a recent price near $100.69 per unit, that means that analysts see 9.90% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although HALO has traded at a recent price of $11.90/share, the average analyst target is 47.06% higher at $17.50/share. Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. | Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). | Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. |
36106.0 | 2017-08-09 00:00:00 UTC | Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today | ACAD | https://www.nasdaq.com/articles/heres-why-acadia-pharmaceuticals-inc-soaring-today-2017-08-09 | nan | nan | What happened
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday.
So what
Here's a review of the key financial numbers from the second quarter:
Revenue from sales of the company's Parkinson's disease psychosis (PDP) drug Nuplazid totaled $30.5 million -- far ahead of the $19.6 million that Wall Street had expected. However, it should be noted that the figure included a one-time benefit of $3.6 million because the company transitioned its revenue recognition method of accounting to the sell-in method.
Net loss was $67.4 million, or $0.55 per share -- far lower than $0.71 loss that market watchers had anticipated.
Acadia's cash balance at quarter end was $417 million.
Management guided for full-year sales of Nuplazid to land between $105 million and $115 million. The midpoint of this range is far ahead of the $94 million in revenue that Wall Street had projected.
Acadia also shared a few non-financial highlights from the quarter with investors:
The company held an end-of-phase-2 meeting with the FDA related to its Alzheimer's disease psychosis program. Management says that the meeting went well, and that a phase 3 study will kick off in the next few months.
25 new sales reps were deployed to expand the company's focus on the long-term care market. The company now has more than 150 total sales reps deployed in the field.
Given the better-than-expected Q2 results, upbeat guidance, and positive meeting with the FDA, it is easy to understand why shares are rising today.
Now what
Acadia's Q2 results continue to support the idea that Nuplazid is off to a fast start. That's great news for investors, and illustrates the benefits of entering a market where there is no competition in sight .
Looking ahead, Acadia will be presenting data from its phase 2 Alzheimer's disease psychosis (ADP) trial at a medical conference in November. Since ADP represents a larger market opportunity for Nupalzid than PDP, it remains a must-watch program for shareholders.
Beyond that, Acadia's report shows it's having success at moving its clinical pipeline forward. Long-term shareholders have plenty of reasons to remain optimistic about this company's future.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia also shared a few non-financial highlights from the quarter with investors: The company held an end-of-phase-2 meeting with the FDA related to its Alzheimer's disease psychosis program. Looking ahead, Acadia will be presenting data from its phase 2 Alzheimer's disease psychosis (ADP) trial at a medical conference in November. What happened In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday. | What happened In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday. Looking ahead, Acadia will be presenting data from its phase 2 Alzheimer's disease psychosis (ADP) trial at a medical conference in November. Acadia's cash balance at quarter end was $417 million. | What happened In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday. Acadia also shared a few non-financial highlights from the quarter with investors: The company held an end-of-phase-2 meeting with the FDA related to its Alzheimer's disease psychosis program. Acadia's cash balance at quarter end was $417 million. | Acadia also shared a few non-financial highlights from the quarter with investors: The company held an end-of-phase-2 meeting with the FDA related to its Alzheimer's disease psychosis program. What happened In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday. Acadia's cash balance at quarter end was $417 million. |
36107.0 | 2017-08-07 00:00:00 UTC | Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More | ACAD | https://www.nasdaq.com/articles/drug-stocks-q2-earnings-roster-for-aug-8%3A-acad-jazz-more-2017-08-07 | nan | nan | The second-quarter 2017 earnings season is nearing its last leg and the picture so far appears to be quite encouraging. After a few turbulent quarters, earnings for the second quarter of 2017 showed solid strength. As of Aug 4, approximately 420 S&P 500 companies or 86.1% of the index's total market capitalization have reported results. A deep look into the results show that earnings for the companies reported are up 11.6% year over year on 5.6% higher revenues. Of these, 74.3% have topped earnings estimates while 68.3% have beat on revenue estimates resulting in a blended beat of 55.0%.
Growth in the second quarter came on the back of strong contribution from the Finance, Technology and Energy sectors. The growth is expected to persist in the second half of 2017 as well. Even though the pace of growth has been sluggish, total Q2 earnings for the index are currently up 10% from the same period last year on 5.1% higher revenues, much better than the 7.9% earnings growth projected at the start of the quarter. Going forward, the estimate for Q3 growth is 4.3%, down from 6.3% projected at the start of July.
How Did the Medical Sector Perform?
The Medical sector has more or less combated the overall decline in the financial markets and maintained momentum. So far 83.6% of the companies in the sector have reported results. Earnings are up 7.1% on 4% higher revenues resulting in a blended beat of 65.2%. Among these, industry bellwether Johnson & Johnson JNJ reported mixed second-quarter results, beating on earnings but missing on sales estimates. Biotech giants Gilead Sciences GILD and Biogen Inc. surpassed expectations both for earnings and sales in the second quarter of 2017 and raised their annual guidance.
Let's take a look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. The company has a dismal track record. ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP . Although the current rank increases the predictive power of ESP, its 0.00% ESP makes it unlikely for the stock to beat estimates this quarter. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
The FDA's approval of Nuplazid in Apr 2016 was a major boost for the company. The drug is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and the drug has shown promising growth since its launch in May 2016. (Read more: Will ACADIA Pull Off a Surprise this Earnings Season? )
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Jazz Pharmaceuticals Public Limited Company JAZZ is scheduled to report results after the closing bell. Jazz has an encouraging earnings track record. The company has topped estimates in three of the last four quarters with an average positive earnings surprise of 14.48%. Currently, the company has a Zacks Rank #3 and a 0.00% Earnings ESP.
Investor focus will be on the performance of Jazz's lead product, Xyrem, for cataplexy and excessive daytime sleepiness. Investors will also be looking out for the company's pipeline progress. Defitelio's sales ramped up in the U.S., while Xyrem face issues related to patent litigations. The company's business development plans are also expected to draw attention. (Read more: Can Jazz Pharma Spring a Surprise in Q2 Earnings? )
Jazz Pharmaceuticals PLC Price and EPS Surprise
Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote
Kite Pharma, Inc. KITE is expected to report results before the market opens. The company has a mixed record of earnings surprises. It has reported positive earnings surprises in two and negative surprise in the other two of the last fourquarters, bringing the average surprise to a positive 2.07%.Currently, the company has a Zacks Rank #3 and a ESP of -0.51%.
With no approved products in its portfolio, investor focus will primarily be on Kite Pharma's cash burn and pipeline updates. Kite Pharma's lead drug axicabtagene ciloleucel is currently under priority review in the U.S. for treating aggressive non-Hodgkin lymphoma with a FDA decision expected on Nov 29. (Read more: What's in the Cards for Kite Pharma in Q2 Earnings )
Kite Pharma, Inc. Price and EPS Surprise
Kite Pharma, Inc. Price and EPS Surprise | Kite Pharma, Inc. Quote
Mallinckrodt plc MNK is set to report second-quarter 2017 results. Mallinckrodt has delivered an average positive earnings surprise of 5.27% in the trailing four quarters. Mallinckrodt currently carries has a Zacks Rank #3 and an ESP of +0.58%. The combination of Mallinckrodt's Zacks Rank #3 and positive ESP makes us reasonably optimistic of an earnings beat.
Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. Acthar, Ofirmev and Inomax should drive the upside in our view. However, Mallinckrodt's Specialty Generics segment continues to be a laggard. The weakness is expected to persist as stiff competition continues to hurt both volumes and prices. (Read more: Can Mallinckrodt Deliver a Beat this Earnings Season? )
Mallinckrodt PLC Price and EPS Surprise
Mallinckrodt PLC Price and EPS Surprise | Mallinckrodt PLC Quote
Endo International plc ENDP is expected to report second-quarter 2017 before the opening bell. The company has delivered a positive surprise in each of the trailing four quarters, recording an average positive surprise of 14.4%.Endo currently carries a Zacks Rank #4 (Sell) and an ESP of +1.35. We caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement.
2017 will continue to be challenging year for Endo as the generics base business and the legacy branded pain franchise are expected to decline further. Further, In Jul 2017, Endo had to withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following the FDA's request in June. The move comes in wake of the widespread opioid abuse epidemic. (Read more: What's in the Cards for Endo this Earnings Season? )
Endo International PLC Price and EPS Surprise
Endo International PLC Price and EPS Surprise | Endo International PLC Quote
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Endo International PLC (ENDP): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
Mallinckrodt PLC (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP . (Read more: Will ACADIA Pull Off a Surprise this Earnings Season? ) | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endo International PLC (ENDP): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP . | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endo International PLC (ENDP): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP . | ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP . ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. (Read more: Will ACADIA Pull Off a Surprise this Earnings Season? ) |
36108.0 | 2017-07-18 00:00:00 UTC | These 2 Companies Have No Competition | ACAD | https://www.nasdaq.com/articles/these-2-companies-have-no-competition-2017-07-18 | nan | nan | Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from competitors and generate strong returns for shareholders
But if investing a company with a strong moat is a great idea, wouldn't it be even better to buy one that has no direct competition at all? Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) .
The fourth modality of cancer treatment
For decades, healthcare providers have relied on three primary tools to fight cancer: surgery, radiation, and chemotherapy. Novocure is a small-cap medical device maker that believes it has created a brand new modality of treatment it calls Tumor Treating Fields, or TTFields for short. The idea is to surround a cancerous tumor with electric fields that disrupt cell division . The tumor's ability to grow is restricted, which leads to better treatment outcomes.
This might sound like science fiction -- I was highly skeptical of TTFields when I first learned about them -- but Novocure has actually been successfully selling this therapy on the market for a few years now. The company won FDA approval for its device called Optune back in 2011 as a treatment for glioblastoma multiforme (GBM), which is a deadly form of brain cancer. Using Optune simply requires a patient to place a series of transducer arrays on their skin near the tumor. Then, the device is turned on and Optune begins to emit the TTFields that slowly go to work on limiting cell division in the tumor.
While Novocure has faced plenty of obstacles in convincing the healthcare community to give this therapy a try, the company recently announced some data from a long-term clinical trial that should go a long way toward silencing the critics. Novocure's data showed that using Optune in combination with chemotherapy lead to better rates of overall survival at year two, three, four and five. Overall, patients who used Optune and chemotherapy together showed an overall survival rate of 21 months , which was a meaningful benefit when compared to the 15 month average in the control group.
While this clinical data is great news, investors should be particularly excited about the fact that this data showed that Optune can be used in combination with chemotherapy. This means that Optune is not competing directly against other types of cancer treatments, but instead works with them to make them more effective.
What's more, Novocure doesn't believe that Optune's usefulness will be limited to treating brain cancer. The company is currently funding several studies testing Optune as a treatment for lung cancer, ovarian cancer, pancreatic cancer, and mesothelioma. And Novocure Executive Chairman Bill Doyle recently told me in an exclusive interview with the Motley Fool that the data they are seeing in other cancers is even better than what they see in glioblastoma multiforme (GBM) :
Better yet, since no other company has commercialized a competing TTField product, this is a market that Novocure has all to itself. Given all of the above, I recently decided to take a small position in this exciting business.
An indication all to itself
Roughly 1 million patients in the U.S. currently suffer from Parkinson's disease, a progressive condition of the central nervous system that causes tremors, muscular rigidity, and imprecise movement. Unfortunately, nearly 40% of these patients will go on to develop Parkinson's disease psychosis (PDP) as well. Patients with this condition experience hallucinations and delusions in daily life, which makes caring for them that much harder. For that reason, many patients who develop PDP wind up being sent to nursing homes for care.
Up until recently, there weren't any real treatment options for PDP. Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid. Clinical data showed that patients who used the drug had fewer and less severe PDP symptoms.
Given the huge unmet medical need, sales of Nuplazid were strong right out of the gate. Acadia sold more than $17 million worth of product in the back half of 2016, which is impressive given that the drug was only launched mid-year and had limited reimbursement access. With reimbursement and awareness on the rise, market watchers expect sales of Nuplazid to exceed $91 million in 2017, and to continue growing rapidly thereafter. Since Nuplazid has this market all to itself, I think these growth assumptions are quite reasonable.
While Acadia's market opportunity in PDP is looking bright, the company also believes that Nuplazid could be used in a number of other disease states as well. It's funding several late-stage clinical trials of Nuplazid for diseases such as schizophrenia, Alzheimer's disease psychosis, Alzheimer's disease agitation, and depression. While Acadia will face plenty of competition in many of these disease states, the company could enjoy the same virtual monopoly it has in PDP in Alzheimer's disease psychosis, since there are currently no FDA-approved treatments for it on the market.
Given Nuplazid's huge market potential and lack of competition in PDP, perhaps it isn't surprising to learn that the company's market cap currently exceeds $3.3 billion. That could be considered a pricey valuation when compared to Nuplazid's PDP peak sales estimates of about $1 billion. However, I think it could very well be worth its hefty price tag.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Brian Feroldi owns shares of NovoCure. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid. Acadia sold more than $17 million worth of product in the back half of 2016, which is impressive given that the drug was only launched mid-year and had limited reimbursement access. | Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid. Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia sold more than $17 million worth of product in the back half of 2016, which is impressive given that the drug was only launched mid-year and had limited reimbursement access. | While Acadia will face plenty of competition in many of these disease states, the company could enjoy the same virtual monopoly it has in PDP in Alzheimer's disease psychosis, since there are currently no FDA-approved treatments for it on the market. Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid. | Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid. Acadia sold more than $17 million worth of product in the back half of 2016, which is impressive given that the drug was only launched mid-year and had limited reimbursement access. |
36109.0 | 2017-07-12 00:00:00 UTC | The Math Shows BBH Can Go To $140 | ACAD | https://www.nasdaq.com/articles/math-shows-bbh-can-go-140-2017-07-12 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $139.67 per unit.
With BBH trading at a recent price near $125.76 per unit, that means that analysts see 11.06% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. Similarly, BMRN has 28.90% upside from the recent share price of $90.92 if the average analyst target price of $117.20/share is reached, and analysts on average are expecting BIIB to reach a target price of $322.31/share, which is 18.60% above the recent price of $271.76. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB:
Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. |
36110.0 | 2017-06-26 00:00:00 UTC | Minerva On Track to Initiate Phase III Schizophrenia Study | ACAD | https://www.nasdaq.com/articles/minerva-on-track-to-initiate-phase-iii-schizophrenia-study-2017-06-26 | nan | nan | Minerva Neurosciences, Inc.NERV announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
The company said that it has completed a bridging study to select a new and safer formulation of MIN-101, while using the same dose strengths used in phase IIb study for use in the scheduled phase III study. The company may also file an NDA with the same.
Additionally, the selected formulation showed no food effect while maintaining the overall safety and tolerability profile of the candidate as observed in the successfully completed phase IIb study.
The company expects to aggregate data from both the studies - phase IIb and phase III - to evaluate efficacy of MIN-101 as the used and new formulation has the same exposure. Moreover, the improved new formulation has the potential to enhance the safety profile of the candidate in phase III study.
The phase III trial design will be a 12-week, placebo-controlled, monotherapy study testing two doses of MIN-101 in patients with negative symptoms and a diagnosis of schizophrenia. The patients will be required to have stable negative and positive symptoms over several months prior to enrollment, with a specified minimum threshold baseline score on the Positive and Negative Syndrome Scale (PANSS) negative sub-scale in order to be eligible for the study.
The phase III study is similar to the phase IIb study, which met its primary endpoint. The phase IIb study showed improvement in schizophrenic patients with negative symptoms treated with MIN-101 compared to placebo. The phase IIb study was completed in 2016.
Based on positive data from the phase III study, along with the positive data from the phase IIb study, Minerva plans to file a new drug application with the FDA.
Moreover, the company plans to conduct additional trials to expand the profile of MIN-101. These may potentially include a study comparing the rate of psychosis relapses in patients treated with MIN-101, standard of care with antipsychotics or placebo.
However, the schizophrenia market is competitive as evident from declining sales of AstraZeneca plc's AZN Seroquel XR. Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Alkermes PLC (ALKS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Minerva Neurosciences, Inc.NERV announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia. The phase IIb study showed improvement in schizophrenic patients with negative symptoms treated with MIN-101 compared to placebo. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia. The company said that it has completed a bridging study to select a new and safer formulation of MIN-101, while using the same dose strengths used in phase IIb study for use in the scheduled phase III study. | Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the improved new formulation has the potential to enhance the safety profile of the candidate in phase III study. |
36111.0 | 2017-06-23 00:00:00 UTC | 3 Biotech Stocks for Enterprising Investors | ACAD | https://www.nasdaq.com/articles/3-biotech-stocks-enterprising-investors-2017-06-23 | nan | nan | Biotech stocks are a natural area of exploration for aggressive investors with high expectations for their stocks. After all, this high-growth industry is chock-full of novel growth platforms, some of which can be challenging to understand at times.
With this theme in mind, we asked three of our contributors which biotech stocks might be particularly appealing for enterprising investors. They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Read on to find out why.
Invest in the next wave of immuno-oncology
George Budwell ( Kite Pharma ): A year ago, no one knew who would end up leading the race for chimeric antigen receptor T-cell (CAR-T) therapy, or even if any of these promising therapies would prove safe enough to warrant a regulatory filing. Now this rapidly emerging field sports multiple therapies under review with the U.S. Food and Drug Administration, with Kite Pharma's Axi-Cel leading the way.
In May, the FDA granted priority review status to Axi-Cel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and issued a Prescription Drug User Fee Act target action date of Nov. 29 for the experimental T-cell therapy at the same time, according to Kite.
Kite has a good chance of becoming the go-to CAR-T therapy for NHL in the years to come, thanks to its all-important first-mover advantage over its likely competitors. Thus, Kite might be able to build a megablockbuster NHL franchise off this single therapy, which is a juicy proposition for a company sporting a market cap under $5.3 billion.
Why is Kite's stock arguably undervalued relative to its long-term commercial prospects? Since it's dealing with a largely unproven technology -- and one that may even have trouble keeping up with demand because of the unique manufacturing process required to make CAR-Ts -- Kite is a high-risk biotech stock. Yet it's the exact type of high-risk, high-reward opportunity that may be of interest to enterprising investors.
A picture-perfect biotech stock worth buying
Sean Williams ( Celgene ): Enterprising investors looking for smart plays in the biotech industry are probably going to have a hard time overlooking Celgene.
Profitability among biotech stocks is already a rarity, but it's what Celgene's lead drug brings to the table that's really worth marveling about. Revlimid, the leading therapy in question, which treats multiple myeloma, has been growing at a steady double-digit pace since the Food and Drug Administration approved it in 2005. This growth rate hasn't slowed much, because of longer duration of use, label expansion opportunities, strong pricing power, and better diagnostic equipment that's leading to quicker diagnoses and thus a higher number of patients with multiple myeloma diagnoses than ever. Sales of the drug are expected to hit a range of $8 billion to $8.3 billion in 2017.
But it's not just this confluence of factors that makes Celgene and Revlimid special -- it's the deal Celgene worked out with generic-drug makers back in December 2015. That's when Celgene agreed to allow Natco Pharma the ability to produce a small quantity of generic Revlimid beginning in March 2022, with a full complement of generics hitting pharmacy shelves by Jan. 31, 2026. In other words, Celgene bought itself another decade of substantial, high-margin cash flow. Mind you, there's a genuine possibility that Revlimid could become the top-selling drug worldwide by the early 2020s.
Beyond Revlimid, Celgene has several means by which to grow its top and bottom line. In July 2015, it gobbled up Receptos for $7.2 billion, bringing experimental drug ozanimod under its wing. Ozanimod has sailed through multiple sclerosis trials and could be expanded to treat ulcerative colitis, too. If approved for both indications, ozanimod has $4 billion-plus annual peak sales potential.
Celgene also has dozens of ongoing collaborations and licensing agreements. Though these collaborations could mean Celgene shells out some serious dollars to cover its milestone obligations, it also allows the company the opportunity to license a number of first-in-class oncology and anti-inflammatory meds, if successful.
You'd struggle to find a biotech stock the size of Celgene that has double-digit sales and EPS growth potential for the next five years or beyond. It's a stock that smart investors are really going to like.
No competition in sight
Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start . Nuplazid is the only FDA-approved treatment for Parkinson's disease psychosis (PDP), which causes patients to experience hallucinations or delusions. Roughly 40% of patients with Parkinson's disease suffer from PDP, which represents about 400,000 patients in the U.S. alone.
Given the lack of alternative treatment options, demand for Nuplazid has been high right out of the gate. Nuplazid's sales reached $17 million in 2016, which is impressive since the drug was approved for sale midyear and also had limited reimbursement access. This figure is expected to soar to $91 million in 2017 and should continue growing thereafter as awareness continues to build.
While Nuplazid's potential in PDP is exciting, the company is also in late-stage trials studying the drug as a treatment for other diseases of the central nervous system. That list includes schizophrenia, depression, and Alzheimer's disease, all of which could prove to be huge opportunities for the business down the road. While handicapping the odds of success in these other disease states is difficult, I'd say that Acadia stands a decent shot since regulators have already approved Nuplazid to treat PDP.
Acadia promises investors fast revenue growth in the near term and the potential for additional upside if its other clinical programs work out. That's a nice one-two punch that should appeal to any biotech investor.
10 stocks we like better than Celgene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Brian Feroldi owns shares of Celgene. George Budwell has no position in any stocks mentioned. Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . No competition in sight Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start . | They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . No competition in sight Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start . | They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . No competition in sight Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start . | They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . No competition in sight Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start . |
36112.0 | 2017-06-19 00:00:00 UTC | 3 Value Stocks You Haven't Thought Of | ACAD | https://www.nasdaq.com/articles/3-value-stocks-you-havent-thought-2017-06-19 | nan | nan | You can always find some value stocks in every industry regardless of how high the markets are. That's because the markets aren't always rational, which means some fundamentally strong companies with growth catalysts intact might find themselves at the receiving end for no justifiable reasons, offering value investors a great chance to add deeply discounted stocks to their portfolios.
Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. Here's why.
Baidu had a lousy quarter -- but it's got a great stock price
Rich Smith(Baidu): At a price tag of more than $187 a share, and a valuation 45 times trailing earnings, China's Baidu might not be the first name that springs to mind when you hear "value stock" -- but that's precisely what makes it a value stock you probably haven't thought of.
Still often referred to as "the Chinese Google ," Baidu bears a lot of resemblance to the U.S. internet star (even if Google itself has changed its name ). Like Google, Baidu is the dominant search engine in its home country. Like Google, Baidu makes much of its money selling ads tied to internet search. And like Google, Baidu has tried its hand at a whole series of related tech ventures, from artificial intelligence to e-commerce.
Unlike Google, Baidu has stumbled in recent months, with sales roughly flat year over year in first-quarter 2017 and quarterly profits down about 19%. That's compared to Alphabet's 22% revenue gain and 28% increase in the first-quarter earnings. Baidu's free cash flow declined roughly 10% year over year in the first quarter, which puts free cash flow for the past 12 months at $2.55 billion. That's a bit less than the $2.6 billion that Baidu generated last year -- but it's still nearly $900 million more cash profit than the $1.66 billion in "earnings" the company reported under GAAP.
So why does this make Baidu a value stock? At a market capitalization of $65.1 billion, but with $5 billion in net cash on its books, Baidu sports an enterprise value of only $60.1 billion and an enterprise value-to-free cash flow ratio of just 23.5. Compared to the stock's estimated long-term profits growth rate of 26%, this gives Baidu stock an EV/FCF/growth ratio of only 0.9, which is firmly in "value" territory.
The moral of this story: Don't be fooled by the seemingly high P/E ratio or the bad headlines surrounding Baidu today. At these prices, and with these prospects, Baidu really is a value stock -- even if you haven't thought of it that way lately.
Sometimes fundamentals are misleading
George Budwell (Acadia Pharmaceuticals): With its shares trading at 15.4 times the company's projected 2018 revenue, Acadia may not look like a particularly attractive value play.But there are some good reasons to think otherwise.
First off, the company's first commercial product -- Nuplazid for Parkinson's disease psychosis -- is off to a blazing start. In the first quarter of this year, for instance, Acadia reported that Nuplazid sales jumped by a healthy 28% to $15.3 million compared to the fourth quarter of 2016. Most importantly, the company said that 90% of commercial lives are now covered, and its sales force has been expanding by leaps and bounds in an effort to keep the momentum headed in the right direction.
At this rate, Nuplazid's sales are on track to more than quadruple this year, and are expected to more than double again next year. The point is that Acadia appears to have a potential megablockbuster on its hands -- even though it may take some time to get there.
The real reason Acadia's present valuation might be terribly misleading, though, is Nuplazid's ongoing studies that could lead to extremely lucrative label expansions into indications such as Alzheimer's disease agitation and schizophrenia. These upcoming clinical catalysts are a big reason why Wall Street has an implied upside potential of 61% for Acadia's shares over the next 12 months -- despite its already rich valuation based on the stock's underlying fundamentals.
That being said, Acadia's cash burn is likely to skyrocket as its clinical plans for Nuplazid unfold, and that may mean a secondary offering sometime down the road. Additionally, there's no guarantee that Nuplazid will become a bona fide franchise-level drug as many expect. This drug, after all, has a long way to go before being considered a commercial success. But if things do continue to go Acadia's way, this stock is undoubtedly an outright bargain at current levels and an overlooked value play.
More growth bandwidth than you might know
Neha Chamaria(Dycom Industries): The earnings season is the perfect hunting ground for traders, which is why you'll often find stocks surging or diving on earnings releases regardless of what the numbers are. That's exactly what happened with telecommunications infrastructure provider Dycom, which has lost nearly 17% value as of this writing since releasing its third-quarter numbers on May 24.
Consider that Dycom's third-quarter contract revenues -- it is a contracting service company -- improved 18% year over year with its organic revenue growing 14.9%, pushing its net income up by roughly 17% to $38.8 million. For the nine months ended April 29, Dycom reported 21% higher contract revenues and nearly 43% jump in net income.
Clearly, there's a disconnect between Dycom's numbers and the stock's reaction post-earnings, which is exactly where prudent investors like you can find value. Dycom is on solid footing, counting leading telecommunications companies like AT&T , Comcast , and CenturyLink among its key clients.
With telecom giants pulling out all stops to scale up their fiber-optics network, Dycom has tremendous growth opportunities ahead. The company is already growing at a strong pace, having earned double-digit returns each on equity and invested capital during the twelve months. At roughly 17 times trailing P/E and 10 times price to cash flows, Dycom is currently trading way below the industry and its five-year averages, offering thrifty investors with the perfect opportunity to scoop up some shares even as the market overlooks Dycom's potential.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. George Budwell has no position in any stocks mentioned. Neha Chamaria has no position in any stocks mentioned. Rich Smith owns shares of Alphabet (C shares) and Baidu. The Motley Fool owns shares of and recommends Alphabet (C shares) and Baidu. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The real reason Acadia's present valuation might be terribly misleading, though, is Nuplazid's ongoing studies that could lead to extremely lucrative label expansions into indications such as Alzheimer's disease agitation and schizophrenia. These upcoming clinical catalysts are a big reason why Wall Street has an implied upside potential of 61% for Acadia's shares over the next 12 months -- despite its already rich valuation based on the stock's underlying fundamentals. Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. | Sometimes fundamentals are misleading George Budwell (Acadia Pharmaceuticals): With its shares trading at 15.4 times the company's projected 2018 revenue, Acadia may not look like a particularly attractive value play.But there are some good reasons to think otherwise. Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. In the first quarter of this year, for instance, Acadia reported that Nuplazid sales jumped by a healthy 28% to $15.3 million compared to the fourth quarter of 2016. | Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. Sometimes fundamentals are misleading George Budwell (Acadia Pharmaceuticals): With its shares trading at 15.4 times the company's projected 2018 revenue, Acadia may not look like a particularly attractive value play.But there are some good reasons to think otherwise. In the first quarter of this year, for instance, Acadia reported that Nuplazid sales jumped by a healthy 28% to $15.3 million compared to the fourth quarter of 2016. | Sometimes fundamentals are misleading George Budwell (Acadia Pharmaceuticals): With its shares trading at 15.4 times the company's projected 2018 revenue, Acadia may not look like a particularly attractive value play.But there are some good reasons to think otherwise. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. |
36113.0 | 2017-06-16 00:00:00 UTC | Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ... | ACAD | https://www.nasdaq.com/articles/baker-bros-advisors-lp-buys-incyte-corp-avexis-inc-la-jolla-pharmaceutical-co-sells-abbvie | nan | nan | Baker Bros. Advisors Lp
New Purchases: ANAB , JNCE , TNXP , BPMX, WINT,
Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO,
Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO,
Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX,
For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP
These are the top 5 holdings of BAKER BROS. ADVISORS LP
Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. Shares added by 45.15%
Seattle Genetics Inc ( SGEN ) - 45,715,556 shares, 23.93% of the total portfolio. Shares added by 0.01%
ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio.
Alexion Pharmaceuticals Inc ( ALXN ) - 6,544,130 shares, 6.61% of the total portfolio. Shares added by 0.01%
Genomic Health Inc ( GHDX ) - 13,770,982 shares, 3.61% of the total portfolio.
New Purchase: AnaptysBio Inc (ANAB)
Baker Bros. Advisors Lp initiated holdings in AnaptysBio Inc. The purchase prices were between $16.62 and $28.78, with an estimated average price of $23.3. The stock is now traded at around $23.72. The impact to the portfolio due to this purchase was 0.03%. The holdings were 150,000 shares as of 2017-03-31.
New Purchase: Jounce Therapeutics Inc (JNCE)
Baker Bros. Advisors Lp initiated holdings in Jounce Therapeutics Inc. The purchase prices were between $16.58 and $25.58, with an estimated average price of $21.19. The stock is now traded at around $15.50. The impact to the portfolio due to this purchase was 0.02%. The holdings were 100,000 shares as of 2017-03-31.
New Purchase: Tonix Pharmaceuticals Holding Corp (TNXP)
Baker Bros. Advisors Lp initiated holdings in Tonix Pharmaceuticals Holding Corp. The purchase prices were between $3.49 and $6.32, with an estimated average price of $5.13. The stock is now traded at around $4.13. The impact to the portfolio due to this purchase was 0.02%. The holdings were 449,500 shares as of 2017-03-31.
New Purchase: Windtree Therapeutics Inc (WINT)
Baker Bros. Advisors Lp initiated holdings in Windtree Therapeutics Inc. The purchase prices were between $1.13 and $1.69, with an estimated average price of $1.3. The stock is now traded at around $0.87. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 254,973 shares as of 2017-03-31.
New Purchase: BioPharmX Corp (BPMX)
Baker Bros. Advisors Lp initiated holdings in BioPharmX Corp. The purchase prices were between $0.38 and $0.55, with an estimated average price of $0.46. The stock is now traded at around $0.47. The impact to the portfolio due to this purchase was less than 0.01%. The holdings were 377,295 shares as of 2017-03-31.
Added: Incyte Corp ( INCY )
Baker Bros. Advisors Lp added to the holdings in Incyte Corp by 45.15%. The purchase prices were between $102.32 and $152.66, with an estimated average price of $127.32. The stock is now traded at around $118.05. The impact to the portfolio due to this purchase was 11.81%. The holdings were 34,110,011 shares as of 2017-03-31.
Added: AveXis Inc (AVXS)
Baker Bros. Advisors Lp added to the holdings in AveXis Inc by 58.58%. The purchase prices were between $47.26 and $84, with an estimated average price of $61.9. The stock is now traded at around $70.88. The impact to the portfolio due to this purchase was 0.12%. The holdings were 500,000 shares as of 2017-03-31.
Added: La Jolla Pharmaceutical Co (LJPC)
Baker Bros. Advisors Lp added to the holdings in La Jolla Pharmaceutical Co by 2658.14%. The purchase prices were between $16.97 and $38.44, with an estimated average price of $25.53. The stock is now traded at around $26.56. The impact to the portfolio due to this purchase was 0.09%. The holdings were 379,134 shares as of 2017-03-31.
Added: Ascendis Pharma A/S (ASND)
Baker Bros. Advisors Lp added to the holdings in Ascendis Pharma A/S by 32.07%. The purchase prices were between $19.91 and $29.92, with an estimated average price of $25.27. The stock is now traded at around $24.00. The impact to the portfolio due to this purchase was 0.08%. The holdings were 1,351,463 shares as of 2017-03-31.
Added: CymaBay Therapeutics Inc (CBAY)
Baker Bros. Advisors Lp added to the holdings in CymaBay Therapeutics Inc by 357.05%. The purchase prices were between $1.6 and $4.3, with an estimated average price of $2.87. The stock is now traded at around $4.98. The impact to the portfolio due to this purchase was 0.04%. The holdings were 1,413,499 shares as of 2017-03-31.
Added: Dermira Inc (DERM)
Baker Bros. Advisors Lp added to the holdings in Dermira Inc by 27.27%. The purchase prices were between $27.98 and $38.03, with an estimated average price of $32.26. The stock is now traded at around $28.75. The impact to the portfolio due to this purchase was 0.03%. The holdings were 415,448 shares as of 2017-03-31.
Sold Out: AbbVie Inc (ABBV)
Baker Bros. Advisors Lp sold out the holdings in AbbVie Inc. The sale prices were between $60 and $66.55, with an estimated average price of $62.87.
Sold Out: Derma Sciences Inc (DSCI)
Baker Bros. Advisors Lp sold out the holdings in Derma Sciences Inc. The sale prices were between $5 and $7.03, with an estimated average price of $6.68.
Sold Out: Alcobra Ltd (ADHD)
Baker Bros. Advisors Lp sold out the holdings in Alcobra Ltd. The sale prices were between $0.94 and $2.52, with an estimated average price of $1.32.
Sold Out: Minerva Neurosciences Inc (NERV)
Baker Bros. Advisors Lp sold out the holdings in Minerva Neurosciences Inc. The sale prices were between $7.6 and $12.35, with an estimated average price of $9.71.
Sold Out: Ionis Pharmaceuticals Inc (IONS)
Baker Bros. Advisors Lp sold out the holdings in Ionis Pharmaceuticals Inc. The sale prices were between $37.93 and $54.7, with an estimated average price of $44.91.
Sold Out: Enanta Pharmaceuticals Inc (ENTA)
Baker Bros. Advisors Lp sold out the holdings in Enanta Pharmaceuticals Inc. The sale prices were between $27.72 and $36.05, with an estimated average price of $31.14.
Warning! GuruFocus has detected 3 Warning Signs with INCY. Click here to check it out.
INCY 15-Year Financial Data
The intrinsic value of INCY
Peter Lynch Chart of INCY
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares added by 0.01% ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio. Baker Bros. Advisors Lp New Purchases: ANAB , JNCE , TNXP , BPMX, WINT, Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO, Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO, Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX, For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP These are the top 5 holdings of BAKER BROS. ADVISORS LP Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. Alexion Pharmaceuticals Inc ( ALXN ) - 6,544,130 shares, 6.61% of the total portfolio. | Shares added by 0.01% ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio. Baker Bros. Advisors Lp New Purchases: ANAB , JNCE , TNXP , BPMX, WINT, Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO, Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO, Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX, For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP These are the top 5 holdings of BAKER BROS. ADVISORS LP Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. New Purchase: Tonix Pharmaceuticals Holding Corp (TNXP) Baker Bros. Advisors Lp initiated holdings in Tonix Pharmaceuticals Holding Corp. | Shares added by 0.01% ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio. Baker Bros. Advisors Lp New Purchases: ANAB , JNCE , TNXP , BPMX, WINT, Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO, Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO, Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX, For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP These are the top 5 holdings of BAKER BROS. ADVISORS LP Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. The purchase prices were between $16.62 and $28.78, with an estimated average price of $23.3. | Shares added by 0.01% ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio. Baker Bros. Advisors Lp New Purchases: ANAB , JNCE , TNXP , BPMX, WINT, Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO, Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO, Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX, For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP These are the top 5 holdings of BAKER BROS. ADVISORS LP Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. Alexion Pharmaceuticals Inc ( ALXN ) - 6,544,130 shares, 6.61% of the total portfolio. |
36114.0 | 2017-06-06 00:00:00 UTC | Sum Up The Pieces: BBH Could Be Worth $138 | ACAD | https://www.nasdaq.com/articles/sum-pieces-bbh-could-be-worth-138-2017-06-06 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $138.03 per unit.
With BBH trading at a recent price near $120.25 per unit, that means that analysts see 14.78% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. Similarly, BMRN has 28.90% upside from the recent share price of $90.92 if the average analyst target price of $117.20/share is reached, and analysts on average are expecting TSRO to reach a target price of $169.69/share, which is 19.10% above the recent price of $142.48. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO:
Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO: Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO: Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF. Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO: Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF. | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO: Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. |
36115.0 | 2017-05-10 00:00:00 UTC | Oversold Conditions For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/oversold-conditions-acadia-pharmaceuticals-acad-2017-05-10 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 66.7. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $28.51.
According to the ETF Finder at ETF Channel, ACAD makes up 2.96% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.3% on the day Wednesday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $28.51. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $28.51. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $28.51. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.96% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.3% on the day Wednesday. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36116.0 | 2017-05-10 00:00:00 UTC | Mid-Day Market Update: Crude Oil Down 3%; Proteon Therapeutics Shares Spike Higher | ACAD | https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-down-3-proteon-therapeutics-shares-spike-higher-2017-05-10 | nan | nan | Midway through trading Wednesday, the Dow traded down 0.08 percent to 20,959.85 while the NASDAQ declined 0.12 percent to 6,113.15. The S&P also rose, gaining 0.02 percent to 2,397.31.
Leading and Lagging Sectors
Energy sector was the top gainer in the US market on Wednesday. Top gainers in the sector included TETRA Technologies, Inc. (NYSE: TTI ), Approach Resources Inc. (NASDAQ: AREX ), and Atwood Oceanics, Inc. (NYSE: ATW ).
In trading on Wednesday, healthcare shares were relative laggards, down on the day by about 0.32 percent. Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent.
Top Headline
NVIDIA Corporation (NASDAQ: NVDA ) reported better-than-expected results for its first quarter and issued a strong sales forecast for the current quarter on Tuesday.
NVIDIA said it earned $0.85 per share in the first quarter on revenue of $1.94 billion; Analysts were expecting the company to earn $0.67 per share on revenue of $1.91 billion.
Equities Trading UP
Medical Transcription Billing Corp (NASDAQ: MTBC ) shares shot up 54 percent to $3.02. MTBC reported Q1 adjusted loss of $0.08 per share on revenue of $8.2 million.
Shares of Proteon Therapeutics Inc (NASDAQ: PRTO ) got a boost, shooting up 31 percent to $1.77 after the company disclosed that it has received the FDA Breakthrough Therapy designation for Vonapanitase. Proteon Therapeutics posted a narrower-than-expected quarterly loss.
Array Biopharma Inc (NASDAQ: ARRY ) shares were also up, gaining 24 percent to $8.70 after the company reported positive top-line results from part 2 of Phase 3 study of binimetinib and encorafenib. Array BioPharma reported a Q3 loss of $0.21 per share on revenue of $33.3 million.
Equities Trading DOWN
Rocket Fuel Inc (NASDAQ: FUEL ) shares dropped 33 percent to $3.32. Rocket Fuel reported a Q1 loss of $22.5 million on revenue of $95.2 million. Credit Suisse downgraded Rocket Fuel from Outperform to Neutral.
Shares of Concordia International Corp (NASDAQ: CXRX ) were down around 24 percent to $1.58. Concordia posted a quarterly net loss from continuing operations of $78.8 million, and total revenue of $160.6 million.
Fossil Group Inc (NASDAQ: FOSL ) was down, falling around 22 percent to $14.19 after the company posted downbeat quarterly results and issued a weak outlook for the second quarter.
Commodities
In commodity news, oil traded up 3 percent to $47.25 while gold traded up 0.44 percent to $1,221.40.
Silver traded up 0.70 percent Wednesday to $16.18, while copper rose 0.06 percent to $2.4995.
Eurozone
European shares were mostly higher today. The eurozone's STOXX 600 climbed 0.06 percent, the Spanish Ibex Index fell 0.26 percent, while Italy's FTSE MIB Index gained 0.20 percent. Meanwhile the German DAX slipped 0.06 percent, and the French CAC 40 declined 0.09 percent while U.K. shares rose 0.60 percent.
Economics
Import prices rose 0.5 percent in Aril, versus a 0.1 percent revised growth in March. Export prices increased 0.2 percent for April, following a revised 0.1 percent growth in March. Economists were expecting a 0.2 percent gain in import prices and a 0.1 percent growth in export prices.
Crude supplies declined 5.25 million barrels for the week ended May 5, the U.S. Energy Information Administration reported. However, analysts expected a drop of 1.79 million barrels. Gasoline stockpiles slipped 150,000 barrels, while distillate stockpiles declined 1.59 million barrels last week.
Boston Federal Reserve Bank President Eric Rosengren is set to speak in South Burlington, VT at 12:30 p.m. ET.
The Treasury will auction 10-year notes at 1:00 p.m. ET.
Minneapolis Federal Reserve Bank President Neel Kashkari will speak in Minneapolis, MN at 1:20 p.m. ET.
The Treasury budget data for April is schedule for release at 2:00 p.m. ET.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent. Shares of Proteon Therapeutics Inc (NASDAQ: PRTO ) got a boost, shooting up 31 percent to $1.77 after the company disclosed that it has received the FDA Breakthrough Therapy designation for Vonapanitase. Array Biopharma Inc (NASDAQ: ARRY ) shares were also up, gaining 24 percent to $8.70 after the company reported positive top-line results from part 2 of Phase 3 study of binimetinib and encorafenib. | Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent. NVIDIA said it earned $0.85 per share in the first quarter on revenue of $1.94 billion; Analysts were expecting the company to earn $0.67 per share on revenue of $1.91 billion. Equities Trading DOWN Rocket Fuel Inc (NASDAQ: FUEL ) shares dropped 33 percent to $3.32. | Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent. Midway through trading Wednesday, the Dow traded down 0.08 percent to 20,959.85 while the NASDAQ declined 0.12 percent to 6,113.15. Meanwhile the German DAX slipped 0.06 percent, and the French CAC 40 declined 0.09 percent while U.K. shares rose 0.60 percent. | Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent. The S&P also rose, gaining 0.02 percent to 2,397.31. Proteon Therapeutics posted a narrower-than-expected quarterly loss. |
36117.0 | 2017-05-10 00:00:00 UTC | Is This Why Acadia Pharmaceuticals Inc. Is Plunging Today? | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-plunging-today-2017-05-10 | nan | nan | What happened
In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT.
So what
Here's a review of the headline numbers from the quarter:
Revenue was $15.3 million, which was a sequential increase of 28% and ahead of the $13.8 million in revenue that Wall Street had projected.
Net loss for the period was $87.8 million, or $0.72 per share. This result also compared favorably to the $0.73 loss that market watchers were expecting.
Acadia's cash balance at quarter-end was $469.5 million.
Management expects research and development expense in the second quarter to "be in the high $30 million range" and that SG&A expense will "be in the high $60 million to low $70 million range."
Financial numbers aside, here's a look at a few other highlights from the report:
Nuplazid, the company's one and only drug used to treat Parkinson's disease psychosis, is now available on Medicare's formulary. In addition, 94% of commercial lives are covered.
Acadia hired 25 new sales reps to focus on long-term care facilities.
The company's phase 3 study of Nuplazid in Alzheimer's disease psychosis is planned to start in the second half of the year.
Given all of the good news from the report, it isn't clear why shares are tumbling today. Perhaps investors are simply worried that the company's cash hoard is being depleted too rapidly given its torrid rate of spending. With a phase 3 study kicking off in the coming months and new reps on board, it is possible that losses will grow from here. That could mean that yet another capital raise could be coming down the road.
Now what
Despite today's share price action, I think that Acadia continues to show that there are reasons to be optimistic about its future. Nuplazid sales continue to grow rapidly and that is likely to continue now that there are more reps in the field and insurers are on board. Meanwhile, the potential for Nuplazid to win label expansion claims down the road into disease states like Alzheimer's disease psychosis, Alzheimer's disease agitation, schizophrenia, and depression remains possible. If that happens, then sales growth could really be turbocharged from here.
In total, Acadia remains a high-risk and expensive stock that is likely to remain volatile for the time being. Still, if you are bullish on Nuplazid's long-term potential, I see no reason to change your stance.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT. Acadia's cash balance at quarter-end was $469.5 million. Acadia hired 25 new sales reps to focus on long-term care facilities. | What happened In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT. Acadia's cash balance at quarter-end was $469.5 million. Acadia hired 25 new sales reps to focus on long-term care facilities. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT. Acadia's cash balance at quarter-end was $469.5 million. | Acadia's cash balance at quarter-end was $469.5 million. Acadia hired 25 new sales reps to focus on long-term care facilities. What happened In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT. |
36118.0 | 2017-05-04 00:00:00 UTC | Analysts Forecast 12% Upside For BBH | ACAD | https://www.nasdaq.com/articles/analysts-forecast-12-upside-bbh-2017-05-04 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $136.75 per unit.
With BBH trading at a recent price near $121.78 per unit, that means that analysts see 12.29% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. Similarly, BMRN has 18.36% upside from the recent share price of $95.95 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ALKS to reach a target price of $68.00/share, which is 15.45% above the recent price of $58.90. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS:
Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS: Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS: Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF. Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS: Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF. | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS: Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. |
36119.0 | 2017-05-02 00:00:00 UTC | What's in the Cards for ACADIA (ACAD) this Earnings Season? | ACAD | https://www.nasdaq.com/articles/whats-in-the-cards-for-acadia-acad-this-earnings-season-2017-05-02 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4.
The company's track record has been dismal. Evidently, ACADIA missed estimates in three of the trailing four quarters, bringing the average negative surprise to 13.67%. In the last reported quarter, ACADIA posted in line earnings.
ACADIA's share price has increased 19.3% year to date compared with the Zacks classified Medical - Biomedical and Genetics industry's gain of 4.9%.
Factors at Play
In Apr 2016, the FDA approved ACADIA's first drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In fact, the company made good progress with the commercial launch of this drug. Nuplazid became available for prescription in the U.S. on May 31, 2016.
This newly launched drug generated revenues of $12 million in the fourth quarter and $17.3 million for the full year 2016. The company expects sales to grow steadily in 2017 and thereafter The companywitnessed very good reimbursement and access for Nuplazid. In 2017, ACADIA also plans to expand its sales force from 133 to around 155 representatives in order to broaden and deepen awareness about the drug.
Meanwhile, the company is also on track with its multiyear plans of developing Nuplazid in indications beyond PD psychosis. It reported positive top-line results from its phase II exploratory study (-019 Study) of the drug in patients with Alzheimer's disease (AD) psychosis in Dec 2016. Please note that, the FDA has not yet approved any drug to treat AD Psychosis.
Moreover, Nuplazid (primavanserin) has shown antipsychotic effects in clinical studies in three major central nervous system (CNS) disorders like Parkinson's disease, schizophrenia and Alzheimer's disease. In fact, the company had already added four new clinical programs for Nuplazid- Alzheimer's disease agitation, Schizophrenia inadequate response, Schizophrenia negative symptoms and major depressive disorders in the fourth quarter of 2016. Thus pursuing the total of six indications with primavanserin. Each one of these indications independently represents the potentials to impact the long-term growth of the company, thereby leading ACADIA to be a strong leader in the CNS space.
Earnings Whispers
Our proven model does not conclusively show an earnings beat for ACADIA this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP: ACADIA has an Earnings ESP of +13.70%. That is because the Most Accurate estimate is at a loss of 63 cents and the Zacks Consensus Estimate is pegged at a loss of 73 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: ACADIA has a Zacks Rank #4 (Sell). Please note that we caution against stocks with Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Ultragenyx Pharmaceutical Inc. RARE has an Earnings ESP of +0.59% and a Zacks Rank #3. The company is expected to release results on May 8. You can see the complete list of today's Zacks #1 Rank stocks here
Fibrogen Inc. FGEN has an Earnings ESP of +23.81% and a Zacks Rank #3. The company is expected to release results on May 8.
Editas Medicine, Inc. EDIT has an Earnings ESP of +33.33% and a Zacks Rank #3. The company is expected to release results on May 15.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
FibroGen, Inc (FGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Each one of these indications independently represents the potentials to impact the long-term growth of the company, thereby leading ACADIA to be a strong leader in the CNS space. ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4. Evidently, ACADIA missed estimates in three of the trailing four quarters, bringing the average negative surprise to 13.67%. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks to Consider Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report FibroGen, Inc (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks to Consider Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report FibroGen, Inc (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks to Consider Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter. ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4. Evidently, ACADIA missed estimates in three of the trailing four quarters, bringing the average negative surprise to 13.67%. |
36120.0 | 2017-04-25 00:00:00 UTC | Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-may-just-be-best-long-term-play-alzheimers-disease-treatment-market | nan | nan | Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis.
Alzheimer's is a tough nut to crack
For pharmaceutical companies, a treatment for Alzheimer's disease (AD) has remained the holy grail. This devastating disease impacts millions of people, and potential treatments have garnered significant attention from patients and investors alike.
Famous "breakthrough" therapies such as Pfizer / Johnson & Johnson 's bapineuzumab and, most recently, Eli Lilly 's solanezumab have all failed to demonstrate disease-slowing effects in late-stage clinical trials. In fact, over the last decade, it has been estimated that around 99% of potential Alzheimer's treatments have failed.
The issue with each of these products is that they all realy on the "amyloid hypothesis" of understanding Alzheimer's disease. The underlying cause of AD is still unknown, but scientists have a theory based on the observation that a protein called "amyloid-beta" tends to build up in large quantities in the brains of patients with AD. These proteins then group together to form a plaque, which blocks cell-to-cell communication. The amyloid hypothesis (which is as yet unproven) says that the underlying cause of AD is this buildup of amyloid-beta plaque.
Assuming the amyloid hypothesis has merit, the next logical step would be to destroy the plaque buildups in patients' brains. And that's exactly what the aforementioned bapineuzumab and solanezumab set out to do. Both drugs were highly effective in clearing amyloid plaques from the brain. However, in long-term, phase 3 studies, neither drug showed an ability to halt or slow the progression of the underlying disease.
Following the failures of bapineuzumab and solanezumab, the industry has now turned its watchful gaze to Biogen 's aducanumab, which is currently in phase 3 trials. Although this drug did show potential efficacy in phase 2 studies, this product still fundamentally adheres to the amyloid hypothesis of Alzheimer's. Although the entire Alzheimer's disease community would love to see aducanumab succeed, the odds are long.
Could a different approach hold the solution?
Acadia's main product, Nuplazid, takes a different approach to the treatment of Alzheimer's. Rather than attempting to halt or slow the progression of the underlying disease, Nuplazid is being studied in Alzheimer's disease psychosis (ADP), a psychiatric condition associated with the progression of Alzheimer's disease.
Nuplazid is currently approved as a treatment for Parkinson's disease psychosis (PDP). According to company estimates, Parkinson's disease affects an estimated 1 million Americans, and around 40% of this population is affected by PDP. Since Nuplazid is currently priced at $24,000 for an annual treatment, the U.S. market alone is, in theory, worth $9.6 billion. As Nuplazid is both the first and only drug approved for this indication, Acadia shares could have more room to run based on continual growth in PDP alone.
The Alzheimer's disease psychosis market has even more potential: Alzheimer's disease affects an estimated 5.4 million people in the United States alone. The company estimates that between 25% to 50% of patients diagnosed with Alzheimer's will eventually develop ADP. Should Nuplazid succeed in phase 3 studies for ADP, assuming annual pricing remains similar to PDP, Acadia would be targeting a total addressable market of between $32 billion and $65 billion.
In December of last year, Acadia released positive top-line data for Nuplazid in a phase 2 study in ADP. In this 181-patient study, Nuplazid met its primary endpoint of demonstrating significant improvement over placebo at week 6 of the study. The company has indicated that it intends to begin phase 3 trials in the second half of 2017.
Aside from Alzheimer's disease psychosis, Acadia is also in the process of advancing Nuplazid in mid-stage trials as a treatment for Alzheimer's disease agitation as well as adjunctive therapy for both schizophrenia and major depressive disorder. As all three of these are large indications with patient populations numbering in the millions, a hit in any one of these indications could be huge for Acadia.
The risks involved
While Nuplazid has multiple large shots-on-goal, this stock is definitely not for the faint-of-heart. As I have pointed out before , while Nuplazid did succeed in its phase 2 study as treatment for ADP, this study was not without its controversies. Namely, while the results were significant, they were barely so, with Nuplazid beating placebo at a p-value of .0451 (for reference, the cutoff for p-values is .05, and the closer to "0" the better).
In addition, while Acadia ended 2016 with $163 million in cash and cash equivalents, commercializing a drug is expensive. The company may need to undergo future equity raises -- thus diluting existing shareholders.
Finally, it must be said that even for PDP, the results are still too early to discern trends. First launched commercially in May of 2016, Nuplazid has only been on the market for 11 months now. However, with so many shots-on-goal and the potential to tackle one of the largest indications out there, I would say Acadia is well worth the risk. After a significant pullback in April, I'd say now is a good time for risk-tolerant investors to consider buying shares of Acadia.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
David Liang has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen and Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis. Acadia's main product, Nuplazid, takes a different approach to the treatment of Alzheimer's. | Should Nuplazid succeed in phase 3 studies for ADP, assuming annual pricing remains similar to PDP, Acadia would be targeting a total addressable market of between $32 billion and $65 billion. Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis. | Aside from Alzheimer's disease psychosis, Acadia is also in the process of advancing Nuplazid in mid-stage trials as a treatment for Alzheimer's disease agitation as well as adjunctive therapy for both schizophrenia and major depressive disorder. Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis. | Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis. Acadia's main product, Nuplazid, takes a different approach to the treatment of Alzheimer's. |
36121.0 | 2017-04-05 00:00:00 UTC | Acadia Pharmaceuticals Becomes Oversold (ACAD) | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-becomes-oversold-acad-2017-04-05 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 49.9. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $32.67.
According to the ETF Finder at ETF Channel, ACAD makes up 3.21% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 2% on the day Wednesday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $32.67. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $32.67. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $32.67. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. According to the ETF Finder at ETF Channel, ACAD makes up 3.21% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 2% on the day Wednesday. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36122.0 | 2017-03-26 00:00:00 UTC | 3 Top Biotech Stocks to Buy in 2017 | ACAD | https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-2017-2017-03-26 | nan | nan | Political uncertainties aside, the future is looking bright for the biotech industry. Acadia Pharmaceuticals (NASDAQ: ACAD) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Eagle Pharmaceuticals (NASDAQ: EGRX) , in particular, all appear primed for prosperity. Here's a closer look at why all three companies could be great investment candidates.
A market all to itself
Acadia Pharmaceuticals has been a home run stock over the last few years thanks to investor enthusiasm around its drug Nuplazid. Nuplazid is the first and only Food and Drug Administration-approved treatment for Parkinson's disease psychosis, or PDP, a condition that causes hallucinations and delusions. Since caring for the patients who develop PDP is extremely difficult, the demand for Nuplazid is expected to be huge.
While we are still early into the launch of Nuplazid, the initial results are encouraging. Total sales reached $17 million in 2016, which is a solid result given that the drug only launched halfway through the year. In 2017, market watchers expect this figure to exceed $89 million thanks to growing awareness among providers and better reimbursement access.
However, what makes Acadia such a compelling investment is that the company believes that Nuplazid can also be useful in a handful of other conditions. This includes major diseases such as schizophrenia, Alzheimer's disease, and even major depression.
Even though success in these other indications is far from guaranteed, I think the company's odds are better than average. After all, the FDA already gave Nuplazid the thumbs-up for treating PDP, so I'd argue that raises the company's chance of success. If all goes well, then peak sales of Nuplazid could cross the multibillion-dollar mark, which would easily justify a higher valuation.
New drugs to the rescue
Regeneron Pharmaceuticals has been one of the best-performing stocks of the past decade, and for good reason. Regeneron owns a megahit drug called Eylea, which treats age-related macular degeneration, macular edema, and diabetic retinopathy. Eylea's 2016 worldwide sales topped $5 billion, making it one of the best-selling drugs on the planet.
Despite Eylea's success, Regeneron's shares have been running in reverse for nearly two years. Why? You can blame the downfall on a handful of clinical , regulatory , and legal setbacks. In particular, Regeneron is on the losing side of a courtroom battle with Amgen related to Regeneron's new cholesterol-lowering drug Praluent. In January, a U.S. District Court sided with Amgen and blocked the marketing of Praluent in the U.S. While a stay of the injunction was granted, the future of this hopeful blockbuster drug is up in the air.
While potentially losing out on Praluent sales in the U.S. would be a big blow, Regeneron has a few other drugs coming to market soon that promise to reverse the company's fortunes. This includes Dupixent, an eczema drug candidate, and Kevzara, a potential treatment for rheumatoid arthritis. Both of these drugs are up for FDA approval in 2017 and could go a long way toward reigniting top-line growth.
In total, Wall Street expects Eylea and these new drugs to power bottom-line growth of nearly 19% annually for the foreseeable future. That's an attractive growth rate for a company that is only trading for 28 times forward earnings estimates.
High-flying potential
The final stock on today's list is Eagle Pharmaceuticals, a specialty pharmaceutical company focused on the critical care and oncology markets. However, unlike traditional drug developers, Eagle isn't focused on developing brand-new molecules. Instead, the company's strategy is to take drugs that have already been approved and make them better. This strategy is much less expensive and risky than traditional drug development.
Eagle's current cash cow is a drug called Bendeka. This compound is a rapid-acting formulation of Teva Pharmaceutical 's cancer drug Treanda. Eagle won FDA approval for Bendeka and licensed the drug to Teva in exchange for a $30 million up-front payment and up to $90 million in milestone payments, plus a 25% royalty on any sales. Teva jumped at this deal since Treanda is a highly profitable drug that lost patent protection. Licensing Bendeka allows the company to remain relevant in this highly lucrative market. Bendeka is clearly a winner -- Eagle states that the drug already boasts a market share of 92%. That fact puts Eagle in great shape to earn all of its milestone payments and big royalties for years to come.
Ryanodex, Eagle's other drug of interest, is a treatment for malignant hyperthermia. While sales of this drug are still small, Eagle has submitted Ryanodex to the FDA as a treatment for exertional heat stroke and is researching it as a treatment for drug-induced hyperthermia. Winning label expansion claims in either indication could help to spur strong sales growth from here.
Between Bendeka and Ryanodex, analysts expect Eagle to churn out profit growth of roughly 15% annually over the coming years. That's not too shabby for a company that is trading at 17 times trailing earnings.
10 stocks we like better than Regeneron Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Regeneron Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Brian Feroldi owns shares of Regeneron Pharmaceuticals. The Motley Fool recommends Teva Pharmaceutical Industries. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (NASDAQ: ACAD) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Eagle Pharmaceuticals (NASDAQ: EGRX) , in particular, all appear primed for prosperity. A market all to itself Acadia Pharmaceuticals has been a home run stock over the last few years thanks to investor enthusiasm around its drug Nuplazid. However, what makes Acadia such a compelling investment is that the company believes that Nuplazid can also be useful in a handful of other conditions. | Acadia Pharmaceuticals (NASDAQ: ACAD) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Eagle Pharmaceuticals (NASDAQ: EGRX) , in particular, all appear primed for prosperity. A market all to itself Acadia Pharmaceuticals has been a home run stock over the last few years thanks to investor enthusiasm around its drug Nuplazid. However, what makes Acadia such a compelling investment is that the company believes that Nuplazid can also be useful in a handful of other conditions. | Acadia Pharmaceuticals (NASDAQ: ACAD) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Eagle Pharmaceuticals (NASDAQ: EGRX) , in particular, all appear primed for prosperity. A market all to itself Acadia Pharmaceuticals has been a home run stock over the last few years thanks to investor enthusiasm around its drug Nuplazid. However, what makes Acadia such a compelling investment is that the company believes that Nuplazid can also be useful in a handful of other conditions. | Acadia Pharmaceuticals (NASDAQ: ACAD) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Eagle Pharmaceuticals (NASDAQ: EGRX) , in particular, all appear primed for prosperity. A market all to itself Acadia Pharmaceuticals has been a home run stock over the last few years thanks to investor enthusiasm around its drug Nuplazid. However, what makes Acadia such a compelling investment is that the company believes that Nuplazid can also be useful in a handful of other conditions. |
36123.0 | 2017-03-02 00:00:00 UTC | Analysts Expect BBH Will Reach $134 | ACAD | https://www.nasdaq.com/articles/analysts-expect-bbh-will-reach-134-2017-03-02 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $134.11 per unit.
With BBH trading at a recent price near $121.84 per unit, that means that analysts see 10.07% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although BMRN has traded at a recent price of $93.81/share, the average analyst target is 20.02% higher at $112.59/share. Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD:
Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD: Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. | Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD: Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF. | Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD: Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF. | Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD: Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. |
36124.0 | 2017-02-28 00:00:00 UTC | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 50.0% Follow-Through Indicator, 5.9% Sensitive | ACAD | https://www.nasdaq.com/articles/earnings-reaction-history-acadia-pharmaceuticals-inc-500-follow-through-indicator-59 | nan | nan | Expected Earnings Release: 02/28/2017, After-hours
Avg. Extended-Hours Dollar Volume: $2,686,645
ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 60%
Average next regular session additional gain: 3.5%
Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 3.2%
Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $2,686,645 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $2,686,645 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $2,686,645 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $2,686,645 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
36125.0 | 2017-02-28 00:00:00 UTC | After-Hours Earnings Report for February 28, 2017 : CRM, ROST, PANW, UHS, TSRO, JAZZ, AR, DXCM, EPR, LOGM, ACAD, BUFF | ACAD | https://www.nasdaq.com/articles/after-hours-earnings-report-february-28-2017-crm-rost-panw-uhs-tsro-jazz-ar-dxcm-epr-logm | nan | nan | The following companies are expected to report earnings after hours on 02/28/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Salesforce.com Inc ( CRM ) is reporting for the quarter ending January 31, 2017. The computer software company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.04. This value represents a 300.00% increase compared to the same quarter last year. CRM missed the consensus earnings per share in the 1st calendar quarter of 2016 by -75%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CRM is 354.52 vs. an industry ratio of 62.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Ross Stores, Inc. ( ROST ) is reporting for the quarter ending January 31, 2017. The discount retail company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.75. This value represents a 13.64% increase compared to the same quarter last year. In the past year ROST has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ROST is 24.61 vs. an industry ratio of 15.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Palo Alto Networks, Inc. ( PANW ) is reporting for the quarter ending January 31, 2017. The information technology services company's consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.38. This value represents a 54.22% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for PANW is -148.03 vs. an industry ratio of 9.50.
Universal Health Services, Inc. ( UHS ) is reporting for the quarter ending December 31, 2016. The hospital company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.79. This value represents a 4.68% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for UHS is 17.28 vs. an industry ratio of 13.20, implying that they will have a higher earnings growth than their competitors in the same industry.
TESARO, Inc. ( TSRO ) is reporting for the quarter ending December 31, 2016. The drug company's consensus earnings per share forecast from the 12 analysts that follow the stock is $-1.96. This value represents a 3.70% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for TSRO is -25.29 vs. an industry ratio of 6.60.
Jazz Pharmaceuticals plc ( JAZZ ) is reporting for the quarter ending December 31, 2016. The drug company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.65. This value represents a 27.31% decrease compared to the same quarter last year. In the past year JAZZ has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 37.58%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for JAZZ is 22.38 vs. an industry ratio of 6.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Antero Resources Corporation ( AR ) is reporting for the quarter ending December 31, 2016. The oil (us exp & production) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.13. This value represents a no change for the same quarter last year. In the past year AR has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 200%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for AR is 67.00 vs. an industry ratio of -8.80, implying that they will have a higher earnings growth than their competitors in the same industry.
DexCom, Inc. ( DXCM ) is reporting for the quarter ending December 31, 2016. The medical instruments company's consensus earnings per share forecast from the 14 analysts that follow the stock is $-0.10. This value represents a 600.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for DXCM is -100.27 vs. an industry ratio of 3.40.
EPR Properties ( EPR ) is reporting for the quarter ending December 31, 2016. The reit company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.23. This value represents a 4.24% increase compared to the same quarter last year. In the past year EPR has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2016 Price to Earnings ratio for EPR is 16.16 vs. an industry ratio of 16.50.
LogMein, Inc. ( LOGM ) is reporting for the quarter ending December 31, 2016. The computer services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.36. This value represents a 2.86% increase compared to the same quarter last year. In the past year LOGM has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 14.29%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for LOGM is 90.14 vs. an industry ratio of 26.40, implying that they will have a higher earnings growth than their competitors in the same industry.
ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.65. This value represents a 44.44% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10.
Blue Buffalo Pet Products, Inc. ( BUFF ) is reporting for the quarter ending December 31, 2016. The consumer company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.18. This value represents a 12.50% increase compared to the same quarter last year. In the past year BUFF has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 10%. The "days to cover" for this stock exceeds 12 days. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BUFF is 31.01 vs. an industry ratio of -5.60, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. The computer software company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.04. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. Zacks Investment Research reports that the 2017 Price to Earnings ratio for CRM is 354.52 vs. an industry ratio of 62.10, implying that they will have a higher earnings growth than their competitors in the same industry. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. Zacks Investment Research reports that the 2016 Price to Earnings ratio for JAZZ is 22.38 vs. an industry ratio of 6.60, implying that they will have a higher earnings growth than their competitors in the same industry. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. In the past year JAZZ has beat the expectations every quarter. |
36126.0 | 2017-02-24 00:00:00 UTC | 3 Earnings Reports That Should Be on Your Radar | ACAD | https://www.nasdaq.com/articles/3-earnings-reports-that-should-be-on-your-radar-2017-02-24 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The markets have posted another solid week overall, with the S&P 500 gaining nearly 6% already this year. With regards to earnings, tech companies largely stole the spotlight, with Tesla Inc (NASDAQ: TSLA ) cooling a bit after releasing fourth-quarter numbers and announcing the departure of its CFO on Thursday.
Source: Shutterstock
But earnings season is far from over. In addition to GDP, manufacturing and other important indicators coming out next week, there are also several earnings reports all investors should keep an eye on.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017.
The 10 Best Stock Charts on Wall Street Right Now
Will their earnings reports add more fuel to the fire? Let's take a look.
Earnings Reports: Priceline (PCLN)
Source: Priceline.com
Earnings Date: Feb. 27
Compared to the other picks on this list, Priceline is a much more traditional stock and one that's growing slowly with acquisitions. Most recently, Priceline bought European travel company Momondo Group for $550 million in cash.
But when it comes to reporting earnings Priceline has a long string of missed earnings. In fact, PCLN hasn't topped Wall Street's earnings in any of the past three quarters. For the current quarter, earnings are only expected to grow by 3%. But longer-term, the five-year average is slated for 17%, which is right in line with the company's organic growth.
That's solid growth. Keep an eye on Wall Street's reaction to see how much of a premium investors are willing to swallow for this internet play.
Earnings Reports: 3D Systems (DDD)
Source: Image via 3D Systems
Earnings Date: Feb. 28
3D-printing play 3D Systems ran up like crazy in 2013 before plummeting in the years that followed. That drop bred opportunity for any bottom-fishers, though; DDD has gained 75% over the past 12 months, including 25% in 2017 alone.
Much like the next pick in this list, 3D Systems has largely been fueled by acquisition chatter. However, DDD has met or beat earnings expectations in each of the past four quarters, with the beats coming in 55%, 100% and 500%, respectively, better than Wall Street's consensus.
7 Blue-Chip Stocks That Are Flush With Cash
This quarter, a slight earnings contraction is expected. But considering the wildcard nature of DDD stock, I don't expect investors to be phased. Long-term growth is trend-driven and quarterly fluctuations aren't as important for such plays.
Earnings Reports: Acadia Pharmaceuticals (ACAD)
Earnings Date: Feb. 28
One thing that hasn't been driving ACAD stock? Earnings. The company has missed Wall Street's expectations in each of the past four quarters. And when it reports on Tuesday, Acadia is expected to lose 65 cents per share - wider than the 45-cent-per-share loss of a year ago. Still, insane sales growth is what has investors coming back, which is why the top line is where your eye should go when ACAD releases its numbers.
Keep an eye on sales growth of Nuplazid and any updates about potential future treatments.
Hilary Kramer is the editor of GameChangers, Breakout Stocks, High Octane Trader,Absolute Capital Return and Value Authority. She is an accomplished investment specialist and market strategist with more than 25 years of experience in portfolio management, equity research, trading, and risk management. She has extensive expertise in global financial management, asset allocation, investment banking and private equity ventures, and is regularly sought after to provide her analysis on Bloomberg, CNBC, Fox Business Network and other media.
The post 3 Earnings Reports That Should Be on Your Radar appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017. Earnings Reports: Acadia Pharmaceuticals (ACAD) Earnings Date: Feb. 28 One thing that hasn't been driving ACAD stock? And when it reports on Tuesday, Acadia is expected to lose 65 cents per share - wider than the 45-cent-per-share loss of a year ago. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017. Earnings Reports: Acadia Pharmaceuticals (ACAD) Earnings Date: Feb. 28 One thing that hasn't been driving ACAD stock? And when it reports on Tuesday, Acadia is expected to lose 65 cents per share - wider than the 45-cent-per-share loss of a year ago. | Earnings Reports: Acadia Pharmaceuticals (ACAD) Earnings Date: Feb. 28 One thing that hasn't been driving ACAD stock? Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017. And when it reports on Tuesday, Acadia is expected to lose 65 cents per share - wider than the 45-cent-per-share loss of a year ago. | Still, insane sales growth is what has investors coming back, which is why the top line is where your eye should go when ACAD releases its numbers. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017. Earnings Reports: Acadia Pharmaceuticals (ACAD) Earnings Date: Feb. 28 One thing that hasn't been driving ACAD stock? |
36127.0 | 2017-02-23 00:00:00 UTC | ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time? | ACAD | https://www.nasdaq.com/articles/acadia-pharma-acad-q4-earnings%3A-whats-in-store-this-time-2017-02-23 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is expected to report fourth-quarter 2016 results on Feb 28.
The company's track record is dismal. ACADIA has missed estimates in all the trailing four quarters, bringing the average negative earnings surprise to 19.07%.
ACADIA's share price increased 35.7% year- to -date compared with the Zacks classified Medical - Biomedical and Genetics industry's gain of 8.6%.
Factors at Play
In Apr 2016, the FDA approved the ACADIA's first drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid became available for prescription in the U.S. on May 31, 2016. ACADIA made good progress with the commercial launch of Nuplazid drug, which is used for the treatment of hallucinations and delusions.
This newly launched drug generated revenues of $5.3 million in the third quarter and sales are expected to grow steadily over years to come. The company witnessed very good reimbursement and access for Nuplazid from public and private payers, who had been successful earlier over getting on formularies.
Hence, the company expects sales to ramp up further. All these makes the company confident about the initial positive experiences reported by physicians, which is expected to continue to accelerate prescribing of Nuplazid for patients with Parkinson's disease psychosis.
Meanwhile, the company is also on track with its multiyear plans of developing Nuplazid in indications beyond PD psychosis. It reported positive top-line results from its phase II exploratory study (-019 Study) of Nuplazid in patients with Alzheimer's disease (AD) psychosis in Dec 2016. However, the FDA has not yet approved any drug to treat AD Psychosis.
Additionally, in Dec 2016 the company had initiated CLARITY, a phase II study to evaluate Nuplazid for adjunctive treatment in patients with major depressive disorder (MDD), who have an inadequate response to first-line therapies for clinical depression. The candidate is also being studied in a phase III trial called ENHANCE-1 for the treatment of schizophrenia as well as a Phase II study- ADVANCE, to evaluate Nuplazid for adjunctive treatment in patients with negative symptoms of schizophrenia.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Earnings Whispers
Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP : ACADIA has an Earnings ESP of 0.00%. That is because the both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 65 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : ACADIA has a Zacks Rank #3, which increases the predictive power of ESP. However, 0.00% ESP makes surprise prediction difficult for the quarter. You can see the complete list of today's Zacks #1 Rank stocks here .
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. PCRX has an Earnings ESP of +20% and a Zacks Rank #2. The company is scheduled to release results on Mar 1.
Syndax Pharmaceuticals, Inc. SNDX has an Earnings ESP of +18.18% and a Zacks Rank #3. The company is scheduled to release results on Mar 2.
Exelixis, Inc. EXEL has an Earnings ESP of +200% and a Zacks Rank #2. The company is scheduled to release results on Feb 27.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report
Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factors at Play In Apr 2016, the FDA approved the ACADIA's first drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA Pharmaceuticals Inc.ACAD is expected to report fourth-quarter 2016 results on Feb 28. ACADIA has missed estimates in all the trailing four quarters, bringing the average negative earnings surprise to 19.07%. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Earnings Whispers Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report fourth-quarter 2016 results on Feb 28. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Earnings Whispers Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. Zacks Rank : ACADIA has a Zacks Rank #3, which increases the predictive power of ESP. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA Pharmaceuticals Inc.ACAD is expected to report fourth-quarter 2016 results on Feb 28. ACADIA made good progress with the commercial launch of Nuplazid drug, which is used for the treatment of hallucinations and delusions. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Earnings Whispers Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. |
36128.0 | 2017-02-22 00:00:00 UTC | First Week of April 21st Options Trading For Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/first-week-april-21st-options-trading-acadia-pharmaceuticals-2017-02-22 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 21st contracts and identified one put and one call contract of particular interest.
The put contract at the $39.00 strike price has a current bid of $3.40. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $39.00, but will also collect the premium, putting the cost basis of the shares at $35.60 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $39.43/share today.
Because the $39.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 57%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 8.72% return on the cash commitment, or 54.90% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $39.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $3.20. If an investor was to purchase shares of ACAD stock at the current price level of $39.43/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $40.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.56% if the stock gets called away at the April 21st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red:
Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 47%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 8.12% boost of extra return to the investor, or 51.11% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 64%, while the implied volatility in the call contract example is 63%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $39.43) to be 62%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 21st contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $39.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $3.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 21st contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration. |
36129.0 | 2017-02-14 00:00:00 UTC | Caution: Acadia Pharmaceuticals Is Overvalued | ACAD | https://www.nasdaq.com/articles/caution-acadia-pharmaceuticals-overvalued-2017-02-14 | nan | nan | Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months. While current shareholders are undoubtedly pleased with their returns, plenty more eager investors are on the sidelines considering buying in. If you're in the latter camp, take caution: Acadia Pharmaceuticals' dramatic rise is based on controversial phase 2 data, and a lot would have to go right for the company to maintain its current premium valuation.
Nuplazid
Acadia only has one drug product, Nuplazid, which is approved solely for the treatment of Parkinson's disease psychosis (PDP). Nuplazid (also known as pimavanserin) is a once-daily oral medication that targets a serotonin receptor called 5-HT2A. This receptor is believed to play an important role in psychosis.
Acadia announced positive phase 3 data for pimavanserin in PDP way back in 2012. Pimavanserin met both its primary and secondary endpoints with a very convincing p-value of .001. Since then, after two delays and a CEO exit, Acadia finally submitted an application to the FDA for Nuplazid for PDP in late 2015.
Acadia is currently studying Nuplazid in trials related to schizophrenia, chronic pain, major depressive disorder, and Alzheimer's disease psychosis/agitation in hopes of expanding the drug's addressable market.
The Alzheimer's disease controversy
Toward the end of last year, Acadia released topline data from a phase 2 study of Nuplazid in Alzheimer's disease psychosis. While the results were positive and Nuplazid technically met its primary endpoint, this outcome was met with both controversy and criticism. The primary endpoint of this trial was a statistically significant reduction in psychosis at week 6 of dosing. While the resulting reduction was statistically significant, it was just barely so, coming in at a p-value of .0451. For reference, a p-value of .05 is generally considered the upper boundary for statistical significance, and the lower the better. Acadia reported a p-value of .001 for Nuplazid in its phase 3 trial for PDP -- indicating a much stronger significance.
Moreover, while Nuplazid did meet its primary endpoint of significance vs placebo in week 6, the drug failed to show statistical significance versus placebo at week 12. As Alzheimer's disease is a life-long disease, durability of response is paramount for approval and wide-spread usage within this indication.
And finally, the FDA's approval for the drug in PDP came with a black box warning stating that "elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death." As an estimated 5.2 million of the 5.4 million Americans with Alzheimer's are age 65 and older, this could pose a significant hurdle toward penetrating the Alzheimer's market.
Valuation
We only have one full quarter worth of sales data for Nuplazid, but so far, revenue looks promising. But does it warrant what is currently nearing a $5 billion valuation? Let's do some back of the napkin math. Acadia's $5.3 million in third quarter revenue easily beat Wall Street's expectations of $2.9 million. Moving onward toward the fourth quarter, management has guided toward $8 to $9 million in revenue. Taking the midpoint of this range, $8.5 million, this implies a 60% quarter-over-quarter growth rate. If we take this rate and annualize it, ($13.6 million for the first quarter of 2017 and $21.8 million for the second quarter), we end with a sum of $49 million in sales for the drug's first year on the market. At a $4.5 billion market cap, Acadia is trading at a whopping 92 times current year revenues.
An overheated market
While Nuplazid is undoubtedly treating a large and underserved PDP population, I believe the market may have gotten ahead of itself. Judging from the price climb since Acadia's readout of its phase 2 ADP data, it seems that the market feels Alzheimer's success is baked in. All told, the combination of a single product portfolio, a black box warning, and shaky Alzheimer's data makes me feel that the risks may outweigh the rewards at today's prices.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
David Liang has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you're in the latter camp, take caution: Acadia Pharmaceuticals' dramatic rise is based on controversial phase 2 data, and a lot would have to go right for the company to maintain its current premium valuation. Acadia is currently studying Nuplazid in trials related to schizophrenia, chronic pain, major depressive disorder, and Alzheimer's disease psychosis/agitation in hopes of expanding the drug's addressable market. Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months. | The Alzheimer's disease controversy Toward the end of last year, Acadia released topline data from a phase 2 study of Nuplazid in Alzheimer's disease psychosis. Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months. If you're in the latter camp, take caution: Acadia Pharmaceuticals' dramatic rise is based on controversial phase 2 data, and a lot would have to go right for the company to maintain its current premium valuation. | Nuplazid Acadia only has one drug product, Nuplazid, which is approved solely for the treatment of Parkinson's disease psychosis (PDP). The Alzheimer's disease controversy Toward the end of last year, Acadia released topline data from a phase 2 study of Nuplazid in Alzheimer's disease psychosis. Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months. | Acadia announced positive phase 3 data for pimavanserin in PDP way back in 2012. Acadia reported a p-value of .001 for Nuplazid in its phase 3 trial for PDP -- indicating a much stronger significance. Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months. |
36130.0 | 2017-02-11 00:00:00 UTC | A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease | ACAD | https://www.nasdaq.com/articles/potential-20-billion-indication-2-must-have-biotechs-taking-alzheimers-disease-2017-02-11 | nan | nan | Alzheimer's disease is a terrible illness which affects an estimated 5.4 million Americans today. Alzheimer's is also the 6 th leading cause of death nationally. Unfortunately, there are currently only two types of FDA-approved drugs (memantine and cholinesterase inhibitors), which solely function to slow down the effects of the disease.
Luckily, pharmaceutical companies remain hard at work in their attempts to combat this debilitating illness. Two candidates making noteworthy strides in this indication are Biogen (NASDAQ: BIIB) and Acadia Pharmaceuticals (NASDAQ: ACAD) . The $20 billion Alzheimer's disease treatment market should have investors wanting to grab a slice of the pie -- but which company is the better buy? Read on to find out.
Image source: Pixabay.
Biogen
Biogen made headlines in early 2015 when its early stage trial of Alzheimer's disease drug aducanumab produced positive results for both the 3mg and 10mg dosing. While the 3mg dose did not show as much efficacy as the 10mg dose, the 10mg dose led to dangerous brain swelling in some patients. Investors hoped that a 6mg "goldie locks" dosage would show the merits of both increased efficacy and decreased brain swelling. Unfortunately, these hopes were dashed later on that year when the 6mg dosing trial failed to show a dosage-dependent clinical efficacy profile. However, upon further analysis of the data, Biogen showed that the treatment did have a dose-dependent slowing of cognitive decline for mild and prodromal (early stage) patients. On this news, the company pushed forward with its phase 3 study for aducanumab which hopes to enroll 1,350 patients for a 5-year study.
Aducanumab is an amyloid-targeting monoclonal antibody. Aducanumab functions by targeting what are called "amyloid plaques" which build up in the brain of Alzheimer's patients. Unfortunately, the underlying cause of (and involvement of amyloid plaques in) Alzheimer's disease is still the subject of much debate. This controversy became more apparent when Eli Lilly decided to abandon its anti-amyloid product solanezumab after it failed to show benefit in patients with mild Alzheimer's disease. Since solanezumab attacks the same target as aducanumab, the failure of solanezumab threw cold water on Biogen. The company is still optimistic about aducanumab's chances, though, for a number of reasons . Topline data from Biogen's phase 3 studies of aducanumab don't read out until 2018, so until then investors will have to be patient.
Acadia Pharmaceuticals
Acadia received approval for its Parkinson's disease psychosis (PDP) drug, Nuplazid, in April of last year. Since its launch, sales of the drug have been growing like a weed -- totaling $5.4 million in the third quarter of 2016. While the Parkinson's disease indication is huge (an estimated 1 million individuals in the U.S. suffer from Parkinson's and 40% suffer from PDP), an even larger market could come in the form of Alzheimer's disease psychosis (ADP). According to Acadia's internal data, an estimated 25% to 50% of Alzheimer's patients could develop ADP -- making this a potentially massive indication.
Dreams of a treatment came closer to reality late last year when the company released positive phase 2 data of Nuplazid in ADP patients. While estimates vary, Leerink believes that the expansion into ADP could double or triple potential sales estimates. Currently, with only the approved PDP indication, sales are forecast at around $1 billion by 2022.
While Nuplazid does have blockbuster potential, it also has a checkered past. Nuplazid initially failed to meet its primary endpoint of a decrease in antipsychotic activity due to a high placebo response back in 2009. In addition, although approved in PDP, the drug contains a black box warning stating, "Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death." And lastly, while Nuplazid did show a statistically significant reduction in psychosis versus placebo in its phase 2 study in ADP, the result was barely significant with a p-value of .0451. (Researchers typically look for p-values under .05.) Overall,Nuplazid's entry into the larger ADP market will require a successful phase 3 study.
The better buy?
To say that Alzheimer's disease has been a tough disease to fight would be an understatement. In fact, over 99% of drugs in the past decade have failed to demonstrate efficacy against this disease. However, it is good to know that pharmaceutical companies continue to give it all they've got. In Biogen's case, the company recently released good data from a long-term phase 1b study demonstrating the durable effects of aducanumab. However, the fact that aducanumab relies on a very similar mechanism of action as solanezumab calls into question whether Biogen is simply throwing good money after bad. Regardless, an approval for aducanumab would be transformative even for this large-cap company.
In Acadia's case, while the company does have great potential, it is important to remember that this biotech only has 1 approved drug and has had no experience bringing a product to market prior to the launch of Nuplazid. Overall, however, I believe the combination of a large total addressable market combined with expanding indications makes Acadia a better buy for the risk-tolerant investor looking to get exposure to this potentially huge market.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
David Liang has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In Acadia's case, while the company does have great potential, it is important to remember that this biotech only has 1 approved drug and has had no experience bringing a product to market prior to the launch of Nuplazid. Two candidates making noteworthy strides in this indication are Biogen (NASDAQ: BIIB) and Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia Pharmaceuticals Acadia received approval for its Parkinson's disease psychosis (PDP) drug, Nuplazid, in April of last year. | Acadia Pharmaceuticals Acadia received approval for its Parkinson's disease psychosis (PDP) drug, Nuplazid, in April of last year. Two candidates making noteworthy strides in this indication are Biogen (NASDAQ: BIIB) and Acadia Pharmaceuticals (NASDAQ: ACAD) . According to Acadia's internal data, an estimated 25% to 50% of Alzheimer's patients could develop ADP -- making this a potentially massive indication. | Acadia Pharmaceuticals Acadia received approval for its Parkinson's disease psychosis (PDP) drug, Nuplazid, in April of last year. Two candidates making noteworthy strides in this indication are Biogen (NASDAQ: BIIB) and Acadia Pharmaceuticals (NASDAQ: ACAD) . According to Acadia's internal data, an estimated 25% to 50% of Alzheimer's patients could develop ADP -- making this a potentially massive indication. | Two candidates making noteworthy strides in this indication are Biogen (NASDAQ: BIIB) and Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia Pharmaceuticals Acadia received approval for its Parkinson's disease psychosis (PDP) drug, Nuplazid, in April of last year. According to Acadia's internal data, an estimated 25% to 50% of Alzheimer's patients could develop ADP -- making this a potentially massive indication. |
36131.0 | 2017-02-02 00:00:00 UTC | Notable ETF Inflow Detected - XBI, CLVS, ACAD, UTHR | ACAD | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-clvs-acad-uthr-2017-02-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the XBI: SPDR S&P Biotech ETF, US Equities (Symbol: XBI) where we have detected an approximate $136.6 million dollar inflow -- that's a 5.3% increase week over week in outstanding units (from 39,550,000 to 41,650,000). Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the XBI: SPDR S&P Biotech ETF, US Equities (Symbol: XBI) where we have detected an approximate $136.6 million dollar inflow -- that's a 5.3% increase week over week in outstanding units (from 39,550,000 to 41,650,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. | Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the XBI: SPDR S&P Biotech ETF, US Equities (Symbol: XBI) where we have detected an approximate $136.6 million dollar inflow -- that's a 5.3% increase week over week in outstanding units (from 39,550,000 to 41,650,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. |
36132.0 | 2017-02-02 00:00:00 UTC | Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys | ACAD | https://www.nasdaq.com/articles/forget-gw-pharmaceuticals-these-2-stocks-are-better-buys-2017-02-02 | nan | nan | Britain's GW Pharmaceuticals (NASDAQ: GWPH) has certainly captured the market's imagination with its cannabidiol drug development platform. Over the past three years, its stock is up by an astounding 1200%:
GWPH data by YCharts
Although the market's glowing enthusiasm is seemingly based on the repeated clinical success of GW's experimental epilepsy treatment Epidiolex, it's probably safe to say that this high-flying stock is going to have trouble pushing much higher -- at least in the near-term. Backing this assertion, the drugmaker's shares are already trading at close to 17 times next year's projected revenue estimate, and that's assuming a successful regulatory filing for Epidiolex this year.
So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. Here's why.
This battleground stock has momentum on its side
Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. On the bull side of the debate, Nuplazid appears to be a megablockbuster in the making, with the drug's peak sales estimated to reach upwards of $2 billion.
Bears, for their part, believe that Nuplazid's outstanding safety question marks will ultimately slow its commercial uptake in PDP, and its weak Phase 2 results in Alzheimer's disease psychosis (ADP) imply that a pivotal-stage trial is largely unwarranted and perhaps a waste of resources.
Personally, I side with the bulls in this particular fight. The first reason is that Nuplazid also produced mixed results in its PDP clinical program, but eventually got the green light from the FDA.
While the drug's only mildly significant result in ADP at six weeks ( p-value = 0.0451) don't exactly inspire a whole lot of confidence, it's also important to bear in mind that these types of cognitive disorders are extremely difficult to treat. In other words, there's reason to believe that even a hint of effectiveness may be enough to get a drug on the market for this particular indication.
That's not to say that Nuplazid is destined to get a label expansion in ADP that could add another million or so patients to its target market. But I think the doom and gloom certainly needs to be weighed against the current unmet medical need and the exceedingly poor track record of experimental Alzheimer's drugs in general.
On the safety front, Nuplazid's better-than-expected commercial launch suggests that doctors are indeed interested in prescribing this novel medication for PDP and that the potential safety issues may be outweighed by its real world benefits. Long story short, I'm cautiously optimistic that Nuplazid's commercial momentum will continue unabated over the next three to four years, putting it on track to reach blockbuster status by perhaps 2021.
If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition.
Buy this biotech while it's still cheap
Shares of the rare disease specialist Sarepta Therapeutics are currently trading well below their 52-week highs at the moment because of the rough start to Exondys 51's commercial launch.
SRPT data by YCharts
According to a recent investor update, this newly launched Duchenne muscular dystrophy, or DMD, drug, indicated for around 13% of the total DMD patient population, generated only $5.4 million in sales in the fourth quarter of 2016 -- dashing investors' hopes that it would get off to a quick start.
The underlying issues are that some payers have balked at the idea of paying for a drug that hasn't proven its effectiveness in a late-stage trial, and it takes time to properly identify the exact types of patients that would benefit from Exondys 51 (i.e., exon 51 amenable patients).
As a direct result, the Street's outlook on Exondys' initial penetration rate has essentially bifurcated of late. The bullish estimate, which assumes that these coverage issues will ease as Exondys' commercial launch unfolds, suggests that the drug could haul in around $487 million in sales next year; the bearish figure, on the other hand, falls closer to a mere $66 million.
If history is any guide, though, the bullish estimate should turn out to be the more realistic figure. Drugs for rare diseases, after all, tend to show a hockey stick-like uptake due to the necessity of identifying patients via genetic testing, and the need to convince payers to cover medicines that sport jaw-dropping price tags. Exondys 51, for instance, costs a whopping $300,000 per year.
Although not without risk, I think Sarepta is a deeply undervalued growth stock based on Exondys' overall commercial opportunity, combined with the stock's steep pullback from its former highs.
10 stocks we like better than Sarepta Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Sarepta Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. This battleground stock has momentum on its side Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition. | So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. This battleground stock has momentum on its side Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition. | This battleground stock has momentum on its side Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition. | This battleground stock has momentum on its side Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition. |
36133.0 | 2017-02-01 00:00:00 UTC | Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys | ACAD | https://www.nasdaq.com/articles/forget-anavex-life-sciences-corp-these-2-biotech-stocks-are-better-buys-2017-02-01 | nan | nan | Investors are right to focus on potential Alzheimer's disease drugs because of the huge market, but Anavex Life Sciences Corp. (NASDAQ: AVXL) is an awfully long way from from the finish line with its lead candidate. Clinical-stage biotech stocks are inherently risky, but I'd like to walk you through some figures that show why Geron Corporation (NASDAQ: GERN) and its cancer drugs might make a better addition to your portfolio. If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond.
Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. Here's why.
Geron Pharmaceuticals: Advancing a contender
Anavex and Geron don't have a product to sell yet, but it looks like the latter has a much better chance of bringing its first clinical-stage drug into the commercial arena. Geron's lead candidate, imetelstat, appears to have an important advantage over the leading treatment (Jakafi) for a rare form of blood cancer known as myelofibrosis, a disorder marked by overactive blood cell production in bone marrow.
In 2011, Jakafi from Incyte earned approval to treat myelofibrosis based on observed spleen size reductions. Enlarged spleens are a key myelofibrosis symptom, but the therapy's lackluster improvement in 3-year survival rates to 70% over 61% observed in a group receiving a placebo suggests a strong contender could quickly earn a significant share of the available patient population.
In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage.
By contrast, Anavex's lead candidate's ability to slow progression of cognitive decline among Alzheimer's patients is questionable at best. So far the only clinical-efficacy data for the drug consists of a less-than-impressive change in cognitive ability test scores from baseline. Without a control group for comparison, observations to data are hardly worth getting excited about. Observed responses in patients treated with Geron's imetelstat, though, is the sort of data worth getting excited about.
Another advantage Geron has over Anavex is a deep-pocketed partner ready to fund a trial large enough to support an application. Anavex wrapped up a mid-stage study with its lead candidate, but hasn't begun a larger, more expensive late-stage trial yet. The company is open to collaboration to continue its development, but hasn't announced one yet.
Geron, on the other hand, is far less likely to delay development due to a lack of resources. It's partner, Johnson & Johnson , is awaiting more data this year from imetelstat. If mid-stage trial results fall in line with previous observations, J&J will fund a late-stage study, and possibly commercialization activities, cutting Geron checks for milestones and royalties along the way. As Geron's market cap is just $335.8 million at recent prices, success for imetelstat could lead to market-crushing gains over the long run.
Acadia Pharmaceuticals: An important expansion
If you're looking for a biotech with potential upside and a commercial-stage product, you'll want to consider the purveyor of the first drug specifically approved to treat Parkinson's disease psychosis. An estimated 40% of an estimated 1 million U.S. Parkinson's disease patients suffer delusions and hallucinations, and treating these symptoms is a huge burden on families and healthcare budgets.
Acadia's Nuplazid generated $5.2 million in sales during its first full quarter on pharmacy shelves, and is expected to climb much higher with it having the Parkinson's disease indication essentially to itself. Acadia's recent market cap of around $3.85 billion suggests a great deal of success for the drug is already priced in, but a possible expansion to the much larger Alzheimer's disease (AD) indication could send the stock higher still.
So how is Acadia faring in its quest for expanding Nuplazid's label? Well, Acadia's shares slid recently after top-line data barely squeaked by with a statistically significant reduction in psychosis test scores among AD patients at six weeks. While the slim success is concerning, it's also important to note Nuplazid wasn't associated with impaired-cognition side effects. Sadly, anti-psychotics currently available for Alzheimer's patients often exacerbate the disease's main symptom, cognitive decline, which cold give Nuplazid an advantage..
If trials for AD psychosis don't clear a path for expansion to this enormous population, an ongoing mid-stage trial for AD agitation could do the job. AD agitation affects perhaps half of America's 5.4 million AD patients, and often leads to costly nursing-home placement. Given the lack of available treatment options for AD psychosis or agitation, Nuplazid's lack of adverse cognitive side effects could make it popular enough to generate more than $2 billion in annual sales with an expansion to such a large population.
Beyond Parkinson's and Alzheimer's, Acadia also has a chance to expand Nuplazid to the large schizophrenia indication. Schizophrenia affects about 1% of the the adult population in the U.S., and perhaps 30% suffer an inadequate response to existing antipsychotics. The company is running a late-stage trial that could support an application for the medicine to become the first treatment for this group as well.
Further out, a mid-stage trial will shed more light on Nuplazid's potential as an additional treatment for a majority of America's 16 million adults with major depressive disorder inadequately managed by their existing therapies.
Of course, if Nuplazid remains locked into Parkinson's disease without a chance of expanding to any of these additional indications, investors would probably suffer losses. Unlike Anavex, though, Acadia has already proved it can advance a drug from clinical to commercial stage. Label-expansion approvals are far from certain, but several trials that could lead to key expansions under way give the stock a much better chance of beating the broad market in the long run.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Cory Renauer owns shares of Johnson and Johnson, which The Motley Fool recommends. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia's recent market cap of around $3.85 billion suggests a great deal of success for the drug is already priced in, but a possible expansion to the much larger Alzheimer's disease (AD) indication could send the stock higher still. If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond. Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. | If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond. Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. Acadia Pharmaceuticals: An important expansion If you're looking for a biotech with potential upside and a commercial-stage product, you'll want to consider the purveyor of the first drug specifically approved to treat Parkinson's disease psychosis. | Acadia's recent market cap of around $3.85 billion suggests a great deal of success for the drug is already priced in, but a possible expansion to the much larger Alzheimer's disease (AD) indication could send the stock higher still. If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond. Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. | Beyond Parkinson's and Alzheimer's, Acadia also has a chance to expand Nuplazid to the large schizophrenia indication. If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond. Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. |
36134.0 | 2017-02-01 00:00:00 UTC | 3 Big Mergers & Acquisitions That We Could See in 2017 | ACAD | https://www.nasdaq.com/articles/3-big-mergers-acquisitions-that-we-could-see-in-2017-2017-02-01 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
It looks like 2017 is likely to be a big year for mergers & acquisitions. Several factors have come together over the past few months that have made the coming year ripe for consolidation. Industries like biotechnology and retail were beaten down in 2016, and that has opened the door for a flurry of activity within those sectors.
Not only that, but the Donald Trump administration could also provide a boost for M&A activity. Trump's "America first" focus, as well as his plans to loosen regulations weighing on U.S. corporations, may make it easier for companies to merge.
One of President Trump's campaign promises was to reduce the tax burden that U.S. companies face. A lower corporate tax rate means U.S. firms will enjoy an influx of cash, which could in turn give them the means they need to invest in growth via mergers & acquisitions.
The Top 10 Dow Dividend Stocks for February
Here's a look at three firms that are likely to see some M&A action in the year ahead.
Possible Mergers & Acquisitions: Netflix (NFLX)
Source: Vivian D Nguyen via Flickr (Modified)
Streaming service Netflix Inc. (NASDAQ: NFLX ) has seen its share price soar over the past two years as the firm expanded its reach across the globe. NFLX has been able to tap into popular culture and create original series that appeal to the masses. The firm has also made its way overseas and proven that online streaming services are gaining traction across the globe.
As one of the most popular names in the industry, Netflix's expertise makes it an appealing takeover target for tech firms that need to add streaming to their business model. While companies like Walt Disney Co (NYSE: DIS ) or Alphabet Inc (NASDAQ: GOOG , NASDAQ: GOOGL ) might be interested in snapping NFLX up, it's Apple Inc. (NASDAQ: AAPL ) that has the most potential as a buyer.
Apple not only has the cash necessary to make such a large acquisition, but the company stands to gain quite a lot by owning NFLX.
Netflix has done for movies and TV what Apple did for music back in the early 2000's. However, in recent months AAPL has taken a lot of flak for being unable to innovate. By adding NFLX stock's streaming business to its repertoire, Apple would put itself at the forefront of the entertainment business.
Possible Mergers & Acquisitions: Barnes & Nobel (BKS)
Source: Mike Kalasnik via Flickr (modified)
Brick-and-mortar bookstore Barnes & Nobel, Inc. (NYSE: BKS ) has been struggling under the weight of online retailers, namely Amazon.com, Inc. (NASDAQ: AMZN ), and now the company's depressed stock price makes it an appealing takeover target.
One firm that is likely to be interested in adding BKS to its business is the company that single-handedly pressured the bookstore into this position- Amazon. AMZN has recently made a push into having its own physical bookstores , and Barnes and Nobel's locations could be easily converted into Amazon locations with very few expensive upgrades.
7 Stocks to Buy That Could Double by 2018
Not only has Barnes & Noble followed in Amazon's footsteps by offering an electronic e-reader, but BKS locations have a designated space in each store where the e-readers are sold. That would make it relatively easy for Amazon to rebrand the stores and sell their own Kindle devices.
Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD)
Source: Shutterstock
The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. Investors can expect to see a flurry of M&A activity in this space throughout the coming year as bigger firms look to beef up their drug portfolios by acquiring their smaller, more specialized peers.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. The company has already been the subject of takeover rumors over the past few months, and 2017 looks like the year it might happen.
One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease. However, what's more promising is the fact that Nuplazid may also gain approval to be used for other mental illnesses, including Alzheimer's disease - which could become a major money maker.
It's unclear which firm will strike first, but rumor has it that everyone from Pfizer Inc. (NYSE: PFE ) to Biogen Inc (NASDAQ: BIIB ) to Gilead Sciences, Inc. (NASDAQ: GILD ) is interested in buying Acadia.
As of this writing, Laura Hoy was long AAPL and NFLX stock.
The post 3 Big Mergers & Acquisitions That We Could See in 2017 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD) Source: Shutterstock The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease. Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. | Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD) Source: Shutterstock The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease. | Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD) Source: Shutterstock The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease. | Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD) Source: Shutterstock The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease. |
36135.0 | 2017-01-30 00:00:00 UTC | How Risky Is Acadia Pharmaceuticals Stock? | ACAD | https://www.nasdaq.com/articles/how-risky-acadia-pharmaceuticals-stock-2017-01-30 | nan | nan | Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. The biotech won approval last year for its lead product, Nuplazid, in treating Parkinson's disease psychosis. Acadia's stock is up more than 30% over the past 12 months. Additional studies are under way that could expand the number of indications for Nuplazid. But plenty of uncertainty remains. Just how risky is Acadia's stock right now?
There's no such thing as a free launch
Acadia received the green light from the FDA for Nuplazid on April 29. The company kicked off the commercial launch of the drug just over a month later. It had a national sales force of over 130 representatives. Nuplazid is the first drug to receive approval for Parkinson's disease psychosis, so there wasn't any real competition to go against.
So where do things stand? As of Sept. 30, sales for Nuplazid totaled $5.4 million, most of which was made in the third quarter. During that quarter, though, Acadia spent over $50 million on selling, general, and administrative expenses. There's clearly a long way to go. In fact, Acadia's management team acknowledges that the company will continue to lose money for at least the next few years.
Launching a new drug isn't free -- and it isn't easy. That's especially true when the drug carries a black-box warning that says elderly people with dementia-related psychosis taking antipsychotic drugs are at an increased risk of death, as Nuplazid does.
A successful launch is even more challenging the first time around for a company. This is Acadia's first approved drug. The biotech doesn't have experience with rolling out a new product, which increases the risk that the launch might not successful.
Trials -- and maybe troubles
Acadia's market cap currently stands at $3.8 billion. There are some high expectations for Nuplazid baked into that valuation. To achieve those expectations, Acadia needs to win approval for additional indications.
The company is exploring the potential for Nuplazid in treating five other indications. A late-stage clinical trial is under way for evaluating the drug as an adjunct treatment of schizophrenia in patients with an inadequate response to current antipsychotic therapy. Another mid-stage study began in November for Nuplazid as an adjunct treatment in patients with negative symptoms of schizophrenia.
Acadia is also advancing to a late-stage clinical trial evaluating Nuplazid in treating Alzheimer's disease psychosis. This could be a huge opportunity for the company if it can ultimately win approval for the indication.
The company reported positive results from a mid-stage study focusing on Alzheimer's disease psychosis. If you looked at the details from this clinical trial, though, there were reasons for concern. Reduction of psychosis was observed in patients after six weeks of taking Nuplazid, but the level of reduction was just below the point of being considered statistically insignificant.
It's possible that the larger late-stage study will clearly show Nuplazid to be effective in treating Alzheimer's disease psychosis. However, there is significant risk for Acadia with its clinical trials. A pipeline setback would likely take a big bite out of the company's stock price.
Great potential
Acadia definitely faces considerable risks with the commercial launch of Nuplazid and the possibilities for clinical study disappointments. However, the biotech also still has tremendous potential.
Although sales for Nuplazid didn't soar right out of the gate, part of the problem related to Acadia's providing samples of the drug to physicians earlier in 2016. That should be only a temporary issue. Nuplazid could still reach peak annual sales of up to $1 billion for the Parkinson's disease psychosis indication. Additional approvals would drive that number even higher.
There's also a decent chance that Acadia attracts interest from larger companies looking to make an acquisition. Several biopharmaceutical companies could be good fits. I'd put Eli Lilly (NYSE: LLY) high on the list.
Lilly experienced a big setback with the late-stage clinical study failure for solanezumab in treating Alzheimer's disease. Despite this major disappointment, the big drugmaker continues to invest in developing drugs targeting the disease. Lilly also has early-stage programs focused on dementia and schizophrenia.
Nuplazid would be a solid addition to Lilly's neuroscience portfolio. The company could also bring plenty of experience to bear in marketing the drug. If Lilly is looking to make a significant acquisition in the near future, I wouldn't be surprised to see Acadia in its cross-hairs.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Great potential Acadia definitely faces considerable risks with the commercial launch of Nuplazid and the possibilities for clinical study disappointments. Although sales for Nuplazid didn't soar right out of the gate, part of the problem related to Acadia's providing samples of the drug to physicians earlier in 2016. Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. | Acadia is also advancing to a late-stage clinical trial evaluating Nuplazid in treating Alzheimer's disease psychosis. Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. Acadia's stock is up more than 30% over the past 12 months. | Acadia is also advancing to a late-stage clinical trial evaluating Nuplazid in treating Alzheimer's disease psychosis. Great potential Acadia definitely faces considerable risks with the commercial launch of Nuplazid and the possibilities for clinical study disappointments. Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. | This is Acadia's first approved drug. Acadia is also advancing to a late-stage clinical trial evaluating Nuplazid in treating Alzheimer's disease psychosis. Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. |
36136.0 | 2017-01-22 00:00:00 UTC | Top Biotech Stocks to Buy in 2017 | ACAD | https://www.nasdaq.com/articles/top-biotech-stocks-buy-2017-2017-01-22 | nan | nan | The past 18 months haven't been very pleasant for biotech investors. The SPDR S&P Biotech ETF (NYSEMKT: XBI) has fallen nearly 30% from its all-time highs set back in the summer of 2015. Many individual biotech stocks have performed far worse.
One bright side to all of that selling is that a handful of high-quality biotech stocks are currently trading for attractive prices. With that in mind, here's a look at three biotech stocks that I think are well positioned to outperform in the new year.
The low-risk play
Biotech giant Celgene (NASDAQ: CELG) may be down from its 2015 high, but it has held up much better than its large-cap peers. That's owed to the company's ability to consistently put up great numbers .
Celgene recently provided investors with a sneak peak at its fourth-quarter results that suggest that trend remains intact. Sales grew by 18% thanks to strong numbers from drugs such as Revlimid, Pomalyst/Imnovid, and Otezla. Earnings grew by an even stronger 21% thanks to the company's healthy appetite for buying back stock and its unparalleled ability to raise margins.
The results were encouraging enough for management to reaffirm its 2020 goals of $21 billion in revenue and EPS of at least $13. Those figures represent compound annual growth of 17% and 22%. With shares trading around 16 times forward earnings, Celgene offers investors a lower-risk way to buy into the crazy world of biotech.
More risk, but more upside
Regeneron Pharmaceuticals (NASDAQ: REGN) is a former biotech darling that has gone through a bit of a rough patch. The company announced two majorclinical setbacks in 2016 that caused investors concerns. To add insult to injury, the FDA also issued a surprise rejection for its rheumatoid arthritis drug candidate sarilumab, over manufacturing concerns. If all of that wasn't bad enough, a U.S. district court recently issued an injunction that threatens to inhibit the company from selling its hopeful blockbuster cholesterol-reducer Praluent in the United States.
Given the slew of negativity, it is easy to understand why shares have been on the decline. Thankfully, shareholders like me have a few reasons to believe that things are looking up in 2017.
First, Regeneron and Sanofi will hear from the FDA in March about their new eczema drug candidate, Dupixent. This drug is believed to hold blockbuster potential, so an approval would go a long way toward rebuilding investor confidence. Second, the FDA has recently cleared Sanofi's facility in France that caused the initial rejection of sarilumab. That means that a resubmission will be on the way soon. Finally, Eylea continues to put up impressive growth numbers in the U.S. and abroad, which bodes well for the company's near-term earnings growth. When added together, these positives make Regeneron's forward P/E of 26 look quite reasonable.
Higher risk, but multi-bagger potential
The final stock on today's list is Acadia Pharmaceuticals (NASDAQ: ACAD) . This company recently converted into a commercial-stage business with the launch of Nuplazid, the first and only FDA-approved treatment for Parkinson's disease psychosis, which affects roughly 400,000 patients in the U.S.
Image source: Acadia Pharmaceuticals.
While it's still too early to tell if Nuplazid will be a hit, the early signs are quite encouraging. Sales blew past analysts' expectations in its first full quarter on the market, which hints that there is a lot of pent-up demand for the drug.
Looking ahead, 2017 promises to be a banner year for the company. Sales are expected to grow by more than 500%, and investors can look forward to data readouts from a handful of studies that are testing Nuplazid as a potential treatment for diseases such as schizophrenia, depression, and Alzheimer's disease. If Nuplazid can ultimately snag a label expansion claim in one of these other disease states, then its peak sales could get big in a hurry.
While Acadia is a high-risk bet since it's still burning through capital, the company looks well positioned to surprise to the upside in 2017. With shares down 37% from their all-time high, it's a fine time to consider getting in.
10 stocks we like better than Celgene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Brian Feroldi owns shares of Celgene and Regeneron Pharmaceuticals.Like this article? Follow him on Twitter where he goes by the handle@BrianFeroldi or connect with him onLinkedInto see more articles like this.
The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Higher risk, but multi-bagger potential The final stock on today's list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Image source: Acadia Pharmaceuticals. While Acadia is a high-risk bet since it's still burning through capital, the company looks well positioned to surprise to the upside in 2017. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Higher risk, but multi-bagger potential The final stock on today's list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Image source: Acadia Pharmaceuticals. | Higher risk, but multi-bagger potential The final stock on today's list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Image source: Acadia Pharmaceuticals. While Acadia is a high-risk bet since it's still burning through capital, the company looks well positioned to surprise to the upside in 2017. | Higher risk, but multi-bagger potential The final stock on today's list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Image source: Acadia Pharmaceuticals. While Acadia is a high-risk bet since it's still burning through capital, the company looks well positioned to surprise to the upside in 2017. |
36137.0 | 2017-01-19 00:00:00 UTC | Surprising Analyst 12-Month Target For FBT | ACAD | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-fbt-2017-01-19 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $118.60 per unit.
With FBT trading at a recent price near $95.05 per unit, that means that analysts see 24.78% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Although JUNO has traded at a recent price of $20.33/share, the average analyst target is 83.84% higher at $37.38/share. Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH:
Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH: Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. | Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH: Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH: Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH: Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF. |
36138.0 | 2017-01-13 00:00:00 UTC | Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016 | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-stock-slipped-19-2016-2017-01-13 | nan | nan | What happened
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . Clinical trials with its lead drug, Nuplazid, gave mixed signals regarding an important label expansion.
ACAD data by YCharts
So what
Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis. Last April, it became the first drug to receive a green light from the FDA for this indication, but the $5.37 million in revenue the drug has recorded since its launch and the end of September didn't come close to stopping the company from bleeding money.
An approval for Alzheimer's disease related psychosis would expand Nuplazid's addressable patient base by perhaps 1 million patients or more. Unfortunately, the stock has been on a roller coaster while analysts argue about the significance of data presented from a trial with Nuplazid in Alzheimer's patients.
In a 181-patient study, patients receiving Nuplazid produced psychosis test scores better than those given a placebo. Unfortunately, the improvement was just strong enough to be considered statistically significant at six weeks, and at 12 weeks the benefit decreased to an insignificant level.
Now what
In the first nine months of 2016, Acadia Pharmaceuticals lost $194.6 million, and advancing Nuplazid into a large enough Alzheimer's disease trial to support an FDA application would probably increase its cash burn rate, with a chance it may not succeed.
With $588.9 million in cash on its books at the end of September, the company probably won't need to visit the equity tap again to keep operations humming along. It's expected to generate about $86 million in revenue this year from Nuplazid in the Parkinson's disease indication.
Investors will want to keep an eye on Nuplazid sales and look for more concrete data on its benefits in Alzheimer's disease. The drug is also being investigated for a benefit in patients with major depressive disorder and schizophrenia, making its peak potential hard to estimate. Nuplazid could top out with annual sales of more than $2 billion, but it's still too early to be certain.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Cory Renauer has no position in any stocks mentioned. You can follow Cory on Twitter @coryrenauer or LinkedIn for more biotech investing insight.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . ACAD data by YCharts So what Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis. Now what In the first nine months of 2016, Acadia Pharmaceuticals lost $194.6 million, and advancing Nuplazid into a large enough Alzheimer's disease trial to support an FDA application would probably increase its cash burn rate, with a chance it may not succeed. | What happened Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . ACAD data by YCharts So what Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis. Now what In the first nine months of 2016, Acadia Pharmaceuticals lost $194.6 million, and advancing Nuplazid into a large enough Alzheimer's disease trial to support an FDA application would probably increase its cash burn rate, with a chance it may not succeed. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . ACAD data by YCharts So what Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis. | What happened Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . ACAD data by YCharts So what Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis. Now what In the first nine months of 2016, Acadia Pharmaceuticals lost $194.6 million, and advancing Nuplazid into a large enough Alzheimer's disease trial to support an FDA application would probably increase its cash burn rate, with a chance it may not succeed. |
36139.0 | 2017-01-07 00:00:00 UTC | Top Stocks to Buy in 2017 | ACAD | https://www.nasdaq.com/articles/top-stocks-buy-2017-2017-01-07 | nan | nan | Obamacare uncertainty and pushback on drug prices sent shockwaves through the healthcare sector in 2016. Will 2017 be a better year for investors? Washington's passage of the 21st Century Cures Act, potential insurance reform, and key data on game-changing drugs could make or break returns next year.
In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell kick off the show by analyzing Acadia Pharmaceuticals '(NASDAQ: ACAD) intriguing Alzheimer's disease drug. Then, the duo let investors in on their top healthcare stock picks for 2017, including stocks that could benefit from the 21st Century Cures Act. Kristine and Todd's shopping list includes top names like Celgene Corporation (NASDAQ: CELG) , UnitedHealth Group (NYSE: UNH) , and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) , but they also like some surprising picks, such as GW Pharmaceuticals plc (NASDAQ: GWPH) .
Tune in to find out if these stocks are right for your portfolio.
A full transcript follows the video.
10 stocks we like better than Celgene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
This podcast was recorded on Dec. 21, 2016.
Kristine Harjes: Welcome to Industry Focus , the podcast that dives into a different sector of the stock market every day. Today is Dec. 21, and I'm your Healthcare show host, Kristine Harjes. Next week, we're going to be replaying our favorite episodes from last year, so for the last time in 2016, I am welcoming our regular healthcare contributor, Todd Campbell, to the show, phoning in. Hi, Todd!
Todd Campbell: Hi! Happy holidays to you and everyone who's tuning in today.
Harjes: Thank you very much, and happy holidays to you and your family as well.
Campbell: Thanks! I tried to find an ugly holiday sweater to wear today, but unfortunately, all I could find was a red one, so I went with that.
Harjes: That counts for something, it's festive. I'm over here in my black and white checkers, maybe not as festive. Just wait until next week, though. Anyhow, we've been pretty news-y on our Healthcare show lately. I figured, in keeping with the trend, the first part of our show will be something interesting from the healthcare news scene in the past week. After that, we'll move on to a listener question about the 21st Century Cures Act, and also some stock picks for 2017. First things first: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday.
Campbell: Really interesting data. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. I don't think this is a stock that we have talked about in the past on the show, Kristine, do you?
Harjes: I don't believe we have ever talked about them. The deal with them is, they have this one drug, it's called Nuplazid. It is already approved for Parkinson's disease psychosis. Now, they're testing it in Alzheimer's disease psychosis.
Campbell: Right. This year, they just launched this drug, Nuplazid, for the treatment of hallucinations and delusions within Parkinson's patients. It's estimated that about 40% of all Parkinson's patients suffer from psychosis that this drug can address. The company is researching this drug across a number of different similar indications where they think they may also be able to help. One of those indications, obviously, is Alzheimer's disease, where they've been evaluating the drug in treating Alzheimer's disease psychosis, which is estimated to affect between 25% to 50% of the Alzheimer's disease population.
Harjes: Correct me if I'm wrong, but that's a much larger number of people total.
Campbell: Yeah. You go from 40% of a million with Parkinson's, so that's 400,000, to even 25% of the 5 million Alzheimer's disease patients, that's an extra million. So, you're talking about potentially going from being able to address 400,000 people to being able to address 1.5 million.
Harjes: So, the news that came out yesterday was some data from phase 2, saying that they had success, and six weeks into the trial there was a statistical benefit. The stock was up 12% on the news.
Campbell: Yeah, the stock was slated to open pre-market up as much as 40%.
Harjes: Wow! I missed that!
Campbell: Yeah, don't ever trust pre-market or after-market, they're illiquid market quotes, and they're not going to tell you anything other than, maybe, direction. They'll tell you if it's indicated up or down. But I wouldn't count on up 40% or down 40% read.
Harjes: That's crazy.
Campbell: Yeah. Once it opened up, the shares traded pretty volitively. It got down to a single-digit gain, then went back up to a double-digit gain by the end of the day. I think the reason for all of that is that first of all we've been desperate for new advances in Alzheimer's disease treatment. There's not a lot of good treatments out there. The only things we have out there treat the symptoms, they don't curb or crimp the disease.
Harjes: Yeah. Every stock working in this space has been extremely volatile, trading emotionally up, down, every which way on Alzheimer's news.
Campbell: Right. Big disclaimer, even the data were giving you today is phase 2 data. If any indication has shown that phase 2 data does not hold a lot of water, it's Alzheimer's disease. So you have to take this with a big grain of salt. But there's another reason that I want investors to take this with a big grain of salt.
Harjes: Yes there is.
Campbell: What was that, Kristine?
Harjes: Yes there is, I was going to say it if you weren't going to, lay it out.
Campbell: Well, I don't know if it's the same thing you're going to mention, but I wasn't thrilled with the P value.
Harjes: Yep. (laughs) That's where I was going, as well. The P value here for the six weeks was 0.045, which, reminder about P values, it's a statistical measure. Basically, you want to see less than 0.05. We had 0.045, that's green light, in the clear, you're fine. But it's kind of close to that threshold of 0.05.
Campbell: Especially with a small patient population. I mean, I don't want to call it tiny --
Harjes: It's 181.
Campbell: Yeah. But compared to how big this indication is, and how big previous Alzheimer's disease studies have been, this doesn't feel like a lot of patients to me.
Harjes: Right. And some other things to note here is that in the Parkinson's disease trial, you had a P value of 0.001. That is way, way below the 0.05 that is the traditional threshold.
Campbell: Right. That's the gold standard number. That's what you would want to have.
Harjes: Absolutely. The other detail that's worth mentioning, I mentioned this data was from six weeks -- when you look at the 12-week numbers, the treatment group that was receiving this drug, their numbers held steady. But the placebo group experienced a placebo effect that brought them in line with the treatment group, essentially closing the delta between the two groups, and then eliminating even that 0.05.
Campbell: Right, so you look at this, you have a P value of 0.045, you have a benefit that loses its statistical significance between the six week and 12 week mark. What does that mean? The approval in Parkinson's disease was based on six week data. So you could make an argument that six week is fine. The other thing I'm curious about is the choice of the study or the scale or the score that they used for evaluating these patients. It was a nursing home score, because all of these were nursing home patients. That isn't necessarily one that you see typically used in psychology trials or Alzheimer's disease trials. They were asked about it on the conference call, and they did say another more common scoring system that was used didn't show a significant benefit. So, there's a lot of question marks here that make me say: Rein in some enthusiasm and let this thing play out, because we have seen, way too often, investors get excited about Alzheimer's disease drugs that just do not pan out in large studies.
Harjes: Yep, it's a lesson that watchers of this space are learning again and again lately. So, keep an eye out for Acadia. But we'll move on from them for now. Before we do, I want to let everybody know that The Motley Fool is now accepting applications for their summer internships. If you or somebody that you know is looking to spend the summer at a company that is consistently rated one of the best places to work in the whole country, careers.fool.com is the URL that you need to know. I personally started my career here as an intern, so I can attest, it's an amazing program. Again, if you're interested or you know somebody that might be, the posting is at careers.fool.com.
Without further ado, the next segment of our show is inspired by a listener question that came in through Twitter. If you guys aren't already following us, our handle is @MFIndustryFocus. This question comes from Harris Arshad. He asks us, if we were to create our own ETF based on the 21st Century Cures Act, what would be included? There's some background necessary before we dive in and actually answer this question. Todd, do you want to give an elevator pitch? We probably need to describe both the Cures Act really quickly, and also what an ETF is.
Campbell: I'll start with the Cures Act. We'll keep it very high level here. The Cures Act was passed by Congress and signed by the president. What it's designed to do is to reduce the regulatory burden on drug and medical device discovery and development, to increase the speed of reviewing those products that have been researched through the FDA, and to get them into patients' hands more quickly. So, they're doing that through a lot of various different carrots, including billions of dollars of additional spending that they're going to be sending to both the National Institute of Health and the FDA.
Harjes: And if you're curious about more, we did an entire half of an episode on the 7th of December. If you missed that episode, be sure to go back and check it out. Meanwhile, the second piece of background necessary for answering this question is: What is an ETF? An ETF is an exchange-traded fund. It's essentially a basket of stocks that trade for a single price. It's kind of similar to a mutual fund, but instead of having its value determined by the underlying assets once per day like a mutual fund does, an ETF is traded like a common stock, so its price will go up and down throughout the day. Basically, all you need to know if you're not super familiar with ETFs is, it's a handful of stocks that we're looking at here.
Campbell: Right. We have plenty of coverage on The Motley Fool's website if anybody is interested in looking more into different ETFs. It was a fascinating question to me, and it really got me thinking about who's going to benefit most, potentially, from the Cures Act.
Harjes: Yeah, absolutely. For me, the first one that came to mind were drugmakers. I'm not going to pick every single drugmaker, but I would pick a couple of them to throw into this basket. One that I would throw out there is BioMarin . This is a company that's focused on rare-disease drugs. One of the things that came up in the Cures Act is that now, the FDA is allowed to consider real-world evidence about a drug's efficacy. So, outside of trials, do we see this drug working? And that could lead to expedited approval, especially for patients with an unmet need. So, your patients that are looking at receiving rare-disease drugs. So, I could definitely see them benefiting from this act.
Campbell: I totally agree with you. I'm actually going to cheat with one name that I would like to include in there. It's going to be an ETF of ETFs. I think people should look at the medical device ETF, the iShares Medical Device ETF -- symbol is IHI -- and that's because one of the most vocal lobbyists involved in creating this act was the medical device lobby. There are lots of different things in this act that help to increase everything from breakthrough designation to the ability to use new devices in more rare diseases. There's a lot of goodies in this act that could help prop up medical device stocks. If you wanted one in particular, I guess Medtronic is kind of the grand-daddy of medical devices.
Harjes: If you think we're cheating by choosing the IHI, then the biggest holding -- this is a guess, but I think it's a pretty strong guess -- is Medtronic.
Campbell: It is. Medtronic is No. 1 at 12%. Abbott Labs at 7.7%, and Thermo Fisher at 7.7%.
Harjes: Yeah, that sounds right. So at Medtronic, they make cardiac devices, diabetes devices, and more. They're a huge company. They're very diversified. They're a Dividend Aristocrat. If you're only looking for one medical device company, that would be my pick.
Campbell: Yep. And if you want to go with a bigger basket, just go with the IHI.
Harjes: Indeed. Another company that I'll throw into our broader ETF is Johnson & Johnson . That's because it has devices and it also has drugs, so you're getting two for one there.
Campbell: Yeah, that's a good pick, and it's a Goliath within both of those areas. I guess I would toss in the ring Biogen , because Biogen is doing a tremendous amount of research and development on neurodegenerative diseases like Alzheimer's and Parkinson's disease. Specifically in the Act, there's a lot of money that's being set aside for the Brain Initiative, and also for the Precision Medicine Initiative, both of which could increase the number of drugs that end up in the clinic targeting cognitive decline.
Harjes: Right. There's a lot of money in here going toward those initiatives, which are trying to harness the power of data to create personalized treatments. Basically, what precision medicine is doing is taking into account the individual variability in your environment and your lifestyle and your genes. You can even see there some genetic companies getting into the mix. Maybe something like an Illumina that does gene sequencing.
Campbell: Absolutely. And they're saying one of the biggest advances, potentially, in Alzheimer's research could come from deep sequencing, which is something relatively new. We have finally gotten the technology now to really dive even deeper than we ever have before into the genome. Perhaps, in doing that, we'll find some more of these common threads that connect different patients who are suffering from this devastating disease.
Harjes: Right. So, thanks again to Harris Arshad for writing in to Twitter and asking us that great question. We were actually inspired by the question to also put together a 2017 healthcare ETF, with a handful of stocks across all sorts of risk spectrums that we thought would be great heading into the new year. Do you want to kick us off with a least-risky pick for the ETF?
Campbell: Yeah! I thought it would be fun and maybe kind of helpful for listeners to break it into three groups: less risky, more risky, and most risky. Because, we know, no matter what, when we're talking about stocks, there's going to be risk. No one has a crystal ball. I went through, and for my least risky pick of 2017, I settled on UnitedHealth, which is the largest U.S. health insurer. The reason that I picked UnitedHealth is because of a few different reasons. One, they backed away significantly from the Obamacare exchanges after losing hundreds of millions of dollars in providing those plans to patients. They will not have that drag on their earnings in 2017. And, following the election of Donald Trump and the potential repeal of Obamacare, to me, it feels like it's going to be less of an adjustment, since they were already planning for that to wind down. It's a very profitable company. They make a lot of money. Actually, over the course of the next year or so, industry watchers think they could earn $9.50 per share. That's up from $9.14 30 days ago.
Harjes: Going into 2017, the biggest thing to watch for the insurers is going to be Obamacare, what's going to happen with Obamacare when Trump comes into office. I think, looking at all the moving pieces there, you will mostly, on net, see a benefit to insurers if Obamacare is rolled back. One place that I would point out to be a little bit skeptical of is if Medicaid shrinks. Medicaid is not super important for UnitedHealth, but it is a quickly growing segment for them. So, if that were to go away, it would be a little bit of a hit on them. But, then again, like I said, I think the end of Obamacare would ultimately be a good thing for insurers, depending on what it's replaced with, of course. With that, I actually would push back a little bit on UNH being the less-risky category, just because of that uncertainty. This is a stock that's up 37% in 2016. It's trading at a premium valuation. I like the stock a lot; I'm not sure I would label it as least risky. Does that make sense?
Campbell: Yeah, I totally get that. That's what makes this show great, sometimes we disagree! And who knows? There is risk associated with this stock and the insurers broadly. You make a great point on Medicaid. Ultimately, I think shares could easily be trading at a P/E (price/earnings ratio) of 20X on trailing earnings. If they can deliver the $9, then you're talking about a share price of about $180 at some point next year, which would be a nice gain from where we are today. The proof will be in the pudding. Will they be able to deliver the kind of earnings growth that everybody wants them to deliver?
Harjes: Yep, all great points. I also picked my own for the least-risky category. Here, I picked CVS, the pharmacy retailer that you all know and love. I think they have a demographic tailwind coming on for them. You have an aging population, that means more chronic diseases, so, more prescription sales, more people coming into their Minute Clinics. This is the second-largest pharmacy, the second-largest pharmacy benefits manager [PBM] in the United States. They are also the largest long-term care and specialty pharmacy. This is just a huge diversified business. They have a 2.13% dividend. I don't think they have a ton of regulatory risk. If anything, I actually think that regulators will be happy with CVS because they are working to drive down the cost of healthcare through their PBM division, which is the majority of their business. What do you think, Todd?
Campbell: There's no question that pricing remains a big issue. Insurers want lower prices. As long as CVS is helping them deliver that, it's a very intriguing stock.
Harjes: Right. And they're down pretty substantially. They are down 18% this year, mostly due to competitive pressure. So, I think they are a pretty low risk pick for 2017. Let's move on to our middle category, the slightly riskier category. What do you have for me?
Campbell: I love Celgene. It's a stock we've talked a lot about on the show before, and will probably talk a lot about again. It's one of the biggest biotechs out there. They have a huge presence in cancer, specifically multiple myeloma, and they have a tremendous number of different collaborations and pipeline candidates that are going to be rolling out data over the course of 2017 and 2018 that can move this stock higher. Given the fact that they're targeting a disease that requires treatment, they've escaped some of the pushback on pricing that maybe others have endured more of, so they're OK on that front. There are very few biotech companies out there that have offered up guidance from 2017 to 2020. Celgene is forecasting pretty remarkable top- and bottom-line growth. If they can hit their internal forecasts, I think that investors will be rewarded.
Harjes: Right. You hit on great points. Two of my favorite parts of Celgene, as you mentioned, their collaboration. This is just a brilliant strategy on their part. Pay a little bit of money to have, potentially, huge upside and minimize your downside. That's just smart right there -- it's smart business. The other thing is their outlook. Projecting to 2020, as you said, is crazy in the biotech world. They're forecasting an EPS of at least $13 in 2020. That's pretty fantastic. And management has shown in the past that they are pretty responsible with their estimates. I think that's a good pick.
Campbell: Yeah. And one thing that people will want to watch, because this could really affect how risky the stock is next year, is they're supposed to roll out some data on Ozanimod and multiple sclerosis in the first half of the year. If that data is bad, obviously, it will be bad news for this stock.
Harjes: Right. One more pick in the middle category, your riskier category, is Regeneron. The reason that I pick this one is they have got 2017 catalysts galore. They have their new cholesterol-lowering drug, Praluent, is set to release cardiovascular data which could potentially justify its kind of high price tag of $14,600, and could potentially turbocharge pretty lackluster -- thus far -- sales. They also have a PDUFA date coming up in March for a drug called Dupixent. This is for a severe form of eczema. They have a resubmission of another drug that had previously been turned down by the FDA in October due to manufacturing issues. They think they've figured out the manufacturing issues and should be able to get the green light now. They're also another stock that's entering 2017 with a depressed price, they're down 33% since a year ago.
Campbell: You're going with these value-oriented growth stocks, I see.
Harjes: Yeah, I am. Actually, all three of my picks are down quite a bit this year. I'll use that to kick right into my pick for the most risky stock. This is a company called Cara . They are down 45% year to date. That is a tough pill to swallow. This is a company that IPO'd in February of 2014, and they're down 11% since their IPO, despite a lot of pipeline progress. This is, essentially, a one-trick pony. Again, they have the 2017 catalysts coming up. The drug that they're making is called CR845. Essentially what makes this intriguing is, it's an opioid pain medication, but it doesn't have the side effects of typical opioids, meaning it's not addictive. If you've been reading health news lately, you know this is a humongous problem in the United States, opioid addiction. They are looking to find a drug that can cure the pain without having those potentially negative side effects. So far, the drug has cleared a ton of trials. They're looking at it in post-operative pain. They're also looking at it in a chronic skin itching condition, as well as chronic pain. The latter thing there is an enormous indication, 100 million prescriptions written in the United States every single year for chronic pain. They should be getting data out in that indication in the first half of next year. They'll also be getting data in the skin itching condition trial, and also in post-op pain by the end of 2017. Definitely a high-risk, high-reward stock to watch.
Campbell: Yeah, Kristine, there's definitely a major need for new drugs that can work the way that opioids do, or, deliver the efficacy that opioids do, without that addiction. That's, I'd say, the main connection between my most risky pick and your most risky pick there is that we both targeted clinical-stage companies that have the potential to meaningfully change a big blockbuster indication.
Harjes: Right. That's why they're the riskiest picks, but they're also still picks.
Campbell: Absolutely. In my view, the most risky stock to consider in 2017 is going to be GW Pharmaceuticals. We've talked about this stock on the show before. They're working on a marijuana-based medicine to treat epilepsy. They've already succeeded in three phase 3 trials. They have one more phase 3 trial reading out data early next year. They want to file with the FDA as quickly as possible. It wouldn't shock me if the FDA gives an accelerated review to this drug because there's a massive need, especially in childhood forms of epilepsy that are resistance to current anti-epileptics. There's a huge need here for new treatment options. It seems like, so far, Epidiolex could fill that need. We'll have to see. The epilepsy indication is big. It's billions of dollars. There's a history of various epilepsy drugs at least reaching nine-figure sales, and there are some that have eclipsed that number. The devil will be in the details with what the label says and when this drug gets to market and what the pricing will be. But, if they can win approval next year, then this stock could trade higher.
Harjes: This is, for sure, a high-interest story to watch. They could completely reshape epilepsy. We should be looking at a potential approval by the end of 2017. That is a wrap for this episode, and also a wrap for new healthcare episodes of Industry Focus in 2016. We will of course be back next year for more industry deep dives. For now, a heartfelt thank you to all of our listeners for tuning in all year, and also to Todd for being my partner in crime here, making this show happen.
Campbell: Thank you, too Kristine!
Harjes: Thank you! As always, people on the program may have interests in the stocks they talk about and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. For Todd Campbell, I'm Kristine Harjes, have happy holidays everyone, and Fool on!
Kristine Harjes owns shares of Johnson and Johnson. Todd Campbell owns shares of Celgene. The Motley Fool owns shares of and recommends Biogen, Celgene, and Illumina. The Motley Fool owns shares of Medtronic. The Motley Fool recommends BioMarin Pharmaceutical, CVS Health, Johnson and Johnson, and UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell kick off the show by analyzing Acadia Pharmaceuticals '(NASDAQ: ACAD) intriguing Alzheimer's disease drug. First things first: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. | In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell kick off the show by analyzing Acadia Pharmaceuticals '(NASDAQ: ACAD) intriguing Alzheimer's disease drug. First things first: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. | In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell kick off the show by analyzing Acadia Pharmaceuticals '(NASDAQ: ACAD) intriguing Alzheimer's disease drug. First things first: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. | In this episode of The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell kick off the show by analyzing Acadia Pharmaceuticals '(NASDAQ: ACAD) intriguing Alzheimer's disease drug. First things first: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. |
36140.0 | 2017-01-07 00:00:00 UTC | 3 Companies Whose Sales Could Double in 2017 | ACAD | https://www.nasdaq.com/articles/3-companies-whose-sales-could-double-2017-2017-01-07 | nan | nan | While companies that promise triple-digit sales growth are rare, they do exist. In fact, market watchers currently believe that ACADIA Pharmaceuticals (NASDAQ: ACAD) , NovoCure Ltd (NASDAQ: NVCR) , and Intercept Pharmaceuticals (NASDAQ: ICPT) will all pull off that feat in the coming year. Does that mean that you should buy these stocks right now? Read on to learn more about these three businesses so you can make an informed decision for yourself.
Images source: Getty Images.
A market all to itself
The first stock on today's list is ACADIA Pharmaceuticals. With the launch of its first drug, Nuplazid, the company recently transitioned from a clinical-stage biopharma to a commercial-stage. Nuplazid is the only FDA-approved treatment for Parkinson's disease psychosis, or PDP, a condition that causes delusions and hallucinations. It is estimated that PDP occurs in about 40% of patients who suffer from Parkinson's disease, which puts the drug's addressable-market opportunity at roughly 400,000 patients in the U.S. alone.
Since Nuplazid is the first approved drug to treat this condition, ACADIA currently has this market all to itself. Perhaps unsurprisingly, the drug is off to a terrific start. Sales during its first full quarter on the market came in at over $5 million , a result far ahead of what Wall Street had anticipated. Sales are expected to nearly double in the upcoming quarter, which is why market watchers are projecting full-year sales in 2016 to come in around $14 million.
Image source: Getty Images.
That's all great, but analysts believe that the company's growth engine will really start to kick in during 2017 as insurers and providers grow more comfortable with the drug. Current estimates call for revenue of more than $85 million in 2017, which would represent better than 500% growth year over year. That's a figure that should grab any growth investor's attention.
The future of cancer treatment is here
Image source: NovoCure.
Cancer is one of the leading causes of death in the developed world, and providers have used chemotherapy for years as a way to fight the disease. However, chemotherapy often causes nasty side effects that can be a deterrent for prospective patients.
NovoCure is an innovating medical-device company that's attempting to change all that. The company created a device that it calls the Optune system, which is worn on the skin. The Optune system emits low-intensity electrical fields that disrupt cell division in cancerous cells, providing patients with a far less invasive treatment option.
The Optune system is currently approved by the FDA to treat only glioblastoma, a form of brain cancer, but that hasn't prevented sales from growing quickly. Wall Street currently believes that sales will exceed $168 million in 2017, which is more than double the $80 million in sales that is expected to be reported for 2016.
While those are lofty expectations, the company has had no problem growing by triple-digit rates in the past. If the company can successfully execute on growth forecasts, then its stock could likely follow suit.
Growth is on the horizon
The final stock on today's list is Intercept Pharmaceuticals, which is another biopharma that offers investors massive growth prospects in the year ahead. The company's only FDA-approved drug is called Ocaliva and is used to treat primary biliary cholangitis, or PBC, a chronic liver disease.
Just like ACADIA, Intercept is off to a good start with its launch of Ocaliva as total sales in 2016 are projected to be around $20 million. However, that number is expected to take a giant leap forward in 2017, with analysts forecasting full-year sales to nearly quadruple to $96 million. Even then there could be plenty of room for growth as peak sales for Ocaliva in PBC are estimated to be about $300 million.
Image source: Getty Images.
Those figures are exciting, but the real bull case for buying Intercept's stock lies in Ocaliva's long-term potential. Management is currently studying Ocaliva as a promising treatment for nonalcoholic steatohepatitis, or NASH, which is a far bigger indication that PBC. Estimates show that roughly between 3% and 12% of American adults have NASH, which if left untreated can lead to scarring of the liver and even cirrhosis. If Intercept can go on to win approval for NASH, then Ocaliva's peak sales figures could easily cross the multibillion-dollar mark. That makes Intercept a great stock for growth investors to get to know.
10 stocks we like better than Intercept Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Intercept Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
Brian Feroldihas no position in any stocks mentioned. Like this article? Follow him on Twitter, where he goes by the handle@BrianFeroldi, or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In fact, market watchers currently believe that ACADIA Pharmaceuticals (NASDAQ: ACAD) , NovoCure Ltd (NASDAQ: NVCR) , and Intercept Pharmaceuticals (NASDAQ: ICPT) will all pull off that feat in the coming year. A market all to itself The first stock on today's list is ACADIA Pharmaceuticals. Since Nuplazid is the first approved drug to treat this condition, ACADIA currently has this market all to itself. | In fact, market watchers currently believe that ACADIA Pharmaceuticals (NASDAQ: ACAD) , NovoCure Ltd (NASDAQ: NVCR) , and Intercept Pharmaceuticals (NASDAQ: ICPT) will all pull off that feat in the coming year. A market all to itself The first stock on today's list is ACADIA Pharmaceuticals. Since Nuplazid is the first approved drug to treat this condition, ACADIA currently has this market all to itself. | In fact, market watchers currently believe that ACADIA Pharmaceuticals (NASDAQ: ACAD) , NovoCure Ltd (NASDAQ: NVCR) , and Intercept Pharmaceuticals (NASDAQ: ICPT) will all pull off that feat in the coming year. A market all to itself The first stock on today's list is ACADIA Pharmaceuticals. Since Nuplazid is the first approved drug to treat this condition, ACADIA currently has this market all to itself. | Since Nuplazid is the first approved drug to treat this condition, ACADIA currently has this market all to itself. In fact, market watchers currently believe that ACADIA Pharmaceuticals (NASDAQ: ACAD) , NovoCure Ltd (NASDAQ: NVCR) , and Intercept Pharmaceuticals (NASDAQ: ICPT) will all pull off that feat in the coming year. A market all to itself The first stock on today's list is ACADIA Pharmaceuticals. |
36141.0 | 2017-01-06 00:00:00 UTC | Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-alzheimers-data-raises-some-questions-2017-01-06 | nan | nan | Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. However, the trial results do raise some important questions regarding the durability of Nuplazid's benefit and the likelihood of a phase 3 success. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease?
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors' minds as Acadia Pharmaceuticals preps for phase 3 studies.
A full transcript follows the video.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
This podcast was recorded on Dec. 21, 2016.
Kristine Harjes: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday.
Todd Campbell: Really interesting data. I think it's very helpful to walk investors through the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals. I don't think this is a stock that we have talked about in the past on the show, Kristine, do you?
Harjes: I don't believe we have ever talked about them. The deal with them is, they have this one drug, it's called Nuplazid. It is already approved for Parkinson's disease psychosis. Now, they're testing it in Alzheimer's disease psychosis.
Campbell: Right. This year, they just launched this drug, Nuplazid, for the treatment of hallucinations and delusions within Parkinson's patients. It's estimated that about 40% of all Parkinson's patients suffer from psychosis that this drug can address. The company is researching this drug across a number of different similar indications where they think they may also be able to help. One of those indications, obviously, is Alzheimer's disease, where they've been evaluating the drug in treating Alzheimer's disease psychosis, which is estimated to affect between 25% to 50% of the Alzheimer's disease population.
Harjes: Correct me if I'm wrong, but that's a much larger number of people total.
Campbell: Yeah. You go from 40% of a million with Parkinson's, so that's 400,000, to even 25% of the 5 million Alzheimer's disease patients, that's an extra million. So, you're talking about potentially going from being able to address 400,000 people to being able to address 1.5 million.
Harjes: So, the news that came out yesterday was some data from phase 2, saying that they had success, and six weeks into the trial there was a statistical benefit. The stock was up 12% on the news.
Campbell: Yeah, the stock was slated to open pre-market up as much as 40%.
Harjes: Wow! I missed that!
Campbell: Yeah, don't ever trust pre-market or after-market, they're illiquid market quotes, and they're not going to tell you anything other than, maybe, direction. They'll tell you if it's indicated up or down. But I wouldn't count on up 40% or down 40% read.
Harjes: That's crazy.
Campbell: Yeah. Once it opened up, the shares traded pretty volitively. It got down to a single-digit gain, then went back up to a double-digit gain by the end of the day. I think the reason for all of that is that first of all we've been desperate for new advances in Alzheimer's disease treatment. There's not a lot of good treatments out there. The only things we have out there treat the symptoms, they don't curb or crimp the disease.
Harjes: Yeah. Every stock working in this space has been extremely volatile, trading emotionally up, down, every which way on Alzheimer's news.
Campbell: Right. Big disclaimer, even the data were giving you today is phase 2 data. If any indication has shown that phase 2 data does not hold a lot of water, it's Alzheimer's disease. So you have to take this with a big grain of salt. But there's another reason that I want investors to take this with a big grain of salt.
Harjes: Yes there is.
Campbell: What was that, Kristine?
Harjes: Yes there is, I was going to say it if you weren't going to, lay it out.
Campbell: Well, I don't know if it's the same thing you're going to mention, but I wasn't thrilled with the P value.
Harjes: Yep. (laughs) That's where I was going, as well. The P value here for the six weeks was 0.045, which, reminder about P values, it's a statistical measure. Basically, you want to see less than 0.05. We had 0.045, that's green light, in the clear, you're fine. But it's kind of close to that threshold of 0.05.
Campbell: Especially with a small patient population. I mean, I don't want to call it tiny --
Harjes: It's 181.
Campbell: Yeah. But compared to how big this indication is, and how big previous Alzheimer's disease studies have been, this doesn't feel like a lot of patients to me.
Harjes: Right. And some other things to note here is that in the Parkinson's disease trial, you had a P value of 0.001. That is way, way below the 0.05 that is the traditional threshold.
Campbell: Right. That's the gold standard number. That's what you would want to have.
Harjes: Absolutely. The other detail that's worth mentioning, I mentioned this data was from six weeks -- when you look at the 12-week numbers, the treatment group that was receiving this drug, their numbers held steady. But the placebo group experienced a placebo effect that brought them in line with the treatment group, essentially closing the delta between the two groups, and then eliminating even that 0.05.
Campbell: Right, so you look at this, you have a P value of 0.045, you have a benefit that loses its statistical significance between the six week and 12 week mark. What does that mean? The approval in Parkinson's disease was based on six week data. So you could make an argument that six week is fine. The other thing I'm curious about is the choice of the study or the scale or the score that they used for evaluating these patients. It was a nursing home score, because all of these were nursing home patients. That isn't necessarily one that you see typically used in psychology trials or Alzheimer's disease trials. They were asked about it on the conference call, and they did say another more common scoring system that was used didn't show a significant benefit. So, there's a lot of question marks here that make me say: Rein in some enthusiasm and let this thing play out, because we have seen, way too often, investors get excited about Alzheimer's disease drugs that just do not pan out in large studies.
Harjes: Yep, it's a lesson that watchers of this space are learning again and again lately.
Kristine Harjes has no position in any stocks mentioned. Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors' minds as Acadia Pharmaceuticals preps for phase 3 studies. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? | Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. Kristine Harjes: Some exciting Alzheimer's research results from a company called Acadia Pharmaceuticals came out yesterday. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? | In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors' minds as Acadia Pharmaceuticals preps for phase 3 studies. Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? | Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors' minds as Acadia Pharmaceuticals preps for phase 3 studies. |
36142.0 | 2017-01-05 00:00:00 UTC | First Week of ACAD February 17th Options Trading | ACAD | https://www.nasdaq.com/articles/first-week-acad-february-17th-options-trading-2017-01-05 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $31.00 strike price has a current bid of $2.40. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $31.00, but will also collect the premium, putting the cost basis of the shares at $28.60 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $32.05/share today.
Because the $31.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 60%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 7.74% return on the cash commitment, or 65.72% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $31.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $2.25. If an investor was to purchase shares of ACAD stock at the current price level of $32.05/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $33.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.98% if the stock gets called away at the February 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red:
Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 50%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 7.02% boost of extra return to the investor, or 59.59% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 74%, while the implied volatility in the call contract example is 70%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $32.05) to be 68%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $31.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $2.25. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration. |
36143.0 | 2017-01-04 00:00:00 UTC | Wednesday's ETF Movers: XBI, XLE | ACAD | https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-xle-2017-01-04 | nan | nan | In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 4.5% on the day. Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day.
And underperforming other ETFs today is the Energy Select Sector SPDR Fund ETF, off about 0.1% in Wednesday afternoon trading. Among components of that ETF with the weakest showing on Wednesday were shares of Valero Energy, lower by about 3.2%, and shares of Marathon Petroleum, lower by about 3% on the day.
VIDEO: Wednesday's ETF Movers: XBI, XLE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day. And underperforming other ETFs today is the Energy Select Sector SPDR Fund ETF, off about 0.1% in Wednesday afternoon trading. Among components of that ETF with the weakest showing on Wednesday were shares of Valero Energy, lower by about 3.2%, and shares of Marathon Petroleum, lower by about 3% on the day. | Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Valero Energy, lower by about 3.2%, and shares of Marathon Petroleum, lower by about 3% on the day. VIDEO: Wednesday's ETF Movers: XBI, XLE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day. And underperforming other ETFs today is the Energy Select Sector SPDR Fund ETF, off about 0.1% in Wednesday afternoon trading. Among components of that ETF with the weakest showing on Wednesday were shares of Valero Energy, lower by about 3.2%, and shares of Marathon Petroleum, lower by about 3% on the day. | Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day. In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 4.5% on the day. And underperforming other ETFs today is the Energy Select Sector SPDR Fund ETF, off about 0.1% in Wednesday afternoon trading. |
36144.0 | 2017-01-04 00:00:00 UTC | Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-breaks-above-200-day-moving-average-bullish-acad-2017-01-04 | nan | nan | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $31.24.
According to the ETF Finder at ETF Channel, ACAD makes up 3.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading up by about 2.6% on the day Wednesday.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $31.24. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $31.24. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $31.24. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. According to the ETF Finder at ETF Channel, ACAD makes up 3.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading up by about 2.6% on the day Wednesday. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. |
36145.0 | 2017-01-04 00:00:00 UTC | Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today | ACAD | https://www.nasdaq.com/articles/why-encana-acadia-pharmaceuticals-and-tenet-healthcare-jumped-today-2017-01-04 | nan | nan | The stock market continued to perform well on Wednesday, sending the S&P 500 to within a point of a new all-time record closing high. The Dow remained stubbornly below 20,000, but major market benchmarks posted gains of around half a percent as the latest release of minutes from the Federal Reserve's Open Market Committee meeting didn't raise any alarms or reveal any big surprises from monetary policymakers. Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Let's look more closely at these stocks to tell you why they did so well.
Image source: Encana.
Encana sees a brighter 2017
Encana climbed 8% after the Canadian energy company said that it expects better results in 2017 than it had previously predicted at its investor day presentation in October. Citing strong performance in the fourth quarter of 2016, Encana now believes that its corporate margin level will exceed $10 per barrel of oil equivalent in 2017, with price assumptions of $55 per barrel of oil and $3 per million BTUs for natural gas. That's 25% better than the $8 margin figure that Encana had previously predicted, and the company also sees production growth at the high end or higher than its previous range of 15% to 20%. In 2018, conditions could improve further, with Encana predicting margins of $13 per barrel equivalent. With so much efficiency-based progress, Encana is well-suited for whatever environment the energy markets throw at it.
Could Acadia find a partner?
Acadia jumped 11% after rumors surfaced that drug-maker Pfizer (NYSE: PFE) might be interested in buying the biopharmaceutical company. Acadia had a tough time in 2016, with investors having grown nervous about the expense and risk involved in marketing its Nuplazid treatment for Parkinson's disease psychosis. With its share price having fallen last year, the prospect of Acadia gaining the attention of a drug giant like Pfizer was highly attractive, especially since it would potentially open up Pfizer's more experienced sales force and marketing team to make the most of Nuplazid's opportunity. Of course, rumor-driven gains can evaporate as quickly as they appear, but for now, investors are riding the wave of interest higher.
Tenet investors look toward a post-Obamacare world
Finally, Tenet Healthcare gained 9%. Analysts at Piper Jaffray late yesterday initiated coverage on the hospital company with a neutral rating, setting a price target of $16 per share on the stock. Yet today's statement by Vice President-elect Mike Pence detailing the Trump administration's plans to repeal Obamacare seemed to suggest an orderly move away from the program, with free-market based alternatives that could ensure that Tenet will not once again have to deal with an influx of uninsured emergency room patients without any ability to pay. Tenet and other hospital stocks gained a lot of ground after the passage of the Affordable Care Act based on the notion that it would no longer have to absorb such losses. As long as any replacement deals with that issue, Obamacare repeal might not be as bad for Tenet as some investors had feared.
10 stocks we like better than Encana
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Encana wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia had a tough time in 2016, with investors having grown nervous about the expense and risk involved in marketing its Nuplazid treatment for Parkinson's disease psychosis. Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Could Acadia find a partner? | Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Could Acadia find a partner? Acadia jumped 11% after rumors surfaced that drug-maker Pfizer (NYSE: PFE) might be interested in buying the biopharmaceutical company. | Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Could Acadia find a partner? Acadia jumped 11% after rumors surfaced that drug-maker Pfizer (NYSE: PFE) might be interested in buying the biopharmaceutical company. | Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Could Acadia find a partner? Acadia jumped 11% after rumors surfaced that drug-maker Pfizer (NYSE: PFE) might be interested in buying the biopharmaceutical company. |
36146.0 | 2017-01-04 00:00:00 UTC | Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today | ACAD | https://www.nasdaq.com/articles/heres-why-acadia-pharmaceuticals-inc-stock-today-2017-01-04 | nan | nan | What happened
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. An unconfirmed rumor that Pfizer is interested in acquiring its set-to-explode antipsychotic drug, Nuplazid, is responsible for the pop.
ACAD Price data by YCharts .
So what
Although it's just an unconfirmed rumor, Pfizer has been in an acquisitive mood. Given its $14 billion offer for Medivation in August, mostly for prostate cancer drug Xtandi, it seems not to be worried about paying premiums, either.
Even tacking on a Pfizer-esque premium to ACADIA's modest $2.7 billion enterprise value , the company might be a value opportunity. Its lead drug, Nuplazid (pimavanserin), has a chance of treating a much wider range of patients, including the rapidly expanding population with Alzheimer's disease.
Now what
Since launching the freshly approved antipsychotic treatment for the underserved Parkinson's disease population in May, the company has yet to report meaningful revenue figures. The first shipments didn't go out until late May, and by the end of September, ACADIA had recorded just $1.9 million in deferred revenue related to its sales.
There's a worthwhile debate over just how well this antipsychotic can perform both in the Alzheimer's population and in the commercial setting as a whole. Statistically speaking, it significantly reduced patient psychosis (as measured by Neuropsychiatric Inventory-Nursing Home inventory scores), but by a slim margin.
There's reasonable doubt that the results seen in the 180-patient phase 2 study can be repeated in a larger study, which will likely be necessary to support an FDA application for expansion from Parkinson's to Alzheimer's.
On the other hand, there is a dearth of effective antipsychotics with minimal anticognitive side effects; additionally, a first approval tends to smooth out the path for a second. Looking a bit further ahead, clinical trials with Nuplazid in major depressive disorder and schizophrenia could push the stock even higher, regardless of Pfizer's intentions.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Cory Renauer has no position in any stocks mentioned. You can follow Cory on Twitter @coryrenauer or LinkedIn for more biotech investing insight.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. ACAD Price data by YCharts . Even tacking on a Pfizer-esque premium to ACADIA's modest $2.7 billion enterprise value , the company might be a value opportunity. | What happened Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. ACAD Price data by YCharts . Even tacking on a Pfizer-esque premium to ACADIA's modest $2.7 billion enterprise value , the company might be a value opportunity. | 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! What happened Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! What happened Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. ACAD Price data by YCharts . |
36147.0 | 2017-01-04 00:00:00 UTC | Exploring an Apple Inc. (AAPL) Takeover of Sirius and Pandora | ACAD | https://www.nasdaq.com/articles/exploring-an-apple-inc.-aapl-takeover-of-sirius-and-pandora-2017-01-04 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
Apple Inc. (NASDAQ: AAPL ) stock improved 10% in 2016, despite posting its first revenue decline since 2001 . Last week, it emerged that Apple would cut iPhone 7 production 10% amid weakening sales. Colin Gillis of BGC Research noted that supply chain info should be taken "with a grain of salt," but nonetheless Apple is approaching a period of seasonal weakness.
Source: Yanki01 via Flickr (Modified)
Apple increased its services revenue 24% to $6.3 billion a quarter last year. As hardware sales weaken, Apple will need to accelerate its transition to software and services, which don't fluctuate as much. Apple could effect this by buying Sirius XM Holdings Inc. (NASDAQ: SIRI ), which itself may buyPandora Media Inc (NYSE: P ).
Barron's already suggested this. By buying Sirius and Pandora, Apple would increase its revenue from services, boost its position in connected car services and strengthen Apple Music against Spotify .
Apple, however, tends to avoid big purchases. People like to speculate about Apple buying everything from Netflix, Inc. (NASDAQ: NFLX ) to Tesla Motors Inc (NASDAQ: TSLA ), but Apple has shied away. Apple's $3 billion purchase of Beats in 2014 was its biggest acquisition so far. Sirius holds a market cap of $21 billion, and may buy Pandora for $20 a share, or $4.5 billion.
And other things could get in the way of a deal.
Buying Sirius/Pandora Will Help Apple Increase Services Revenue and Growth
Services already makes up a substantial chunk of Apple's revenue, at 13%. This is larger than Mac and iPad sales. But iPhone sales still account for 61% of Apple's top line.
The 10 Best Stocks to Buy for 2017
Increasing Apple's revenue from services would reduce risk, since services revenue doesn't swing as much as iPhone sales. Sirius sold $1.3 billion in the third quarter of 2016, with most of that revenue derived from services. Pandora's revenue in that quarter amounted to $351.9 million .
This would represent a 25% increase in Apple's revenue from services, increasing Apple's growth and potentially boosting AAPL's stock price.
It Strengthens Apple's Position in Connected Cars
Although the details on Apple's plans may be uncertain , AAPL stock wants to get into connected car business. Currently Apple offers CarPlay, which allows iPhone users to iOS in the car without touching their phones. Sirius holds a position here.
Sirius purchased the connected-vehicle division of Agero in 2013 for $530 million, getting into the software of the car. Now, the Sirius XM Guardian offers users features such as roadside assistance and remote vehicle start. And Sirius executives have dealt with the automotive business for years. Buying Sirius would help Apple move into the industry.
Sirius/Pandora Help AAPL Stock in Music Streaming
Currently, Apple is locked in a battle against Pandora, Spotify, and Amazon.com, Inc. (NASDAQ: AMZN ) over music streaming. Apple Music's subscriber count rose to 20 million in December. However, Pandora still dwarfs Apple Music, with 77.9 million monthly active users, with 4 million paying $4.99 a month for Pandora Plus.
Apple could move Pandora users over to Apple Music, like it did with Beats Music subscribers, or keep them separate and just enjoy the revenue stream while mining the user data.
Obstacles to Apple buying Sirius and Pandora
That said, some things stand in the way of Apple buying Sirius and Pandora. As mentioned before, Apple prefers organic growth, and has avoided big acquisitions.
And regulators might block a deal as well.
Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout
Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. Malone's Liberty Media owns a 65% stake in Sirius, which it picked up in 2009 by loaning a troubled Sirius $530 million. This has paid off handsomely. Would they want to sell and secure this gain? In February 2016 Greg Maffei talked about Liberty growing its stake to 100%. Liberty tried to buy 100% of Sirius in 2014.
So Liberty would be loath to part with Sirius for anything less than a high premium.
As of writing, Lucas Hahn did not hold a position in any of the aforementioned securities.
More From InvestorPlace
The 10 Best Contrarian Stocks to Buy in the New Year
7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017
The post Exploring an Apple Inc. (AAPL) Takeover of Sirius and Pandora appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. Colin Gillis of BGC Research noted that supply chain info should be taken "with a grain of salt," but nonetheless Apple is approaching a period of seasonal weakness. Apple could effect this by buying Sirius XM Holdings Inc. (NASDAQ: SIRI ), which itself may buyPandora Media Inc (NYSE: P ). | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. Apple could effect this by buying Sirius XM Holdings Inc. (NASDAQ: SIRI ), which itself may buyPandora Media Inc (NYSE: P ). By buying Sirius and Pandora, Apple would increase its revenue from services, boost its position in connected car services and strengthen Apple Music against Spotify . | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. By buying Sirius and Pandora, Apple would increase its revenue from services, boost its position in connected car services and strengthen Apple Music against Spotify . Buying Sirius/Pandora Will Help Apple Increase Services Revenue and Growth Services already makes up a substantial chunk of Apple's revenue, at 13%. | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. By buying Sirius and Pandora, Apple would increase its revenue from services, boost its position in connected car services and strengthen Apple Music against Spotify . The 10 Best Stocks to Buy for 2017 Increasing Apple's revenue from services would reduce risk, since services revenue doesn't swing as much as iPhone sales. |
36148.0 | 2017-01-04 00:00:00 UTC | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc.-acad-flirts-with-a-pfizer-inc.-pfe-buyout-2017-01-04 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) is having a Happy New Year, as ACAD stock sets the second trading day of the year ablaze with 12%-plus gains. It won't last, but that's not what's important here.
I'm not bearish, if that's what I've led you to believe - it's just the nature of the pop that foretells profit-taking. That is, the rumor mill is abuzz with word that the sudden 11 a.m. spike in Acadia shares is due to interest from Pfizer Inc. (NYSE: PFE ), which is up nearly a percentage point as of this writing.
The rumor is just that - a rumor. It's not being reported anywhere. Neither PFE nor Acadia have confirmed it. Nope, it's just screaming down the halls of social media.
The 10 Best Contrarian Stocks to Buy in the New Year
But of course, the Street loves to buy the rumor, just ask Twitter Inc (NYSE: TWTR ) shareholders. Heck, ACAD stock holders are familiar, too. Remember last June when AstraZeneca plc (ADR) (NYSE: AZN ) was the rumored suitor ? Acadia stock jumped 10%, but were back down near-20% by the end of the month.
But Could It Happen to ACAD Stock?
Of course it could.
Acadia's Parkinson's disease treatment, Nuplazid, has potential galore. Nuplazid, which launched in the U.S. on May 31, 2016, is the only drug approved by the Food and Drug Administration toward the treatment of psychosis brought on by the disease. Net sales for Nuplazid hit $5.3 million in its first full quarter on the market. As InvestorPlace contributor Brian Nichols noted, that's something a growth-hungry Pfizer would want .
Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. This has been a thorn in Acadia stock's side since it fell through it in early October.
Like I said, it won't last … but it's nice to see that the bulls are tripping over themselves to kick down the doors on the slightest rumor.
As of this writing, John Kilhefner did not hold a position in any of the aforementioned securities.
More From InvestorPlace
Mobileye NV (MBLY) Stock Soars on Autonomous Vehicle Test
7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017
The 10 Best Fidelity Funds for 2017
The post Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That is, the rumor mill is abuzz with word that the sudden 11 a.m. spike in Acadia shares is due to interest from Pfizer Inc. (NYSE: PFE ), which is up nearly a percentage point as of this writing. Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. More From InvestorPlace Mobileye NV (MBLY) Stock Soars on Autonomous Vehicle Test 7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017 The 10 Best Fidelity Funds for 2017 The post Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout appeared first on InvestorPlace . | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) is having a Happy New Year, as ACAD stock sets the second trading day of the year ablaze with 12%-plus gains. Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. That is, the rumor mill is abuzz with word that the sudden 11 a.m. spike in Acadia shares is due to interest from Pfizer Inc. (NYSE: PFE ), which is up nearly a percentage point as of this writing. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) is having a Happy New Year, as ACAD stock sets the second trading day of the year ablaze with 12%-plus gains. Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. More From InvestorPlace Mobileye NV (MBLY) Stock Soars on Autonomous Vehicle Test 7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017 The 10 Best Fidelity Funds for 2017 The post Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout appeared first on InvestorPlace . | Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. More From InvestorPlace Mobileye NV (MBLY) Stock Soars on Autonomous Vehicle Test 7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017 The 10 Best Fidelity Funds for 2017 The post Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout appeared first on InvestorPlace . InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) is having a Happy New Year, as ACAD stock sets the second trading day of the year ablaze with 12%-plus gains. |
36149.0 | 2016-12-26 00:00:00 UTC | 4 Biotech Stocks to Buy in January | ACAD | https://www.nasdaq.com/articles/4-biotech-stocks-buy-january-2016-12-26 | nan | nan | When an entire sector goes on sale it tends to create bargains. There's no doubt that the biotech sector has the blue-light special flashing right now, as it has massively underperformed the S&P 500 year to date. Knowing that, we asked a team of healthcare contributors to highlight a biotech stock that they think is a smart buy as we head into 2017. Read on to see why they picked Trevena (NASDAQ: TRVN) , Ligand Pharmaceuticals (NASDAQ: LGND) , ACADIA Pharmaceuticals (NASDAQ: ACAD) , and Geron (NASDAQ: GERN) .
While finding success in other indications is never guaranteed, Nuplazid has already made it through the regulatory approval process once, so I'd argue it has a better-than-average chance of doing so again.
In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead. With shares currently trading at a discount , I think it is a fine time to consider getting in.
Look out, Jakafi
Cory Renauer(Geron): My biotech stock pick to begin the new year suffered a market beat-down in 2016, and is now one of its industry's most intriguing long-term value plays. The company doesn't have a product to sell yet, but its lead candidate, imetelstat, has produced compelling trial results that suggest it could eventually dominate a somewhat underserved niche.
Geron's partner Johnson & Johnson is expecting more data from ongoing studies with imetelstat in 2017. If myelofibrosis trial results are consistent with previous observations, the healthcare behemoth will help fund larger trials in order to support New Drug Applications.
Currently, the only treatment for myelofibrosis is Incyte 's Jakafi, which generated sales and royalty revenue at an annualized run rate of $1.01 billion based on third-quarter results. It earned FDA approval in 2011 based on its ability to reduce spleen size, a symptom of the disease. Geron's imetelstat, though, is the first to show clear signs of reduced disease activity and even drive the rare blood cancer into complete remission.
At recent prices, Geron's enterprise value is a mere $340 million. With a deep-pocketed partner ready to usher imetelstat through the regulatory pathway and into the commercial setting, there's a solid chance Geron could provide market-thumping returns to patient investors.
A small biotech with a big biotech's pipeline
Keith Speights (Ligand Pharmaceuticals): Try to find a biotech with a market cap less than $3 billion that has a deeper pipeline than Ligand. I don't think one exists. Ligand has eight programs in late-stage clinical studies and a whopping 18 in mid-stage studies. That count rivals much larger biotechs.
Ligand's key to success is its partnerships. The company has over 90 partners and licensees for its drug development platforms. If you threw a dart at a dartboard with the names of the biggest drugmakers in the world, there's a good chance that you'd hit one of Ligand's partners.
The big draw for Ligand's products is that they help biopharmaceutical companies develop new drugs more effectively. Ligand's leading technology, Captisol, has a chemical structure that improves solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients.
During the first nine months of 2016, Ligand's revenue soared nearly 40% compared to the prior-year period. With climbing sales of current products Kyprolis and Promacta and its robust pipeline likely to crank out more winners, I expect Ligand to keep up this pace of growth for the next several years.
10 stocks we like better than Geron
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Geron wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
Brian Feroldi has no position in any stocks mentioned. Cory Renauer owns shares of Johnson and Johnson. George Budwell has no position in any stocks mentioned. Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Read on to see why they picked Trevena (NASDAQ: TRVN) , Ligand Pharmaceuticals (NASDAQ: LGND) , ACADIA Pharmaceuticals (NASDAQ: ACAD) , and Geron (NASDAQ: GERN) . In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead. The company doesn't have a product to sell yet, but its lead candidate, imetelstat, has produced compelling trial results that suggest it could eventually dominate a somewhat underserved niche. | Read on to see why they picked Trevena (NASDAQ: TRVN) , Ligand Pharmaceuticals (NASDAQ: LGND) , ACADIA Pharmaceuticals (NASDAQ: ACAD) , and Geron (NASDAQ: GERN) . In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead. Look out, Jakafi Cory Renauer(Geron): My biotech stock pick to begin the new year suffered a market beat-down in 2016, and is now one of its industry's most intriguing long-term value plays. | Read on to see why they picked Trevena (NASDAQ: TRVN) , Ligand Pharmaceuticals (NASDAQ: LGND) , ACADIA Pharmaceuticals (NASDAQ: ACAD) , and Geron (NASDAQ: GERN) . In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead. Look out, Jakafi Cory Renauer(Geron): My biotech stock pick to begin the new year suffered a market beat-down in 2016, and is now one of its industry's most intriguing long-term value plays. | Read on to see why they picked Trevena (NASDAQ: TRVN) , Ligand Pharmaceuticals (NASDAQ: LGND) , ACADIA Pharmaceuticals (NASDAQ: ACAD) , and Geron (NASDAQ: GERN) . In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead. Geron's partner Johnson & Johnson is expecting more data from ongoing studies with imetelstat in 2017. |
36150.0 | 2016-12-21 00:00:00 UTC | ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint | ACAD | https://www.nasdaq.com/articles/acadia-phase-ii-alzheimers-drug-hits-primary-endpoint-2016-12-21 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.
Following the news, ACADIA shares rose more than 12%. In fact , the biotech company's share price has gained 6.9% in the past one month, compared with the 4.2% fall witnessed by the Zacks classified Medical-Biomedical and Genetics industry.
Note that pimavanserin is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis under the trade name Nuplazid, which was launched in May 2016.
Interestingly, the FDA has not approved any drug to treat AD Psychosis to date.
The double-blind, placebo-controlled exploratory phase II study randomized 181 patients on a one-to-one basis to receive either 34 mg of pimavanserin or placebo once daily. In the study, pimavanserin met the primary endpoint by leading to significant reduction in psychosis, one of the debilitating symptoms of Alzheimer's disease, compared with placebo.
Psychosis was measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis score at week 6 of dosing (p=0.0451). The data revealed that pimavanserin led to a 3.76 point improvement in psychosis at week 6 compared to a 1.93 point improvement for placebo.
The secondary endpoint was the mean change in NPI-NH Psychosis score at week 12. While pimavanserin maintained the improvement in psychosis observed at week 6, it failed to demonstrate a statistically significant improvement over placebo.
Nevertheless, pimavanserin was generally well tolerated in the study and its safety profile was consistent with the previous studies.
ACADIA plans to present data from this study at a future medical conference.
Zacks Rank & Key Picks
ACADIA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Cambrex Corporation CBM , Heska Corporation HSKA and Anika Therapeutics Inc ANIK . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Heska's earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 85.5% year to date.
Cambrex's earnings estimates increased 3.7% for 2016 and 4.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 14.9% year to date.
Anika Therapeutics' earnings estimates for 2016 and 2017 were up a respective 9.2% and 3.4% respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 28.1% year to date.
ACADIA PHARMA Price
ACADIA PHARMA Price | ACADIA PHARMA Quote
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint. Following the news, ACADIA shares rose more than 12%. ACADIA plans to present data from this study at a future medical conference. | ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint. Following the news, ACADIA shares rose more than 12%. ACADIA plans to present data from this study at a future medical conference. |
36151.0 | 2016-12-20 00:00:00 UTC | Wall Street Sees Higher Open, Uncertainty Looms After Terror Attacks in Berlin, Zurich, Ankara | ACAD | https://www.nasdaq.com/articles/wall-street-sees-higher-open-uncertainty-looms-after-terror-attacks-berlin-zurich-ankara | nan | nan | U.S. stocks were pointing to a higher open on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday.
Oil prices nudged higher with global benchmark Brent Crude up 1.02% recently, and U.S. benchmark West Texas Intermediate up 0.56% ahead of a weekly supply update on U.S. crude stock inventories.
There are no economic data due for release on Tuesday.
In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis.
U.S. PRE-MARKET INDICATORS
-Dow Jones Industrial up 0.30%
-S&P 500 futures up 0.30%
-Nasdaq 100 futures up 0.25%
-Nasdaq 100 pre-market indicator up 0.19%
GLOBAL SENTIMENT
Nikkei up 0.53%
Hang Seng down 0.47%
Shanghai Composite down 1.49%
FTSE-100 up 0.33%
DAX-30 up 0.24%
PRE-MARKET SECTOR WATCH
(+) Large cap tech: unchanged to higher
(+) Chip stocks: unchanged to higher
(+) Software stocks: unchanged to higher
(+) Hardware stocks: unchanged to higher
(+) Internet stocks: unchanged to higher
(+) Oil stocks: unchanged to higher
(+/-) Biotech stocks: mixed
(+) Drug stocks: unchanged to higher
(+) Financial stocks: higher
(+) Retail stocks: unchanged to higher
(+/-) Industrial stocks: mixed
(+/-) Airlines: unchanged
(+) Autos: unchanged to higher
UPSIDE MOVERS
(+) CNAT (+153.1%) Inks collaboration pact with Novartis
(+) AZN (+1.1%) Advancing IONIS-AZ4-2.5-LRx into pre-clinical development
(+) GSK (+0.3%) ViiV Healthcare achieves primary endpoint in two phase 3 studies evaluating safety and efficacy of switching virologically-suppressed patients from a three or four-drug regiment to only two drugs
DOWNSIDE MOVERS
(-) ERIC (-2.6%) To collaborate with Qualcomm and SK Telecom on 5G new radio trials
(-) REN (-5%) Prices stock offering at 7.3% discount
(-) XGTI (-30.4) Shares halted, pending news
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stocks were pointing to a higher open on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. (+) CNAT (+153.1%) Inks collaboration pact with Novartis (+) AZN (+1.1%) Advancing IONIS-AZ4-2.5-LRx into pre-clinical development (+) GSK (+0.3%) ViiV Healthcare achieves primary endpoint in two phase 3 studies evaluating safety and efficacy of switching virologically-suppressed patients from a three or four-drug regiment to only two drugs | In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. (+) Large cap tech: unchanged to higher (+) Chip stocks: unchanged to higher (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: unchanged to higher (+) Oil stocks: unchanged to higher (+/-) Biotech stocks: mixed (+) Drug stocks: unchanged to higher (+) Financial stocks: higher (+) Retail stocks: unchanged to higher (+/-) Industrial stocks: mixed (+/-) Airlines: unchanged (+) Autos: unchanged to higher (-) ERIC (-2.6%) To collaborate with Qualcomm and SK Telecom on 5G new radio trials (-) REN (-5%) Prices stock offering at 7.3% discount (-) XGTI (-30.4) Shares halted, pending news The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. Nikkei up 0.53% Hang Seng down 0.47% Shanghai Composite down 1.49% FTSE-100 up 0.33% DAX-30 up 0.24% (+) Large cap tech: unchanged to higher (+) Chip stocks: unchanged to higher (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: unchanged to higher (+) Oil stocks: unchanged to higher (+/-) Biotech stocks: mixed (+) Drug stocks: unchanged to higher (+) Financial stocks: higher (+) Retail stocks: unchanged to higher (+/-) Industrial stocks: mixed (+/-) Airlines: unchanged (+) Autos: unchanged to higher | In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stocks were pointing to a higher open on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. Oil prices nudged higher with global benchmark Brent Crude up 1.02% recently, and U.S. benchmark West Texas Intermediate up 0.56% ahead of a weekly supply update on U.S. crude stock inventories. |
36152.0 | 2016-12-20 00:00:00 UTC | Health Care Sector Update for 12/20/2016: BMY, ACAD, JNJ, PFE, ABT, MRK, AMGN | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-12202016-bmy-acad-jnj-pfe-abt-mrk-amgn-2016-12-20 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.2%
ABT: flat
MRK: +0.2%
AMGN: -1.7%
Health care shares were mixed in pre-market trade Tuesday.
In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. Pimavanserin met the primary endpoint showing a statistically significant reduction in psychosis versus placebo as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis score at week 6 of dosing. Pimavanserin was generally well tolerated and the safety profile was consistent with what has been observed in previous studies.
And, Bristol-Myers Squibb Company ( BMY ) was up 0.5% after the company said PsiOxus Therapeutics, Ltd granted the company exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus with the goal of addressing solid tumors. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales. Bristol-Myers Squibb will also be responsible for providing PsiOxus funding to support activities related to the preclinical development of NG-348.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. | In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. And, Bristol-Myers Squibb Company ( BMY ) was up 0.5% after the company said PsiOxus Therapeutics, Ltd granted the company exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus with the goal of addressing solid tumors. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. | In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. And, Bristol-Myers Squibb Company ( BMY ) was up 0.5% after the company said PsiOxus Therapeutics, Ltd granted the company exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus with the goal of addressing solid tumors. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. |
36153.0 | 2016-12-20 00:00:00 UTC | Pre-Market Most Active for Dec 20, 2016 : AZN, ACAD, RAD, CNAT, ABB, BAC, GFI, MO, TVIX, BBRY, NVDA, XIV | ACAD | https://www.nasdaq.com/articles/pre-market-most-active-dec-20-2016-azn-acad-rad-cnat-abb-bac-gfi-mo-tvix-bbry-nvda-xiv | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 7.07 to 4,941.92. The total Pre-Market volume is currently 12,859,084 shares traded.
The following are the most active stocks for the pre-market session :
Astrazeneca PLC ( AZN ) is +0.19 at $27.14, with 5,192,937 shares traded. As reported by Zacks, the current mean recommendation for AZN is in the "buy range".
ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock.
Rite Aid Corporation ( RAD ) is +0.48 at $8.65, with 1,385,140 shares traded.RAD is scheduled to provide an earnings report on 12/22/2016, for the fiscal quarter ending Nov2016. The consensus earnings per share forecast is 0.05 per share, which represents a 6 percent increase over the EPS one Year Ago
Conatus Pharmaceuticals Inc. ( CNAT ) is +2.78 at $4.74, with 1,310,128 shares traded. As reported by Zacks, the current mean recommendation for CNAT is in the "strong buy range".
ABB Ltd ( ABB ) is -0.14 at $21.00, with 880,095 shares traded. ABB's current last sale is 96.64% of the target price of $21.73.
Bank of America Corporation ( BAC ) is +0.1 at $22.58, with 549,838 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $0.38. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
Gold Fields Limited ( GFI ) is +0.01 at $2.74, with 296,050 shares traded.GFI is scheduled to provide an earnings report on 12/22/2016, for the fiscal quarter ending Sep2016. The consensus earnings per share forecast is 999 per share, which represents a 3 percent increase over the EPS one Year Ago
Altria Group ( MO ) is +0.21 at $67.36, with 262,688 shares traded. MO's current last sale is 98.34% of the target price of $68.5.
VelocityShares Daily 2x VIX Short Term ETN ( TVIX ) is -0.16 at $8.83, with 187,373 shares traded., following a 52-week high recorded in prior regular session.
BlackBerry Limited ( BBRY ) is +0.21 at $7.92, with 168,330 shares traded. RTT News Reports: BlackBerry Lifts FY17 Forecast, Despite Wider Net Loss In Q3 - Quick Facts
NVIDIA Corporation ( NVDA ) is +2.9 at $104.53, with 101,477 shares traded., following a 52-week high recorded in prior regular session.
VelocityShares Daily Inverse VIX Short Term ETN ( XIV ) is +0.43 at $48.98, with 87,872 shares traded., following a 52-week high recorded in prior regular session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock. ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. RTT News Reports: BlackBerry Lifts FY17 Forecast, Despite Wider Net Loss In Q3 - Quick Facts NVIDIA Corporation ( NVDA ) is +2.9 at $104.53, with 101,477 shares traded., following a 52-week high recorded in prior regular session. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock. The consensus earnings per share forecast is 0.05 per share, which represents a 6 percent increase over the EPS one Year Ago Conatus Pharmaceuticals Inc. ( CNAT ) is +2.78 at $4.74, with 1,310,128 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock. The consensus earnings per share forecast is 0.05 per share, which represents a 6 percent increase over the EPS one Year Ago Conatus Pharmaceuticals Inc. ( CNAT ) is +2.78 at $4.74, with 1,310,128 shares traded. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock. The NASDAQ 100 Pre-Market Indicator is up 7.07 to 4,941.92. |
36154.0 | 2016-12-20 00:00:00 UTC | US Futures Point North, Uncertainty Looms After Terror Attacks in Berlin, Zurich, Ankara | ACAD | https://www.nasdaq.com/articles/us-futures-point-north-uncertainty-looms-after-terror-attacks-berlin-zurich-ankara-2016-12 | nan | nan | U.S. stock futures point north on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday.
Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories.
There are no economic data due for release on Tuesday.
In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stock futures point north on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stock futures point north on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stock futures point north on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories. |
36155.0 | 2016-12-20 00:00:00 UTC | Why ACADIA Pharmaceuticals Inc. Is Soaring Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-inc-soaring-today-2016-12-20 | nan | nan | Image source: Getty Images.
What happened
After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday.
So what
Acadia released top-line results from its Phase II -019 Study today. This trial was designed to test its drug Nuplazid (pimavanserin) as a hopeful treatment for Alzheimer's disease psychosis.
The results from the six-week, placebo-controlled study showed that Nuplazid met its primary endpoint, which was a statistically significant reduction in psychosis as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH) Psychosis score. Patients who used Nuplazid showed a 3.76 point improvement on the test while the placebo group only showed a 1.93 point improvement (p=0.0451).
Acadia's CEO Steve Davis was quite pleased with the study's results, noting:
Given the terrific clinical result, it is easy to understand why traders are bidding up shares today.
Now what
The FDA has not yet approved any drug to treat Alzheimer's disease psychosis, so this news is extremely promising for investors and patients alike. Roughly five million Americans suffer from Alzheimer's disease and somewhere between 25% and 50% of them experience symptoms of psychosis. Thus, if Nuplazid can ultimately go on to win a label expansion claim for this indication then it could be quite lucrative. After all, Nuplazid's wholesale price is $23,500 per year, so even capturing a small fraction of the total addressable market could lead to blockbuster sales.
Of course, this data was only from a Phase II trial, so Acadia still has a long road ahead before it can potentially submit for regulatory review. Still, this is terrific news all around, so it is hard to blame the markets for bidding up shares today.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday. So what Acadia released top-line results from its Phase II -019 Study today. Acadia's CEO Steve Davis was quite pleased with the study's results, noting: Given the terrific clinical result, it is easy to understand why traders are bidding up shares today. | What happened After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday. So what Acadia released top-line results from its Phase II -019 Study today. Acadia's CEO Steve Davis was quite pleased with the study's results, noting: Given the terrific clinical result, it is easy to understand why traders are bidding up shares today. | 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday. So what Acadia released top-line results from its Phase II -019 Study today. | So what Acadia released top-line results from its Phase II -019 Study today. What happened After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday. Acadia's CEO Steve Davis was quite pleased with the study's results, noting: Given the terrific clinical result, it is easy to understand why traders are bidding up shares today. |
36156.0 | 2016-12-19 00:00:00 UTC | ACADIA Pharmaceuticals Inc.'s Stock Has Fallen 27% in 2016 -- Have We Hit Bottom? | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-incs-stock-has-fallen-27-2016-have-we-hit-bottom-2016-12-19 | nan | nan | 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead. Shares of the commercial-stage biopharma focused on diseases of the central nervous system have traded erratically all year long , and they are currently on pace to end the year down more than 27%. That's a loss that exceeds the biotech industry in general as measured by the iShares Nasdaq Biotech ETF (NASDAQ: IBB) .
ACAD data by YCharts .
Why have shareholders had to suffer through terrible returns year to date, and is this company's future still looking bright? Let's take a closer look at the year's key developments to determine if the company's stock could be close to bottoming.
Why it's been a rough year
Acadia's investors got the big news they were looking for in April when the FDA approved the company's first drug, Nuplazid, as a treatment for Parkinson's disease psychosis. This disease affects roughly 400,000 patients in the U.S., and Nuplazid is the first and only medicine to be approved by the FDA to treat the condition.
Since Acadia's management team knew they had this indication all to themselves, they went big and priced the drug at $23,500 per year. That stoked investors' belief that the drug could eventually reach blockbuster status, so enthusiasm was running high.
With a wide-open market opportunity ahead, Acadia made the bold decision to sell Nuplazid all by itself. Thus, the company started to invest heavily in building up its commercial capabilities by hiring its own sales force.
While all of these indications look promising, Alzheimer's disease psychosis looks like an especially lucrative opportunity. Right now, about 5 million Americans suffer from Alzheimer's disease, and somewhere between 25% and 50% have hallucinations and delusions. If Nuplazid can ultimately win approval for this indication, then its potential addressable market could expand substantially. Investors should have a good indication about the drug's chances quite soon, as the company is expected to announce data from its Phase 2 Alzheimer's study any day now.
All in all, Nuplazid is off to a fast start, and there are plenty of reasons to believe in the drug's long-term potential. If Acadia can successfully capitalize on its huge market opportunity -- which, I'll admit, is a big "if" -- then I could easily see 2017 turning into a banner year for shareholders.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016.
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Why it's been a rough year Acadia's investors got the big news they were looking for in April when the FDA approved the company's first drug, Nuplazid, as a treatment for Parkinson's disease psychosis. If Acadia can successfully capitalize on its huge market opportunity -- which, I'll admit, is a big "if" -- then I could easily see 2017 turning into a banner year for shareholders. 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead. | 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD data by YCharts . | Why it's been a rough year Acadia's investors got the big news they were looking for in April when the FDA approved the company's first drug, Nuplazid, as a treatment for Parkinson's disease psychosis. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead. | Why it's been a rough year Acadia's investors got the big news they were looking for in April when the FDA approved the company's first drug, Nuplazid, as a treatment for Parkinson's disease psychosis. 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead. ACAD data by YCharts . |
36157.0 | 2016-11-29 00:00:00 UTC | 3 Biotechs With Save-the-Date Catalysts on Tap | ACAD | https://www.nasdaq.com/articles/3-biotechs-save-date-catalysts-tap-2016-11-29 | nan | nan | Bluebird's immuno-oncology platform focuses on a cell-surface protein (BCMA) expressed in malignant and healthy plasma, but absent in other healthy tissues. Image source: Bluebird.
Major blockbuster opportunity for ACADIA Pharmaceuticals
Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. The biotech has the first and only medication approved for the treatment of Parkinson's disease psychosis. Approved last April, the drug, Nuplazid, exploded out of the launch gate with sales in the third quarter at $5.3 million, almost doubling analysts' expectations for a measly $2.9 million.
The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). The company said it should release that data by the end of 2016, and if Nuplazid succeeds with ADP, the drug's new opportunity could be off the charts. Peak sales estimates for Nuplazid reach up to $3 billion, based on its prospects in PDP, but while around 130,000 people in the U.S. suffer from Parkinson's disease psychosis (PDP), approximately 5.3 million have Alzheimer's, and 25% to 50% of them have the related psychosis.
The downside is that while Nuplazid works in a unique way, its effectiveness isn't as high as some had hoped, and it carries a black box warning for increased risk of mortality. But as anyone who has a loved one with either Parkinson's or Alzheimer's knows, hallucinations and delusions associated with these diseases are disabling, and they're terrifically disturbing to both patients and caregivers. They are also a primary reason these patients are placed in nursing homes, according to physicians interviewed in a study by Decision Resources Group (DRG).
According to the DRG report, interviewed physicians indicated Nuplazid is badly needed, and they expect it to become a first-line treatment for PDP, and even ADP, assuming it nets approval in that indication. Nuplazid is also being tested in schizophrenia, which affects roughly 1% of the U.S. population, and it's also slated for a phase 3 study in Alzheimer's disease agitation, which should begin soon.
Investors can expect that even if the results are subpar in the upcoming catalyst, the drug could well see a huge and expanding addressable market in other indications. If so, patient investors will have a big winner on their hands.
No gain, without some risk of pain
Since none of us has a crystal ball, no one knows which way these high-risk stocks are headed next. But because each has multiple reasons for recovery and outperformance going forward, a short-term market reaction is nothing to fear and shouldn't prompt you to sell in a panic. Another, often better, choice is to use the market's knee-jerk reaction as an opportunity to take a small position at a better price point.
But be aware that these stocks are not for the timid. Be sure to check your guts at the door before you make a decision, do your own homework, and stay tuned.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Cheryl Swanson owns shares of Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Bluebird Bio and Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). Major blockbuster opportunity for ACADIA Pharmaceuticals Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). Major blockbuster opportunity for ACADIA Pharmaceuticals Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Major blockbuster opportunity for ACADIA Pharmaceuticals Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). Major blockbuster opportunity for ACADIA Pharmaceuticals Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. |
36158.0 | 2016-11-22 00:00:00 UTC | 5 Biotech Stocks George Soros Is Buying | ACAD | https://www.nasdaq.com/articles/5-biotech-stocks-george-soros-buying-2016-11-22 | nan | nan | George Soros' namesake fund known as Soros Fund Management has continued to show interest in the beaten-down biotech space this year -- even as most of its hedge fund peers have run for cover due to the political headwinds emanating from the U.S. presidential election.
BIIB data by YCharts .
Biogen's modest success is the result of the stronger-than-expected performance of its top-selling multiple sclerosis (MS) drug Tecfidera in the third quarter, along with the clinical success of Spinraza (nusinersen) as a candidate to treat infantile onset spinal muscular atrophy that could provide the biotech with its next blockbuster product.
The fly in Biogen's ointment, though, is that numerous companies are attempting to cut into the biotech's overwhelming share of the MS drug market at the moment, and its clinical efforts to defend its territory have run into multiple setbacks over the past year. The long and short of it is that Biogen will need to either hit a home run with its moonshot Alzheimer's disease drug aducanumab, or turn to the M&A scene to stave off a marked decline in its top line in the next year or so.
BioMarin isn't cheap -- but for good reason
When it comes to biotechs with rich valuations, the orphan drug specialist BioMarin is nearly always close to the top of the list. The underlying reason is that orphan drugs confer a number of highly coveted benefits for their manufacturers, such as premium pricing schemes that tend to fly under the radar of payers. Moreover, BioMarin is easily one of the top orphan drug companies in the world with five products on the market and a rich clinical pipeline that sports potential blockbusters like vosoritide for achondroplasia (a form of short-limbed dwarfism).
Although the biotech did make a fairly large error by acquiring fledgling company Prosensa for its experimental Duchenne muscular dystrophy drug Kyndrisa that was subsequently rejected by the FDA, BioMarin does have an overall strong track record of rapidly developing novel therapies for rare diseases. So, if you're looking for exposure to this niche pharma market, BioMarin should probably be on your list, despite its elevated valuation relative to the broader biotech landscape.
Opko's stock could heat up in 2017
Opko Health is a highly diversified healthcare company with multiple irons in the fire. But the company's near-term value proposition can arguably be distilled down the success -- or failure -- of its newly approved vitamin D prohormone, Rayaldee, indicated as a treatment for secondary hyperparathyroidism.
The big picture issue at play here is that Rayaldee's addressable market has been estimated to be as large as $12 billion per year -- although some skeptics have suggested otherwise, predicting that the drug's sales will peak at around $500 million. Regardless, this new drug should turn out to be a key growth driver for the company moving forward. The Street, after all, is forecasting Opko's top line to rise by nearly 16% in 2017, based primarily on Rayaldee's projected commercial performance.
Having said that, Opko Health will probably remain cash-flow-negative next year and may even need to raise capital sometime soon to fund its ongoing operations. While cash flow problems shouldn't necessarily be a deal breaker for investors in this case, this issue is likely a big reason why the company's shares are only trading at four times its 2017 estimated revenue.
Are any of these biotech stocks screaming buys right now?
Amgen, BioMarin, and Opko Health are all arguably worth a deeper dive based on their longer-term value propositions. But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. All in all, these Q3 Soros biotech buys seem to me to be best suited for a watch list, as none of them qualify as outright screaming buys right now.
10 stocks we like better than BioMarin Pharmaceutical
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and BioMarin Pharmaceutical wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. The fly in Biogen's ointment, though, is that numerous companies are attempting to cut into the biotech's overwhelming share of the MS drug market at the moment, and its clinical efforts to defend its territory have run into multiple setbacks over the past year. Moreover, BioMarin is easily one of the top orphan drug companies in the world with five products on the market and a rich clinical pipeline that sports potential blockbusters like vosoritide for achondroplasia (a form of short-limbed dwarfism). | But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. BioMarin isn't cheap -- but for good reason When it comes to biotechs with rich valuations, the orphan drug specialist BioMarin is nearly always close to the top of the list. Moreover, BioMarin is easily one of the top orphan drug companies in the world with five products on the market and a rich clinical pipeline that sports potential blockbusters like vosoritide for achondroplasia (a form of short-limbed dwarfism). | But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. The fly in Biogen's ointment, though, is that numerous companies are attempting to cut into the biotech's overwhelming share of the MS drug market at the moment, and its clinical efforts to defend its territory have run into multiple setbacks over the past year. BioMarin isn't cheap -- but for good reason When it comes to biotechs with rich valuations, the orphan drug specialist BioMarin is nearly always close to the top of the list. | But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. BioMarin isn't cheap -- but for good reason When it comes to biotechs with rich valuations, the orphan drug specialist BioMarin is nearly always close to the top of the list. Amgen, BioMarin, and Opko Health are all arguably worth a deeper dive based on their longer-term value propositions. |
36159.0 | 2016-11-20 00:00:00 UTC | Ready to Get In on Biotech? Check Out These 3 Stocks | ACAD | https://www.nasdaq.com/articles/ready-get-biotech-check-out-these-3-stocks-2016-11-20 | nan | nan | There are plenty of reasons for investors to avoid the biotechnology sector altogether. The majority of companies from the industry are unprofitable, forcing them to constantly raise additional capital. Bringing a new drug through the regulatory approval process is incredibly difficult, so shareholders face long odds of success. Even if a drug does manage to win approval, it can still be a huge challenge to get providers and payers on board.
And yet, despite all of those negatives, it can be a mistake to write off the sector entirely. After all, if you buy the right biotech stocks, the returns can be life-changing .
Image source: Getty Images.
With that in mind, we asked a team of Fools to highlight a biotech stock that they think is a good choice for investors who are new to the industry. Read on to see why they chose ACADIA Pharmaceuticals (NASDAQ: ACAD) , Celldex Therapeutics (NASDAQ: CLDX) , and Neurocrine Biosciences (NASDAQ: NBIX) .
Off to a fast start
Brian Feroldi (ACADIA Pharmaceuticals): I'm a conservative investor, so I like to buy biotech stocks only after they've brought a new drug to market. If that strategy appeals to you, then I'd recommend that you give ACADIA Pharmaceuticals a closer look.
ACADIA recently crossed the finish line with its first drug -- Nuplazid -- which is approved to treat Parkinson's disease psychosis, or PDP. This condition affects roughly 40% of the 1 million patients in the U.S. who suffer from Parkinson's disease. PDP causes patients to hallucinate and become delusional, which greatly increases the cost and complexity of their care.
Image source: ACADIA Pharmaceuticals.
Up until Nuplazid was launched a few months ago, physicians didn't really have any effective treatment options. That fact gave Nuplazid automatic demand , so sales were strong right out of the gate. During its first full quarter on the market, sales hit $5.2 million, which was far above the $2.9 million that Wall Street had expected. That's a terrific start, suggesting that ACADIA has a real winner on its hands.
While growth in PDP will likely remain strong for years to come, ACADIA believes that Nuplazid's label could eventually be expanded to include other disease states, too. The drug is already in trials as a potential treatment for Alzheimer's disease psychosis and schizophrenia. If those trials pan out, then Nuplazid's addressable market could greatly expand from here.
ACADIA is far from risk-free, but Nuplazid holds real promise to grow into a blockbuster drug over time. That makes this stock a great choice for new investors who want to take their first step into the biotech industry.
A lot for a little
Cory Renauer (Celldex Therapeutics): If you're looking to get in on biotech, then you'd be hard-pressed to find a stock with more potential bang for your buck than Celldex Therapeutics. Its market cap turned south earlier this year after its brain cancer candidate, Rintega, performed in line with previous studies but failed to outperform the current standard of care in a head-to-head comparison.
The shocking failure led to a market beatdown, and at recent prices, the company's market cap is just $480.6 million. With a nearly debt-free balance sheet that boasted cash, cash equivalents, and marketable securities totaling $203.2 million at the end of September, this is one of the cheapest biotech stocks you can buy right now.
Image source: Getty Images.
Despite its modest price tag, the company has a development pipeline stuffed with targeted cancer therapies. Industry peers 10 times its size would be thrilled to have five separate candidates in nine self-sponsored clinical trials, plus two more sponsored by the National Cancer Institute. Once a planned acquisition of privately held Kolltan Pharmaceuticals is completed, the company will add several more clinical-stage candidates to its roster.
Celldex is currently enrolling a cross section of difficult-to-treat breast cancer patients with tumors that express glycoprotein NMB on their surface. Once the treatment candidate glembatumumab vedotin, or glemba, binds to this target, it releases a lethal dose of chemo inside the tumor cell.
In a previous study, glemba significantly outperformed standard chemo in a similar group of patients, and repeating the success would probably lead to an approval. I think glemba alone justifies Celldex's market cap, and its other candidates are icing on the cake. With so much to look forward to, and at such a low price, this is a great stock for newbies and experienced biotech investors alike.
Poised for a big 2017
Cheryl Swanson (Neurocrine Biosciences): Snagging yourself a biotech winner starts with finding a stock whose lead drugs have blockbuster potential, and it doesn't hurt if they've mostly proved themselves in clinical trials. Neurocrine Biosciences fits the bill on both counts. The $4.75 billion market cap biotech's drug valbenazine has been tagged with the FDA's breakthrough designation and is up for approval on April 11, 2017. Valbenazine should achieve first-to-market advantage for tardive dyskinesia, a debilitating condition affecting the nervous system, over rival med SD-809 from Teva Pharmaceutical (NYSE: TEVA) . With no approved products and decades of pent-up demand, that indication alone gives it blockbuster potential. But valbenazine is also being tested in Tourette's syndrome, a condition that involves involuntary movements or sounds. With data due to be released by the end of 2016, Tourette's could give the drug another $2 billion market in the developed world.
So why is Neurocrine flat for the year? Blame the sectorwide funk and the fact that Wall Street also seems to doubt whether Neurocrine can hold off Teva's much larger sales force. However, valbenazine should easily beat SD-809 to market.
Neurocrine has another budding blockbuster in partnership with big pharma AbbVie (NYSE: ABBV) . AbbVie plans to file a new drug application for elagolix in 2017. The first approval target is endometriosis, but elagolix has a further indication in uterine fibroids. Endometriosis is a primary cause of infertility, with analysts projecting a $2.6 billion market for the indication by 2022. Better yet, investors can expect AbbVie to do the heavy lifting for elagolix's launch, while Neurocrine is well-prepared to handle the neurological drug's commercialization, with $353 million in cash or cash equivalents, which, at the current burn rate, should last at least 18 months. Be forewarned this is a high-risk stock, but if Neurocrine can get these drugs across the finish line, then in my view, it's a steal.
Forget the 2016 Election: 10 stocks we like better than ACADIA Pharmaceuticals
Donald Trump was just elected president, and volatility is up. But here's why you should ignore the election:
Investing geniuses Tom and David Gardner have spent a long time beating the market no matter who's in the White House. In fact, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as ofNovember 7, 2016
Brian Feroldi has no position in any stocks mentioned. Cheryl Swanson has no position in any stocks mentioned. Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Read on to see why they chose ACADIA Pharmaceuticals (NASDAQ: ACAD) , Celldex Therapeutics (NASDAQ: CLDX) , and Neurocrine Biosciences (NASDAQ: NBIX) . Off to a fast start Brian Feroldi (ACADIA Pharmaceuticals): I'm a conservative investor, so I like to buy biotech stocks only after they've brought a new drug to market. If that strategy appeals to you, then I'd recommend that you give ACADIA Pharmaceuticals a closer look. | ACADIA recently crossed the finish line with its first drug -- Nuplazid -- which is approved to treat Parkinson's disease psychosis, or PDP. Read on to see why they chose ACADIA Pharmaceuticals (NASDAQ: ACAD) , Celldex Therapeutics (NASDAQ: CLDX) , and Neurocrine Biosciences (NASDAQ: NBIX) . Off to a fast start Brian Feroldi (ACADIA Pharmaceuticals): I'm a conservative investor, so I like to buy biotech stocks only after they've brought a new drug to market. | Off to a fast start Brian Feroldi (ACADIA Pharmaceuticals): I'm a conservative investor, so I like to buy biotech stocks only after they've brought a new drug to market. Read on to see why they chose ACADIA Pharmaceuticals (NASDAQ: ACAD) , Celldex Therapeutics (NASDAQ: CLDX) , and Neurocrine Biosciences (NASDAQ: NBIX) . If that strategy appeals to you, then I'd recommend that you give ACADIA Pharmaceuticals a closer look. | Off to a fast start Brian Feroldi (ACADIA Pharmaceuticals): I'm a conservative investor, so I like to buy biotech stocks only after they've brought a new drug to market. Image source: ACADIA Pharmaceuticals. Read on to see why they chose ACADIA Pharmaceuticals (NASDAQ: ACAD) , Celldex Therapeutics (NASDAQ: CLDX) , and Neurocrine Biosciences (NASDAQ: NBIX) . |
36160.0 | 2016-11-16 00:00:00 UTC | ACADIA Starts Phase II Schizophrenia Study on Pimavanserin | ACAD | https://www.nasdaq.com/articles/acadia-starts-phase-ii-schizophrenia-study-on-pimavanserin-2016-11-16 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia.
ADVANCE is a randomized, double-blind, placebo-controlled, and multi-center study designed for examining the efficacy and safety of adjunctive use of pimavanserin in treating the above patient group.
Pimavanserin is already approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis under the trade name Nuplazid. Nuplazid was commercially launched in May this year.
According to the company's press reelase, 40-50% of patients suffering from schizophrenia have prominent negative symptoms. Currently no drug is approved by the FDA for the treatment of these symptoms. Pimavanserin is selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors.
Meanwhile, the company is forging ahead with its multi-year plans of developing pimavanserin in indications beyond Parkinson's disease psychosis. The company has completed enrollment in a phase II exploratory study on pimavanserin for the treatment of Alzheimer's disease. Top-line results from this study are expected to be announced by the end of 2016.
ACADIA PHARMA Price
ACADIA PHARMA Price | ACADIA PHARMA Quote
ACADIA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Anika and Heska sport a Zacks Rank #1 (Strong Buy) while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.77 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 301.64%.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote ACADIA currently carries a Zacks Rank #3 (Hold). Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote ACADIA currently carries a Zacks Rank #3 (Hold). Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia. | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote ACADIA currently carries a Zacks Rank #3 (Hold). | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote ACADIA currently carries a Zacks Rank #3 (Hold). Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. |
36161.0 | 2016-11-10 00:00:00 UTC | ACAD Crosses Above Key Moving Average Level | ACAD | https://www.nasdaq.com/articles/acad-crosses-above-key-moving-average-level-2016-11-10 | nan | nan | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33.
According to the ETF Finder at ETF Channel, ACAD makes up 4.52% of the Biotech ETF (Symbol: BBH) which is trading higher by about 0.9% on the day Thursday.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33. |
36162.0 | 2016-11-08 00:00:00 UTC | Why Acadia Pharmaceuticals Stock Is Surging Today | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-stock-surging-today-2016-11-08 | nan | nan | Image source: Getty Images.
What happened
As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. The biotech's surge northward was sparked by a stellar third-quarter earnings release, where the company's recently launched Parkinson's disease psychosis (PDP) drug, Nuplazid, pulled in $5.268 million for the three-month period -- vastly exceeding the Street's consensus sales target of $2.9 million.
So what
Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. In the third quarter, for instance, the Street's sales estimates ranged from a mere $740,000 all the way to $7.04 million. So, Nuplazid's promising start is certainly welcome news for the biotech's shareholders.
Now what
After Nuplazid's strong showing in the third quarter, I expect the Street's sales estimates to begin to narrow in a big way moving forward. This new treatment for PDP, after all, has clearly gotten the attention of physicians based on its fairly rapid uptake.
Putting the drug's impressive start to the side, though, the real question -- at least from a valuation standpoint -- is whether Nuplazid can live up to its megablockbuster hype and perhaps trigger a buyout offer in the process. While it's still early days, I'm of the view that Nuplazid's lofty peak sales projections in the $2 billion to $4 billion stratosphere are indeed realistic, but investors will need to be patient.
The long and short of it is that Acadia still needs to expand Nuplazid's label to include other high-value indications such as Alzheimer's disease agitation before sales really take off. Until then, Acadia's stock is arguably a tad on the expensive side, with its shares trading at a staggering 41 times its estimated 2017 revenue. That's why I'm content to watch this volatile biotech from the sidelines for now.
10 stocks we like better than ACADIA Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and ACADIA Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So what Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. The long and short of it is that Acadia still needs to expand Nuplazid's label to include other high-value indications such as Alzheimer's disease agitation before sales really take off. What happened As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. So what Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. | So what Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. | What happened As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. So what Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. The long and short of it is that Acadia still needs to expand Nuplazid's label to include other high-value indications such as Alzheimer's disease agitation before sales really take off. |
36163.0 | 2016-11-08 00:00:00 UTC | Here's What Caused ACADIA Pharmaceuticals to Drop 27% in October | ACAD | https://www.nasdaq.com/articles/heres-what-caused-acadia-pharmaceuticals-drop-27-october-2016-11-08 | nan | nan | What happened
In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence .
So what
Nuplazid is the first FDA-approved therapy for Parkinson's disease psychosis (PDP) and after deciding to retain the rights to the drug, ACADIA Pharmaceuticals launched it in May. The company raised $500 million this year via dilutive stock offerings to finance Nuplazid's roll-out.
Those capital raises were necessary because the company's operating expenses are soaring. Operating costs were $72 million in Q2, up from $39 million last year, and in Q3, they climbed to $77 million from $39 million a year ago. Selling, general, and administrative costs more than doubled year over year to $50.5 million in Q3 from $20.3 million.
ACAD Total Operating Expenses (TTM) data by YCharts .
So far, Nuplazid's sales aren't offsetting very much of that spending. The company reported sales of $5.3 million in Q3, and as a result, ACADIA Pharmaceuticals lost $71.6 million in the period. Through the first nine months of 2016, the company lost $192.7 million. For comparison, ACADIA Pharmaceuticals' net loss in Q3 2015 was $38.9 million, and its loss through the first nine months of 2015 was $118.7 million.
Now what
ACADIA Pharmaceuticals' management says Nuplazid demand is building, and the potential addressable market for Nuplazid is huge, so there are reasons investors ought to keep tabs on this company's stock.
There are about 1 million Americans with Parkinson's disease, and roughly 40% suffer from PDP. Because there are no other FDA approved treatments, tapping into this patient population could make Nuplazid a top seller. Nuplazid's potential could be even bigger if studies in Alzheimer's disease and schizophrenia pan out.
ACADIA Pharmaceuticals plans to report findings from a phase 2 study of Nuplazid in Alzheimer's disease psychosis later this quarter. There are about 5 million people with Alzheimer's disease in the United States, and over 25% of these patients suffer from psychosis. A phase 3 study in Alzheimer's disease agitation is also on deck to begin soon.
Nuplazid's may offer a new option for patients with schizophrenia as well, because up to 30% of schizophrenia patients have an inadequate response to existing therapies. A phase 3 trial of Nuplazid as an adjunct schizophrenia treatment is planned.
Overall, ACADIA Pharmaceuticals' spending means there's no clarity into when this company could turn profitable, but Nuplazid is an intriguing drug with a big market opportunity. Therefore, this company should be viewed as a high-risk, high-reward play.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence . So what Nuplazid is the first FDA-approved therapy for Parkinson's disease psychosis (PDP) and after deciding to retain the rights to the drug, ACADIA Pharmaceuticals launched it in May. Overall, ACADIA Pharmaceuticals' spending means there's no clarity into when this company could turn profitable, but Nuplazid is an intriguing drug with a big market opportunity. | What happened In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence . The company reported sales of $5.3 million in Q3, and as a result, ACADIA Pharmaceuticals lost $71.6 million in the period. ACADIA Pharmaceuticals plans to report findings from a phase 2 study of Nuplazid in Alzheimer's disease psychosis later this quarter. | The company reported sales of $5.3 million in Q3, and as a result, ACADIA Pharmaceuticals lost $71.6 million in the period. Now what ACADIA Pharmaceuticals' management says Nuplazid demand is building, and the potential addressable market for Nuplazid is huge, so there are reasons investors ought to keep tabs on this company's stock. What happened In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence . | The company reported sales of $5.3 million in Q3, and as a result, ACADIA Pharmaceuticals lost $71.6 million in the period. What happened In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence . So what Nuplazid is the first FDA-approved therapy for Parkinson's disease psychosis (PDP) and after deciding to retain the rights to the drug, ACADIA Pharmaceuticals launched it in May. |
36164.0 | 2016-11-07 00:00:00 UTC | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 42.9% Follow-Through Indicator, 5.0% Sensitive | ACAD | https://www.nasdaq.com/articles/earnings-reaction-history-acadia-pharmaceuticals-inc-429-follow-through-indicator-50 | nan | nan | Expected Earnings Release: 11/07/2016, After-hours
Avg. Extended-Hours Dollar Volume: $1,924,505
ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 50%
Average next regular session additional gain: 1.4%
Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 3.2%
Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,924,505 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,924,505 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,924,505 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $1,924,505 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
36165.0 | 2016-11-04 00:00:00 UTC | Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More | ACAD | https://www.nasdaq.com/articles/drug-stocks-earnings-roster-for-nov-7%3A-hznp-acad-more-2016-11-04 | nan | nan | The bulk of the Q3 earnings season is over, with 364 S&P 500 members (as of Nov 2) - accounting for 72.6% of the index's total market capitalization - having already reported results, according to the latest Earnings Outlook .
While total earnings for these index members were up 1.6% from the year-ago quarter, revenues were also up 1.6% year over year. The beat ratio was 72.3% for earnings and 54.7% for revenues.
Notably, the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. However, though the third-quarter reporting cycle saw numerous positive surprises and stability in current-quarter (Q4 2016) estimates in the beginning, these two attributes have started losing ground this week. Positive surprises, particularly on the revenue side, have become harder to come by and Q4 estimates are moving down.
This change was reflected in the results of pharmaceutical companies as well. Though quite a few of the large-cap pharma companies posted better-than-expected third-quarter results last week, three large pharma companies that have reported so far this week - Allergan plc's AGN , Gilead Sciences Inc. GILD and Pfizer Inc. PFE - announced softer-than-expected Q3 results. While Allergan and Pfizer missed estimates for both earnings and sales, Gilead's third-quarter earnings fell short of expectations while revenues just about surpassed expectations.
Four more companies from the healthcare sector are set to report their quarterly results on Nov 7. Let's see how things are shaping up for their respective announcements.
Horizon Pharma plc HZNP
Horizon Pharma is scheduled to report third-quarter 2016 results before the opening bell. The company posted a negative surprise of 20.75% in the last reported quarter. Horizon's performance has been far from encouraging with the company missing earnings estimates thrice and surpassing the same in one out of the four trailing quarters. Overall, the company has an average negative earnings surprise of 1.85%.
Last month, Horizon provided sales and EBITDA expectations for the third quarter of 2016. Including the impact of the $65 million settlement inked with pharmacy benefit manager (PBM) Express Scripts Holding Company in late September, Horizon expects to record third-quarter net sales in the range of $207-$209 million. Third-quarter EBITDA is projected in the range of $139-$141 million. (Read More: Horizon Q3 Earnings Preview: Stock to Disappoint? ).
HORIZON PHARMA Price and EPS Surprise
HORIZON PHARMA Price and EPS Surprise | HORIZON PHARMA Quote
The Zacks Consensus Estimate for the quarter is pegged at 63 cents per share. The company has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%.
ACADIA Pharmaceuticals Inc. ACAD
ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. The company posted a negative surprise of 31.25% in the last reported quarter. In the four trailing quarters, the company missed estimates thrice, bringing the average negative earnings surprise to 15.72%.
ACADIA PHARMA Price and EPS Surprise
ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote
Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. (Read More: ACADIA Pharma: Will It Disappoint in Q3 Earnings? ).
The Zacks Consensus Estimate for the quarter is pegged at a loss of 55 cents per share. The company has a Zacks Rank #3 and an Earnings ESP of +5.46%, indicating a likely positive surprise. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Our previous article showed ACADIA Pharmaceuticals as unlikely to beat on earnings this time around. However, estimates changed thereafter and we are reasonably confident about an earnings beat.
Catalent, Inc. CTLT
Catalent is expected to report first-quarter fiscal 2017 results after market close.
Last quarter, the company delivered a negative earnings surprise of 3.77%. Catalent hasa dismal track record for the last four quarters. The company surpassed expectations only once, while missed in the remaining two quarters, with the average negative earnings surprise being 17.41%.
CATALENT INC Price and EPS Surprise
CATALENT INC Price and EPS Surprise | CATALENT INC Quote
The Zacks Consensus Estimate for the quarter is pegged at 13 cents per share. The company has an Earnings ESP of -7.69% and a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Ultragenyx Pharmaceutical Inc. RARE
Ultragenyx Pharma is expected to report third-quarter 2016 results after market close.
Last quarter, the company delivered a positive earnings surprise of 0.68%. Ultragenyx Pharma has a dismal track record for the last four quarters. The company surpassed expectations only once, while missed in the remaining three quarters, with the average negative earnings surprise being 13.27%.
ULTRAGENYX PHAR Price and EPS Surprise
ULTRAGENYX PHAR Price and EPS Surprise | ULTRAGENYX PHAR Quote
The Zacks Consensus Estimate for the quarter is pegged at a loss of $1.56 per share. The company has an Earnings ESP of 0.00% and a Zacks Rank #2.
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
ALLERGAN PLC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
HORIZON PHARMA (HZNP): Free Stock Analysis Report
CATALENT INC (CTLT): Free Stock Analysis Report
ULTRAGENYX PHAR (RARE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. (Read More: ACADIA Pharma: Will It Disappoint in Q3 Earnings? | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CATALENT INC (CTLT): Free Stock Analysis Report ULTRAGENYX PHAR (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CATALENT INC (CTLT): Free Stock Analysis Report ULTRAGENYX PHAR (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. | ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. (Read More: ACADIA Pharma: Will It Disappoint in Q3 Earnings? |
36166.0 | 2016-11-04 00:00:00 UTC | What to Expect from Repros (RPRX) This Earnings Season | ACAD | https://www.nasdaq.com/articles/what-to-expect-from-repros-rprx-this-earnings-season-2016-11-04 | nan | nan | Repros Therapeutics Inc.RPRX is expected to report third-quarter 2016 results on Nov 14. The company has reported an average positive surprise of 24.56% in the last two quarters. Let's see how things are shaping up for this quarter.
Factors at Play
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to keep an eye on pipeline-related updates by the company. Repros' pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros' pipeline is enclomiphene, which is currently under review in the EU. The company is looking to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Meanwhile, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with a routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Also, Repros plans to hold a discussion with the FDA regarding the prospects of advancing Proellex into phase III studies for the treatment of women struggling with painful menstruation. In addition, Proellex is being evaluated for the treatment of uterine fibroids.
Repros currently carries a Zacks Rank #3 (Hold).
Stocks that Warrant a Look
Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter.
ARIAD Pharmaceuticals Inc. ARIA is expected to release results on Nov 7. The company has an Earnings ESP of 5.26% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. The company has an Earnings ESP of 5.46% and a Zacks Rank #1.
Synergy Pharmaceuticals Inc SGYP is expected to release results on Nov 14. The company has Earnings ESP of 18.18% and a Zacks Rank #3.
Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
REPROS THERAPEU Price and EPS Surprise
REPROS THERAPEU Price and EPS Surprise | REPROS THERAPEU Quote
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REPROS THERAPEU (RPRX): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ARIAD PHARMA (ARIA): Free Stock Analysis Report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. | Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. REPROS THERAPEU Price and EPS Surprise REPROS THERAPEU Price and EPS Surprise | REPROS THERAPEU Quote Confidential from Zacks Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? | Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Stocks that Warrant a Look Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc.RPRX is expected to report third-quarter 2016 results on Nov 14. |
36167.0 | 2016-11-03 00:00:00 UTC | Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings? | ACAD | https://www.nasdaq.com/articles/will-juno-therapeutics-juno-disappoint-in-q3-earnings-2016-11-03 | nan | nan | Juno Therapeutics Inc.JUNO will be reporting third-quarter 2016 results on Nov 9, after the market closes . Last quarter, the company posted a negative earnings surprise of 27.5%.
The company started trading in Dec 2014. So far, it has had a poor track record, with the company posting negative surprises thrice in the last four quarters and meeting estimates only once. The average negative earnings surprise over the last four quarters is 12.8%.
JUNO THERAPEUTC Price and EPS Surprise
JUNO THERAPEUTC Price and EPS Surprise | JUNO THERAPEUTC Quote
Factors at Play
With no approved products in its portfolio, Juno does not generate any product revenue yet. So, investor focus will primarily be on the company's cash burn and pipeline updates.
Juno is looking to revolutionize cancer treatments by engaging the body's immune system to fight cancer. In doing so, the company is developing cell-based cancer immunotherapies based on CAR and high-affinity TCR technologies. This is a hot therapeutic area with huge commercial potential.
However, the company faced a major setback related to the development of its lead pipeline candidate, JCAR015. In Jul 2016, the FDA placed a clinical hold on the company's phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL). The hold was placed after two patients died within the span of a week due to severe neurotoxicity following the addition of fludarabine to the pre-conditioning regimen.
The hold was lifted a week later and the study has thereafter resumed under a revised protocol.
However, results from a phase I study presented in early Jun 2016 showed that JCAR015 led to a complete remission rate of 82% in 50 evaluable patients. The results also demonstrate a marked improvement over historical results with salvage chemotherapy.
We note that at the time of releasing its second-quarter results, Juno had revealed its expectations of cash burn of $220-$250 million in 2016.
Juno has several other interesting candidates in its pipeline, which along with its collaborations with companies like Celgene Corporation CELG for the global development and commercialization of immunotherapies, bode well.
Earnings Whispers
Our proven model does not conclusively show that Juno is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 64 cents.
Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: Juno Therapeutics currently carries a Zacks Rank #4. As it is, we caution against Sell-rated stocks (#4 or #5) going into the earnings announcement.
Stocks That Warrant a Look
Here are a couple of companies you may want to consider instead as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Ariad Pharmaceuticals Inc. ARIA is scheduled to report earnings on Nov 7.The company has an Earnings ESP of +5.26% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. The company is scheduled to report third-quarter results on Nov 7.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CELGENE CORP (CELG): Free Stock Analysis Report
JUNO THERAPEUTC (JUNO): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ARIAD PHARMA (ARIA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. In Jul 2016, the FDA placed a clinical hold on the company's phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL). | Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. JUNO THERAPEUTC Price and EPS Surprise JUNO THERAPEUTC Price and EPS Surprise | JUNO THERAPEUTC Quote Factors at Play With no approved products in its portfolio, Juno does not generate any product revenue yet. | Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. JUNO THERAPEUTC Price and EPS Surprise JUNO THERAPEUTC Price and EPS Surprise | JUNO THERAPEUTC Quote Factors at Play With no approved products in its portfolio, Juno does not generate any product revenue yet. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises. |
36168.0 | 2016-11-03 00:00:00 UTC | What to Expect from Repros (RPRX) This Earnings Season | ACAD | https://www.nasdaq.com/articles/what-to-expect-from-repros-rprx-this-earnings-season-2016-11-03 | nan | nan | Repros Therapeutics Inc. (RPRX) is expected to report third-quarter 2016 results on Nov 14. The company has reported an average positive surprise of 24.56% in the last two quarters. Let's see how things are shaping up for this quarter.
Factors at Play
Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to keep an eye on pipeline-related updates by the company. Repros' pipeline presently comprises enclomiphene and Proellex.
The most advanced candidate in Repros' pipeline is enclomiphene, which is currently under review in the EU. The company is looking to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.
Meanwhile, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with a routine diet and exercise. Six-month interim data from the study were reported in Aug 2016.
Also, Repros plans to hold a discussion with the FDA regarding the prospects of advancing Proellex into phase III studies for the treatment of women struggling with painful menstruation. In addition, Proellex is being evaluated for the treatment of uterine fibroids.
Repros currently carries a Zacks Rank #3 (Hold).
Stocks that Warrant a Look
Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter.
ARIAD Pharmaceuticals Inc. (ARIA) is expected to release results on Nov 7. The company has an Earnings ESP of 5.26% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. The company has an Earnings ESP of 5.46% and a Zacks Rank #1.
Synergy Pharmaceuticals Inc (SGYP) is expected to release results on Nov 14. The company has Earnings ESP of 18.18% and a Zacks Rank #3.
Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
REPROS THERAPEU Price and EPS Surprise
REPROS THERAPEU Price and EPS Surprise | REPROS THERAPEU Quote
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
REPROS THERAPEU (RPRX): Free Stock Analysis Report
ARIAD PHARMA (ARIA): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. Click to get this free report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. | Click to get this free report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. REPROS THERAPEU Price and EPS Surprise REPROS THERAPEU Price and EPS Surprise | REPROS THERAPEU Quote Confidential from Zacks Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? | Click to get this free report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. Stocks that Warrant a Look Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter. | ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. Click to get this free report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc. (RPRX) is expected to report third-quarter 2016 results on Nov 14. |
36169.0 | 2016-11-03 00:00:00 UTC | Puma Biotechnology (PBYI) Q3 Earnings: What's in Store? | ACAD | https://www.nasdaq.com/articles/puma-biotechnology-pbyi-q3-earnings%3A-whats-in-store-2016-11-03 | nan | nan | Puma Biotechnology, Inc.PBYI is expected to report third-quarter 2016 results in November. The company's track record has been mostly disappointing. While it missed estimates in two of the trailing four quarters, it met the same in one and surpassed in the other. The company recorded an average negative surprise of 5.23%.
PUMA BIOTECHNLG Price and EPS Surprise
PUMA BIOTECHNLG Price and EPS Surprise | PUMA BIOTECHNLG Quote
Let's see how things are shaping up for this announcement.
Neratinib in Focus
Puma Biotech has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer that has previously been treated with Herceptin-based adjuvant therapy.
We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.
At the time of announcing second-quarter 2016 results, the company projected that net loss may narrow in the subsequent quarters due to continued reduction in clinical trial expenses and expenses associated with the completion of regulatory filings for neratinib. The company also expects its research and development expenses to decrease in subsequent quarters for the same reasons.
Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib.
Earnings Whispers
Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP , which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.00. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Zacks Rank: Although Puma Biotech's carries a favorable Zacks Rank #2, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider instead, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
ARIAD Pharmaceuticals Inc. ARIA is scheduled to report on Nov 7. It has an Earnings ESP of +5.26% and carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Synergy Pharmaceuticals, Inc. SGYP has an Earnings ESP of +18.18% and carries a Zacks Rank #3. It is expected to report on Nov 14.
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. It is scheduled to report on Nov 7.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ARIAD PHARMA (ARIA): Free Stock Analysis Report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. PUMA BIOTECHNLG Price and EPS Surprise PUMA BIOTECHNLG Price and EPS Surprise | PUMA BIOTECHNLG Quote Let's see how things are shaping up for this announcement. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. Zacks Rank: Although Puma Biotech's carries a favorable Zacks Rank #2, its 0.00% ESP makes surprise prediction difficult. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. The company also expects its research and development expenses to decrease in subsequent quarters for the same reasons. |
36170.0 | 2016-10-31 00:00:00 UTC | ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings? | ACAD | https://www.nasdaq.com/articles/acadia-pharma-acad%3A-will-it-disappoint-in-q3-earnings-2016-10-31 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3.
In the four trailing quarters, the company has missed estimates thrice, bringing the average negative earnings surprise to 15.72%.
ACADIA PHARMA Price and EPS Surprise
ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote
Let's see how things are shaping up for this announcement.
Factors at Play
ACADIA is expected to benefit from the commercial launch of Nuplazid on May 31 used for the treatment of hallucinations and delusions following its FDA approval on Apr 29. The newly launched drug generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. The introduction of Nuplazid represents a major paradigm shift in the treatment of patients with PD psychosis, as it is the first and only FDA-approved treatment for hallucinations and delusions.
Meanwhile, the company is on track with its multiyear plans of developing Pimavanserin in indications beyond PD psychosis. The company has completed enrollment in a phase II exploratory study on Pimavanserin for the treatment of Alzheimer's disease psychosis. Top-line results from this study are expected to be announced by the end of 2016.
However, Nuplazid pricing may be a cause for concern as physician, patient and payor responses are still uncertain.
Earnings Whispers
Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. However, that is not the case here as you will see below.
Zacks ESP : ACADIA has an Earnings ESP of -1.82%. That is because the Most Accurate estimate stands at a loss of 56 cents while the Zacks Consensus Estimate pegged at a loss of 55 cents.
Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank : ACADIA has a Zacks Rank #3 which increases the predictive power of ESP. However, its negative ESP makes surprise prediction difficult for the quarter.
Note that we caution against stocks with Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a few companies that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Ariad Pharmaceuticals Inc. ARIA is expected to report earnings on Nov 1.The company has an Earnings ESP of +5.26% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Allergan plc AGN has an Earnings ESP of +0.56% and a Zacks Rank #3. The company is scheduled to report third-quarter results on Nov 2.
Infinity Pharmaceuticals, Inc. INFI has an Earnings ESP of +5.81% and a Zacks Rank #1. The company is scheduled to report results on Nov 3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLERGAN PLC (AGN): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ARIAD PHARMA (ARIA): Free Stock Analysis Report
INFINITY PHARMA (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factors at Play ACADIA is expected to benefit from the commercial launch of Nuplazid on May 31 used for the treatment of hallucinations and delusions following its FDA approval on Apr 29. ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Let's see how things are shaping up for this announcement. | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Let's see how things are shaping up for this announcement. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3. | Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Let's see how things are shaping up for this announcement. | Zacks ESP : ACADIA has an Earnings ESP of -1.82%. ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Let's see how things are shaping up for this announcement. |
36171.0 | 2016-10-27 00:00:00 UTC | Acadia Pharmaceuticals Becomes Oversold | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-becomes-oversold-2016-10-27 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 48.1. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $22.56.
According to the ETF Finder at ETF Channel, ACAD makes up 3.41% of the Biotech ETF (Symbol: BBH) which is trading higher by about 0.6% on the day Thursday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $22.56. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $22.56. In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $22.56. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. According to the ETF Finder at ETF Channel, ACAD makes up 3.41% of the Biotech ETF (Symbol: BBH) which is trading higher by about 0.6% on the day Thursday. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36172.0 | 2016-10-19 00:00:00 UTC | Commit To Purchase Acadia Pharmaceuticals At $20, Earn 45.1% Annualized Using Options | ACAD | https://www.nasdaq.com/articles/commit-purchase-acadia-pharmaceuticals-20-earn-451-annualized-using-options-2016-10-19 | nan | nan | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but tentative about paying the going market price of $23.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $20 strike, which has a bid at the time of this writing of $2.30. Collecting that bid as the premium represents a 11.5% return against the $20 commitment, or a 45.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $20 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Acadia Pharmaceuticals Inc sees its shares decline 14.5% and the contract is exercised (resulting in a cost basis of $17.70 per share before broker commissions, subtracting the $2.30 from $20), the only upside to the put seller is from collecting that premium for the 45.1% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $23.38) to be 68%. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com.
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but tentative about paying the going market price of $23.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $23.38) to be 68%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $23.38) to be 68%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares decline 14.5% and the contract is exercised (resulting in a cost basis of $17.70 per share before broker commissions, subtracting the $2.30 from $20), the only upside to the put seller is from collecting that premium for the 45.1% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but tentative about paying the going market price of $23.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com. |
36173.0 | 2016-10-10 00:00:00 UTC | The Implied Analyst 12-Month Target For IWR | ACAD | https://www.nasdaq.com/articles/implied-analyst-12-month-target-iwr-2016-10-10 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell Mid-Cap ETF (Symbol: IWR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $188.79 per unit.
With IWR trading at a recent price near $171.92 per unit, that means that analysts see 9.81% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share. Similarly, SAVE has 27.13% upside from the recent share price of $42.24 if the average analyst target price of $53.70/share is reached, and analysts on average are expecting GPOR to reach a target price of $36.28/share, which is 24.43% above the recent price of $29.16. Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share. Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). | Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share. Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share. | Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share. |
36174.0 | 2016-10-06 00:00:00 UTC | These 2 Biotechs Could Vanish by 2018 | ACAD | https://www.nasdaq.com/articles/these-2-biotechs-could-vanish-2018-2016-10-06 | nan | nan | Investors hoping to suss out the next Amgen or Gilead Sciences -- that is, companies that start small but grow into multi-billion dollar entities -- can be in for rough ride. After all, most early life cycle biotechs tend to meet one of two less glamorous fates: bankruptcy or buyout. Armed with this insight, let's take a look at two high-profile biotech companies that appear destined to vanish from the public markets within the next year or two.
ACAD data by YCharts .
The overarching concern seems to be Acadia's lack of experience in terms of handling a commercial launch. Nuplazid, after all, is the company's maiden voyage into the complex world of pharmaceutical sales, and the biotech is up against a host of bigger competitors that sell a variety of products commonly used off-label to treat PDP.
That said, Nuplazid's estimated target market of 400,000 Parkinson's patients in just the U.S., combined with its annual wholesale price of $23,400 , gives it a real shot at eventually reaching blockbuster status. However, it might take a company with deeper ties to the Parkinson's disease market and a more robust commercial infrastructure to turn these lofty sales projections into reality. So, if Nuplazid gets off to a slower than expected start and Acadia's valuation continues to trend lower as a result, this mid-cap biotech might prove to be a particularly compelling buyout target.
And perhaps as an added buyout trigger, Acadia is close to releasing the results of a mid-stage study assessing pimavanserin in Alzheimer's disease psychosis (ADP) -- an indication that could easily bring in another billion or so in sales. In fact, pimavanserin's overall clinical program has the potential to make it one of the top-selling drugs in the world well before it loses patent protection in the U.S. in 2028:
As drugs with mega-blockbuster potential and over a decade of market exclusivity ahead are exceedingly rare, it's hard to imagine Acadia existing beyond 2018 as an independent entity, especially in this M&A-rich environment. Indeed, Nuplazid's commercial launch would probably have to defy most expectations by a wide margin to the downside in order to deter possible buyers.
MannKind's death spiral is nearly complete
MannKind Corp. (NASDAQ: MNKD) is quickly running out of cash, and sales of its inhaled insulin product Afrezza have continued to underwhelm this year, despite the company's innovative efforts to reenergize its launch following Sanofi 's decision to return the drug's commercial rights. Making matters worse, the biotech recently received a NASDAQ de-listing notice, perhaps necessitating a sizable reverse split (when a company reduces its share count by several fold to up its price per share) to meet the exchange's listing requirements.
Cutting to the chase, this struggling biotech has been averaging a quarterly cash burn rate of $21 million over the last year -- and that's before the company took on Afrezza's commercialization, meaning that MannKind probably has less than two quarters remaining in terms of a rock solid cash runway. Now, MannKind does have some additional financing options available to extend its runway, such as its $50 million or so in at-the-market (ATM) stock offerings, as well as a $30 million loan agreement with The Mann Group. But there's no guarantee that the company will be able to access the entirety of these remaining funds. After all, it's not exactly feasible to tap a $50 million ATM facility with a share price below a buck.
The bottom line is that without a white knight riding in to save the day sometime soon, MannKind probably won't be able to postpone a dreaded bankruptcy filing that much longer.
Key takeaways
While the biotech industry is rife with jaw-dropping growth opportunities, it also contains a fair number of potential landmines. Acadia, for example, made it through the perils of clinical trials and a regulatory review to reach the commercial phase of its life cycle, only to be met with doubt about its ability to properly execute Nuplazid's commercial launch. MannKind, for its part, appeared primed to prove its detractors wrong following the somewhat unexpected approval of Afrezza, but then ran into the harsh reality of commercializing a novel pharma product. Acadia and MannKind thus clearly illustrate the substantial risks associated with investing in early life cycle biotechs and are a good reminder that it's not always smooth sailing after FDA approval.
Even with these risks in mind, though, Acadia does look like a worthwhile buy right now in light of Nuplazid's commercial prospects -- even if they aren't realized immediately out of the gate. MannKind, by contrast, doesn't appear to have the necessary elements in place to reverse course, meaning that investors would probably be wise to avoid this falling knife.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short October 2016 $85 calls on Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And perhaps as an added buyout trigger, Acadia is close to releasing the results of a mid-stage study assessing pimavanserin in Alzheimer's disease psychosis (ADP) -- an indication that could easily bring in another billion or so in sales. ACAD data by YCharts . The overarching concern seems to be Acadia's lack of experience in terms of handling a commercial launch. | Acadia and MannKind thus clearly illustrate the substantial risks associated with investing in early life cycle biotechs and are a good reminder that it's not always smooth sailing after FDA approval. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ACAD data by YCharts . | ACAD data by YCharts . The overarching concern seems to be Acadia's lack of experience in terms of handling a commercial launch. So, if Nuplazid gets off to a slower than expected start and Acadia's valuation continues to trend lower as a result, this mid-cap biotech might prove to be a particularly compelling buyout target. | Acadia, for example, made it through the perils of clinical trials and a regulatory review to reach the commercial phase of its life cycle, only to be met with doubt about its ability to properly execute Nuplazid's commercial launch. ACAD data by YCharts . The overarching concern seems to be Acadia's lack of experience in terms of handling a commercial launch. |
36175.0 | 2016-10-05 00:00:00 UTC | Acadia Pharmaceuticals Enters Oversold Territory (ACAD) | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-enters-oversold-territory-acad-2016-10-05 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 50.3. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $28.82.
According to the ETF Finder at ETF Channel, ACAD makes up 2.78% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading up by about 1% on the day Wednesday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $28.82. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $28.82. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $28.82. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.78% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading up by about 1% on the day Wednesday. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36176.0 | 2016-10-04 00:00:00 UTC | Notable Two Hundred Day Moving Average Cross - ACAD | ACAD | https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-acad-2016-10-04 | nan | nan | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $29.22.
According to the ETF Finder at ETF Channel, ACAD makes up 2.93% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 0.3% on the day Tuesday.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $29.22. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $29.22. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $29.22. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.93% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 0.3% on the day Tuesday. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day. |
36177.0 | 2016-10-03 00:00:00 UTC | 10 Biotech Stocks to Put on Your Radar This Quarter | ACAD | https://www.nasdaq.com/articles/10-biotech-stocks-to-put-on-your-radar-this-quarter-2016-10-03 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the foreseeable future for the broad market may not be clear, there's one group that still moves independently of stocks as a whole - biotech stocks.
These stocks are still pushed and pulled by industry- and company-specific news, which is usually driven by progress (or lack thereof) of a pipeline.
To that end, a handful of biotech stocks have some major catalysts in store for the fourth quarter of 2016. These events have a very good shot at moving stocks after, or even before, the news is released.
Stocks That Could Be Bought Next
Here's a closer look at the 10 names that could serve up the most fireworks over the course of the coming three months.
Biotech Stocks to Watch: Celldex Therapeutics (CLDX)
Celldex Therapeutics, Inc. (NASDAQ: CLDX ) is the first of the major biotech stocks scheduled to release an update on a pretty important drug this quarter; look for news on Oct. 8 concerning melanoma treatment glembatumumab vedotin. And that's a firm date too. Celldex is slated to present an update on the therapy at the European Society for Medical Oncology Congress.
Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate . It targets glycoprotein NMB, which is a protein overexpressed in breast cancer and melanoma cells and has been linked to a cancer cell's ability to metastasize.
Although CLDX stock has been sliding backward for a year and a half now, it does have an ace up its sleeve. It's recently hired a 25-year industry veteran, Elizabeth Crowley , as chief product development officer, as the company is building its drugs from the ground up with approval and marketing potential in mind.
Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD)
Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide.
For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's. Rather, its leveraging its drug Pimavanserin to treat psychosis related to Alzheimer's disease.
Still, that's a symptom common among Alzheimer's patients, and investors have bolstered confidence on the drug in that Pimavanserin has already been approved to combat hallucinations and delusions associated with closely-related Parkinson's disease.
It's only a phase 2 update due in Q4, but a lot of eyes are on ACAD and its work in this tough battle.
Biotech Stocks to Watch: Theravance Biopharma (TBPH)
The exact date Theravance Biopharma Inc (NASDAQ: TBPH ) intends to release a phase 3 update on COPD treatment Revefenacin isn't known. The company simply said in a prior communication with the market it would be sharing an interim look at the trial's progress sometime in early Q4.
Revefenacin is a once-daily, long-acting nebulized muscarinic antagonist
The COPD market is worth more than $11 billion per year .
Biotech Stocks to Watch: The Medicines Company (MDCO)
Another of the key clinical-trial dates traders may want to mark on their calendars is Nov. 15. That's when The Medicines Company (NASDAQ: MDCO ) is going to deliver an update on not one developmental program, but two.
One of them is a phase 2 interim update on PCSKsi, as a therapy for atherosclerotic cardiovascular disease (or ASCVD). PCSK9si is an RNAi drug that utilizes Alnylam Pharmaceuticals' proprietary enhanced stabilization chemistry conjugate delivery platform. It is believed PCSKsi can reduce PCSK9 levels as well as lower LDL-C - one of the "bad" cholesterols levels.
The other update will look at how well MDCO-216 has treated acute coronary syndrome (or ACS). This phase 2 drug is particularly promising in that it may actually remove plaque buildup on artery walls , as opposed to just filtering out of the bloodstream.
The 10 Best Stocks to Buy for the Rest of 2016
The updates will be made as presentations at the American Heart Association's Scientific Sessions conference.
Biotech Stocks to Watch: Dynavax Technologies (DVAX)
Add Dynavax Technologies Corporation (NASDAQ: DVAX ) to the list of biotech stocks to watch on or a little before Dec. 15. That's when the company is going to get a yay or nay from the Food & Drug Administration about Heplisav-B as a treatment for hepatitis B in people with type 2 diabetes
The saga has already become tense. The original PDUFA date of Sept. 15 was postponed until mid-December to give the agency time to consider answers to questions it had for Dynavax . And this is the same drug that was implicated in some autoimmune disorders back in 2013. Although historical stumbles don't outright preclude an approval, they don't exactly bode well either.
On the other hand, this is a sliver of the market that is underserved, and Heplisav-B has performed well. The most recent look at phase 3 results showed the treatment created seroprotection in 90% of participants versus only a 65% response for the go-to HBV treatment Engerix-B.
Biotech Stocks to Watch: Cempra (CEMP)
Like The Medicines Company, Cempra Inc (NASDAQ: CEMP ) doesn't have just one, but two big clinical-trial dates slated for the fourth quarter. Unlike The Medicines Company, these aren't just progress reports on the company's R&D. These are full-blown PDUFA (FDA decision) dates, and they're back to back.
The first date worth noting is Dec. 27. That's when the agency will make a ruling on the oral version of Solithera as a treatment for community-acquired bacterial pneumonia (or CABP). The second date that should prompt current and would-be owners of CEMP to buckle up is Dec. 28. That's when the FDA is going to give a thumbs up or a thumbs down on the injectable version of Solithera as a treatment for CABP.
7 ETFs to Buy for a Christmas Rally
Solithera is a macrolide (and the first fluoro-ketolide) which has proven to be effective on macrolide-resistant bacteria. Phase 3 testing showed it to be more effective than alternatives like azithromycin or clarithromycin against these particular bacterial strains.
Biotech Stocks to Watch: Advanced Accelerator Application (AAAP)
Advanced Accelerator Application SA (ADR) (NASDAQ: AAAP ) isn't exactly one of the better-known biotech stocks. Its drug Lutathera isn't a showstopper either. Indeed, most investors don't even know what the term "inoperable progressive midgut NETs" means.
Yet, the fact that the FDA has opted to give Lutathera a priority review points to perceived need and the odds it will be well-received by the agency.
NETs are neuroendocrine tumors … tumors that can appear anywhere in the body, but are most commonly found within vital organs or within the gastrointestinal tract. Lutathera showed a statistically significant reduction of disease progression or death (79% better) versus the results achieved with a double dose of the standard NETs treatment Octreotide LAR.
The PDUFA date is scheduled for Dec. 28, before New Year's and after Christmas, when many investors may not be watching the market all that closely.
Biotech Stocks to Watch: Puma Biotechnology (PBYI)
The last three of the top ten biotech stocks to watch this quarter don't have specific dates to mark on your calendar. Rather, these companies have simply said updates were due sometime during Q4. The updates could come at any time, so interested parties may want to keep close tabs on all three names on the chance any of these names delivers a notice that news is on the way on a specific date.
The first of these organizations worth putting on your watchlist is Puma Biotechnology Inc (NYSE: PBYI ), which is developing Neratinib as a stand-alone therapy for hormone receptor-positive breast cancer patients. Phase 2 data is due out sometime in the fourth quarter.
Neratinib is also being tried as part of a combination treatment for HER2 breast cancer, however, so don't be surprised if the company delivers an update on that front as well.
7 Stock Charts to Watch in October
It's encouraging that Neratinib was already recently approved for a significant set (the HER2+/HR-) of breast cancer sufferers .
Biotech Stocks to Watch: Medivation (MDVN)
Prostate cancer continues to vex the healthcare industry. Though good treatments like docetaxel are available, there's no showstopper therapy to treat the disease. Medivation Inc (NASDAQ: MDVN ) may get its chance to put a game changer on the market … or at least a portion of it. Xtandi, for metastatic castrate-resistant prostate cancer, has a PDUFA date of Oct. 22.
Xtandi, an androgen receptor inhibitor, was already approved as a treatment for prostate cancer back in 2012 . The company just wants to widen its approved uses. In phase 3 trials, progression-free survival of Xtandi users at the twelve-month mark was 65%, versus only 14% for those not using the drug.
7 Best American Funds for Low-Cost Connoisseurs
Xtandi works by preventing the union of androgen - a male hormone - and androgen receptors in prostate cancer cells. It's been found, when this connection can be blocked, that it may cause the cancer cell to stop replicating itself.
As a note, Pfizer Inc. (NYSE: PFE ) shareholders should be watching this one, as the pharma outfit bought Medivation in August.
Biotech Stocks to Watch: GW Pharmaceuticals (GWPH)
Last but not least, GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) is one of the biotech stocks with the potential to make waves this quarter.
GW Pharmaceuticals - arguably the only legitimized cannabis-based drugmaker - has already won approval of its Sativex as a therapy for multiple-sclerosis spasticity in several countries outside of the United States.
Now the company wants to introduce it as a treatment for for the disease's symptoms here at home, as well as a therapy for cerebral palsy. GW Pharmaceuticals is also expected to deliver some sort of update on GWP-42002 and GWP-42003 as treatments for glioma sometime this quarter.
7 Make-or-Break Earnings Reports Coming in October
Most of the trials are only in phase 2 testing at this time. The news in the aggregate has the potential to move the stock all the same, however, not so much because of the need, but because more progress on this cannabis front adds credibility to everything GWPH is doing .
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.
The post 10 Biotech Stocks to Put on Your Radar This Quarter appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD) Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide. For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's. | Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD) Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide. For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's. | Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD) Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide. For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's. | Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD) Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide. For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's. |
36178.0 | 2016-09-22 00:00:00 UTC | A Critical Couple of Months for Acadia Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/critical-couple-months-acadia-pharmaceuticals-2016-09-22 | nan | nan | Image source: Stockmonkeys.com via Flickr.
ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months. The company recently launched Nuplazid, a Parkinson's disease psychosis therapy, and Q3 results should provide insight into how quickly it's gaining traction with doctors. ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market.
Is ACADIA Pharmaceuticals about to deliver investors a couple of big wins? Let's take a closer look.
Why Nuplazid matters
Parkinson's disease psychosis, or PDP, affects about 40% of the 1 million patients who suffer from Parkinson's disease, and despite its PDP's prevalence, doctors have found few ways to successfully treat it. Historically, doctors use anti-psychotic medications off-label; however, those medications can interfere with commonly used Parkinson's disease drugs, and they're often contraindicated for use in elderly patients.
While anti-psychotics can successfully tamp down hallucinations and delusions associated with PDP, they do so by blocking dopamine receptors. That's a big problem for patients, because the motor symptoms of Parkinson's disease are often treated with Levodopa, which boosts dopamine activity.
Doctors can try control PDP by reducing Levodopa doses, but that can lead to Parkinson's progressing more quickly and patients moving into institutional care sooner than they might have otherwise.
Clearly, PDP treatment options are far from ideal, and because of that, Nuplazid could gain widespread adoption. Unlike anti-psychotics, Nuplazid doesn't target dopamine receptors, and in trials, Nuplazid successfully reduced the number of psychotic events experienced by patients.
Losses for now
Rather than license away its rights to Duplazid, ACADIA Pharmaceuticals has decided to go it alone. The company is knee-deep in an expensive product launch, and negotiations with payers could mean it takes a while before this company turns a profit.
Operating costs were $72 million in Q2, and since most Duplazid prescriptions during its first month on the market were filled with free samples, Nuplazid revenue totaled only $97,000 in the quarter.
Management has set a price of $23,500 per year for the drug, but it can take between three and nine months for Medicare Part D and private insurers to decide on reimbursement. The sooner ACADIA Pharmaceuticals can cut deals with payers, the sooner it can begin generating meaningful enough revenue to get itself into the black.
Targeting Alzheimer's disease
ACADIA Pharmaceuticals is scheduled to update investors on Nuplazid's potential to treat patients suffering from Alzheimer's disease psychosis soon, and if results are solid, it could significantly expand Nuplazid's addressable target market. An estimated 25% to 50% of the 5 million Americans suffering from Alzheimer's disease suffer hallucinations and delusions.
The company's enrolled roughly 200 people in its phase 2 Alzheimer's disease psychosis trial, and the trial's endpoints include measuring psychosis, agitation/aggression, and sleep/nighttime behavior. ACADIA Pharmaceuticals plans to release top-line results from the trial before the end of 2016.
Looking ahead
Nuplazid is the only FDA-approved therapy for PDP, and if it's eventually approved for use in Alzheimer's disease, it will be the only FDA-approved therapy for psychosis in that patient population, too.
A monopoly position in these two big indications means Nuplazid peak sales potential is big, but there's not a lot of evidence (yet) that Nuplazid is catching on with doctors, or that negotiations with payers are bearing fruit. Further, there's no guarantee that the company's Alzheimer's disease trial will pan out.
Overall, ACADIA Pharmaceuticals' success is highly dependent on Nuplazid, and while a stock offering earlier this year gives management some financial wiggle room, there's still a lot of risk associated with owning this stock. For that reason, investors should be watching this company closely over the coming months to see if Nuplazid prescriptions are ramping, and whether or not there's a potential for its use in Alzheimer's disease patients.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months. ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market. Is ACADIA Pharmaceuticals about to deliver investors a couple of big wins? | Targeting Alzheimer's disease ACADIA Pharmaceuticals is scheduled to update investors on Nuplazid's potential to treat patients suffering from Alzheimer's disease psychosis soon, and if results are solid, it could significantly expand Nuplazid's addressable target market. ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months. ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market. | ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market. Targeting Alzheimer's disease ACADIA Pharmaceuticals is scheduled to update investors on Nuplazid's potential to treat patients suffering from Alzheimer's disease psychosis soon, and if results are solid, it could significantly expand Nuplazid's addressable target market. ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months. | Targeting Alzheimer's disease ACADIA Pharmaceuticals is scheduled to update investors on Nuplazid's potential to treat patients suffering from Alzheimer's disease psychosis soon, and if results are solid, it could significantly expand Nuplazid's addressable target market. ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months. ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market. |
36179.0 | 2016-09-11 00:00:00 UTC | Why ACADIA Pharmaceuticals Tumbled 13.3% in August | ACAD | https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-tumbled-133-august-2016-09-11 | nan | nan | What happened
After reporting second-quarter results and announcing a $200 million dilutive stock offering, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) fell 13.3% last month, according to S&P Global Market Intelligence .
So what
ACADIA Pharmaceuticals launched its first and only commercial drug on May 31, and sales of that drug -- Nuplazid -- are only beginning to trickle in. Last quarter, the company reported just $97,000 in Nuplazid sales, despite its status as the only FDA-approved treatment for Parkinson's disease psychosis, or PDP.
The sales pace is unsurprisingly shy of the company's soaring expenses. ACADIA Pharmaceuticals has chosen to launch the drug itself without a large partner, and as a result, hiring and marketing programs caused operating expenses to jump to $72 million in Q2 from $39 million a year ago. Over the two years, trailing-12-month operating expenses have more than doubled.
ACAD Total Operating Expenses (TTM) data by YCharts
Since spending in support of Nuplazid's launch isn't about to tail off anytime soon and it could be a while before Nuplazid revenue reaches meaningful levels, ACADIA Pharmaceuticals' decision to tap investors for more funding isn't surprising.
ACADIA Pharmaceuticals raised $300 million via a stock offering earlier this year, and management announced another $200 million stock offering in early August. The company's cash and investments stockpile totaled $412 million before its August offering, so it should have enough financial firepower on hand now to last it into 2018.
Now what
Parkinson's disease psychosis affects about 40% of the 1 million Parkinson's disease patients in the United States, and it's a major cause for Parkinson's disease patients' admittance to nursing homes. Before Nuplazid's approval, a PDP diagnosis resulted in adjustments to standard-of-care dopamine replacement therapy or the off-label prescribing of anti-psychotic medications that can cause side effects and that can be contraindicated in elderly patients.
Nuplazid is a potentially better option, but the company needs to increase awareness among doctors, caregivers, and patients, and it has to persuade healthcare payers to pay for it. The drug costs $23,500 per year, and it can take nine to 12 months for private insurers to determine where to place a drug in their drug formularies.
ACADIA Pharmaceuticals is negotiating with payers, and a clear pathway to pay for Nuplazid should exist a year from now, but in the meantime, sales could be bumpy because management may need to rely heavily on free samples to keep costs in check for patients.
Overall, ACADIA Pharmaceuticals' stock offering is dilutive, but it does provide the financial footing necessary to build momentum for Nuplazid. Nuplazid's addressable market makes this stock intriguing, and while I don't own shares in it currently, I have added it to my watch list.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened After reporting second-quarter results and announcing a $200 million dilutive stock offering, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) fell 13.3% last month, according to S&P Global Market Intelligence . ACADIA Pharmaceuticals is negotiating with payers, and a clear pathway to pay for Nuplazid should exist a year from now, but in the meantime, sales could be bumpy because management may need to rely heavily on free samples to keep costs in check for patients. So what ACADIA Pharmaceuticals launched its first and only commercial drug on May 31, and sales of that drug -- Nuplazid -- are only beginning to trickle in. | What happened After reporting second-quarter results and announcing a $200 million dilutive stock offering, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) fell 13.3% last month, according to S&P Global Market Intelligence . ACADIA Pharmaceuticals raised $300 million via a stock offering earlier this year, and management announced another $200 million stock offering in early August. Overall, ACADIA Pharmaceuticals' stock offering is dilutive, but it does provide the financial footing necessary to build momentum for Nuplazid. | ACADIA Pharmaceuticals has chosen to launch the drug itself without a large partner, and as a result, hiring and marketing programs caused operating expenses to jump to $72 million in Q2 from $39 million a year ago. ACAD Total Operating Expenses (TTM) data by YCharts Since spending in support of Nuplazid's launch isn't about to tail off anytime soon and it could be a while before Nuplazid revenue reaches meaningful levels, ACADIA Pharmaceuticals' decision to tap investors for more funding isn't surprising. ACADIA Pharmaceuticals raised $300 million via a stock offering earlier this year, and management announced another $200 million stock offering in early August. | ACADIA Pharmaceuticals has chosen to launch the drug itself without a large partner, and as a result, hiring and marketing programs caused operating expenses to jump to $72 million in Q2 from $39 million a year ago. ACADIA Pharmaceuticals raised $300 million via a stock offering earlier this year, and management announced another $200 million stock offering in early August. What happened After reporting second-quarter results and announcing a $200 million dilutive stock offering, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) fell 13.3% last month, according to S&P Global Market Intelligence . |
36180.0 | 2016-09-11 00:00:00 UTC | 3 Stocks Begging for a Buyout | ACAD | https://www.nasdaq.com/articles/3-stocks-begging-buyout-2016-09-11 | nan | nan | Investors should never buy a stock solely because there's a chance that a suitor will buy the company lock, stock, and barrel. However, that doesn't mean that a stock that may attract an acquirer won't also appeal to investors. For instance, our Motley Fool contributors think that these three companies offer investors intriguing reasons to buy beyond an acquisition. Read on to see if these stocks could be a nice fit for your portfolio.
One biotech that could be up for grabs
Todd Campbell : Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ: ACAD) is one of them. With evidence that Nuplazid reduced hallucinations and delusions in Parkinson's disease patients during clinical trials, the FDA approved the drug in April.
That approval makes Nuplazid the only FDA-approved therapy for Parkinson's disease psychosis, and investors will soon discover whether or not that monopoly position translates into a blockbuster commercial success. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. Since about 40% of the 4 million people suffering from Parkinson's disease suffer from psychosis, the potential exists for this drug to be a top seller.
If so, then Acadia Pharmaceuticals would benefit handsomely. Rather than sign on a partner during development, the company retained full global rights to Nuplazid. As a result, if Nuplazid gets off to a strong start, Acadia Pharmaceuticals could be in a prime position to negotiate global rights to the drug, or an outright sale of itself. Potential acquirers wouldn't be limited only to those working on Parkinson's disease, either. Nuplazid is in late-stage studies in Alzheimer's disease psychosis, too. Results from a phase 2 Alzheimer's disease trial are anticipated later this year, and if those results are solid, it could significantly expand Nuplazid's addressable patient population. Between 25% to 50% of the 5 million Americans suffering from Alzheimer's disease also suffer from Alzheimer's disease psychosis.
Admittedly, investors could already be pricing a premium for a potential merger or acquisition into shares. Despite lacking sales and spending $72 million on expenses last quarter, the company's market cap exceeds $3.2 billion. Nevertheless, Nuplazid's potential makes me think that Acadia Pharmaceuticals could fetch even more than that from an acquirer. Of course, that depends a lot on Nuplazid's sales ramp and the upcoming Alzheimer's disease data, so investors will want to stay tuned.
Image source: Workday.
An enterprising cloud play
Steve Symington : After its exceptional fiscal second-quarter 2017 report , I think cloud-based HR and operations software company Workday (NYSE: WDAY) is ripe for the picking. Workday only just expanded its multiyear strategic partnership with IBM for example, and Big Blue will use Workday's Human Capital Management (or HCM) solution to support its entire global workforce of more than 350,000 employees. Workday also welcomed Samsung last quarter as its first South Korean customer, while Dell expanded its use of Workday's products to 125,000 employees given its impending purchase of EMC.
That's not to say the purchase would be cheap, as Workday currently sports a market capitalization of more than $17 billion. And it would need to be on the terms of co-founders David Duffield and (CEO) Aneel Bhusri, who control Workday's votes through a dual-class stock structure they adopted after their previous company, PeopleSoft, was acquired in a hostile takeover by Oracle over a decade ago.
But the appeal is still there with the highly competitive win rates of Workday's core HCM products, which serve as an effective gateway for the company to upsell to other complementary products. Last quarter, almost a third of all new customers purchased Workday Financial Management. And Workday has already secured more than 50 new customers for its Workday Planning product, which will launch with its Workday 27 release within the next month. And that's not to mention the coming releases of Workday Learning, which focuses on encouraging career development for employees, and Workday Student, an education-focused app.
In the end, I think Workday could be an attractive acquisition candidate for a number of tech behemoths looking to streamline costs while establishing a solid presence in the enterprise cloud application market.
A winning combination
JasonHall : I love my Fitbit (NYSE: FIT) Charge HR. Since I started wearing it this past winter, I've regularly and consistently improved my activity levels. And in no small part because I'm a data junkie, but most importantly because I've been able to put the data it gives me to good use, making sure I get enough sleep and make time to exercise.
But I'm not sure that such a pure-play company as Fitbit is really set to succeed for the long term on its own. Sure, it offers a wide range of devices for many needs and lifestyles, but my biggest fear is that the company will at some point feel the pressure to diversify for growth and end up "diworsifying," as legendary investor Peter Lynch would put it. That's why I think it would be an ideal acquisition for Under Armour (NYSE: UA) (NYSE: UA-C) .
Over the past couple of years, Under Armour has spent hundreds of millions of dollars to acquire several fitness apps, including MapMyFitness, MyFitnessPal, and Endomondo, as well as developed its own UA Record app. More recently, it launched the UA Healthbox, a $400 suite of connected products designed to work with its apps.
The endgame for CEO Kevin Plank is fully integrated technology embedded in Under Armour's products. The company has started with its running shoes, but that's only the beginning. Furthermore, truly wearable tech is a threat to a stand-alone Fitbit, taking a bite out of the addressable market for its wrist-based products.
But by becoming part of Under Armour, Fitbit's technology and expertise could accelerate the development of true wearables, a good thing for both companies. It's an unlikely pairing, but one that I think would be a great match.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Jason Hall owns shares of Under Armour (A Shares) and Under Armour (C Shares). Steve Symington owns shares of Under Armour (A Shares) and Under Armour (C Shares). Todd Campbell owns shares of Under Armour (A Shares). The Motley Fool owns shares of and recommends Fitbit, Under Armour (A Shares), Under Armour (C Shares), and Workday. The Motley Fool owns shares of Oracle. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One biotech that could be up for grabs Todd Campbell : Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ: ACAD) is one of them. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. If so, then Acadia Pharmaceuticals would benefit handsomely. | One biotech that could be up for grabs Todd Campbell : Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ: ACAD) is one of them. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. If so, then Acadia Pharmaceuticals would benefit handsomely. | One biotech that could be up for grabs Todd Campbell : Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ: ACAD) is one of them. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. If so, then Acadia Pharmaceuticals would benefit handsomely. | One biotech that could be up for grabs Todd Campbell : Few companies have successfully developed therapies that target Parkinson's disease, but Acadia Pharmaceuticals (NASDAQ: ACAD) is one of them. Acadia Pharmaceuticals officially launched Nuplazid on May 31, so third-quarter results should provide some color on how quickly doctors are embracing it. If so, then Acadia Pharmaceuticals would benefit handsomely. |
36181.0 | 2016-09-10 00:00:00 UTC | 3 Mid-Cap Healthcare Stocks You Can Buy Right Now | ACAD | https://www.nasdaq.com/articles/3-mid-cap-healthcare-stocks-you-can-buy-right-now-2016-09-10 | nan | nan | Image source: Getty Images.
Many investors prefer large-cap stocks, as the underlying companies tend to be mature and stable. However, it's a mistake to overlook mid-cap stocks, which are generally defined as having a market capitalization of between $2 billion and $10 billion. Companies that fit this mold tend to be on firm financial footing, but their smaller size can mean they have greater upside potential.
With that in mind, here are three mid-cap stocks from the healthcare sector that look like buys today.
Growth potential to smile about
While the name Align Technologies (NASDAQ: ALGN) may not ring a bell, my hunch is that you've heard of the company's Invisalign clear aligners. This product gives anyone with malocclusion -- or misaligned teeth -- an "invisible" way to fix their smile instead of traditional braces. Invisalign also allows patients a few other advantages beyond the cosmetic appeal, too: Users can eat whatever food they want, and the device can be removed at any time.
Image source: Align Technologies.
Unsurprisingly, the company's system has proven to be hugely popular. Thanks to years of double-digit growth, Align Technologies has turned into a highly profitable company that's currently valued at over $7 billion dollars. Thankfully, I don't think investors have missed the boat just yet, as recent results suggest that this company's growth story is still going strong.
Last quarter Align put up top-line growth of 29%, which juiced the bottom line by an even stronger 59%. The company's system appears to be a hit in international markets too, with sales up a strong 35% over the year-ago period. Analysts believe the company will be able to sustain that growth rate for quite some time, too: Current projections call for earnings per share growth of more than 23% annually over the next five years.
Of course, Wall Street is aware of the company's growth projections and has priced shares accordingly. Right now Align's stock sports a trailing P/E of 45, which is quite pricey. However, with such high growth coming in the years ahead, I still think investors should considering nibbling on this stock today and then coming back for more when the share price takes a hit.
Sounds like a strong investment
Picture this: A company that has grown profits by more than 20% over the past five years is projected to grow them by more than 18% over the next five years -- and it trades for less than 11 times forward earnings. Sound too good to be true? It's not, as those numbers perfectly sum up the current investing thesis for Jazz Pharmaceuticals (NASDAQ: JAZZ) , a commercial-stage biotech currently valued at $7.5 billion.
Jazz's golden goose is a drug called Xyrem, which treats the rare sleep disorder narcolepsy. This blockbuster drug is projected to grow by double digits this year and ring up more than a billion dollars in annual sales. Combining that with the rest of the company's product portfolio, Jazz currently projects full-year non-GAAP EPS of $9.90 to $10.30.
Sounds great, right? Well, the market doesn't think so, as that range is actually down from its prior outlook of $11.10 to $11.50 in EPS. Thankfully, Jazz has a good reason for the revised guidance.
A few months back, Jazz shelled out $1.5 billion to acquire Celator Pharmaceuticals and thereby get its hands on the company's lead compound, Vyxeos. This drug produced impressive clinical results in treating high-risk acute myeloid leukemia, or AML, a cancer of the blood and bone marrow. In fact, regulators gave it both breakthrough therapy and fast-track designations.
Of course, the acquisition is temporarily inflating the company's cost structure, squeezing profitability at the moment. However, Jazz believes the deal will be accretive to earnings by 2018, and sales of Vyxeos could grow to as much as $900 million by 2020. If so, then that will nicely balance out Xyrem sales and propel revenue and profits higher for years to come. I think that makes Jazz a great candidate for new capital right now.
Image source: Getty Images.
A market all to itself
With a market cap of just under $4 billion, the final company on our list is the smallest and riskiest of the group, but it could offer the greatest upside potential.
The company in question is Acadia Pharmaceuticals (NASDAQ: ACAD) , a biotech that has only just recently reached the commercial stage. In April, Acadia won approval for its first drug, Nuplazid, which is approved to treat Parkinson's disease psychosis, or PDP. This disease afflicts roughly 400,000 Americans and causes them to experience hallucinations and delusions.
Caring for patients with PDP is incredibly difficult, which often forces the patients into nursing homes. Not only is that highly disruptive to the patient's life, but it is also expensive. Since Nuplazid is the first and only approved drug to help treat this condition, the market potential looks huge.
Acadia assigned Nuplazid an annual wholesale price of $23,400, so if patient and provider demand for this drug lives up to expectations, then Nuplazid could easily turn into a blockbuster medication. That's especially true if the company can also introduce Nuplazid into foreign markets and expand its labeling to include conditions like schizophrenia and Alzheimer's disease psychosis.
If Nuplazid can deliver on its expectations, then Acadia's sales could be set to explode, quickly turning the company into a profitable enterprise. If so, then its stock could hold a lot of upside from today's prices, so risk-loving investors might want to give this company a closer look.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.
The Motley Fool recommends Align Technology. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company in question is Acadia Pharmaceuticals (NASDAQ: ACAD) , a biotech that has only just recently reached the commercial stage. In April, Acadia won approval for its first drug, Nuplazid, which is approved to treat Parkinson's disease psychosis, or PDP. Acadia assigned Nuplazid an annual wholesale price of $23,400, so if patient and provider demand for this drug lives up to expectations, then Nuplazid could easily turn into a blockbuster medication. | The company in question is Acadia Pharmaceuticals (NASDAQ: ACAD) , a biotech that has only just recently reached the commercial stage. In April, Acadia won approval for its first drug, Nuplazid, which is approved to treat Parkinson's disease psychosis, or PDP. Acadia assigned Nuplazid an annual wholesale price of $23,400, so if patient and provider demand for this drug lives up to expectations, then Nuplazid could easily turn into a blockbuster medication. | The company in question is Acadia Pharmaceuticals (NASDAQ: ACAD) , a biotech that has only just recently reached the commercial stage. In April, Acadia won approval for its first drug, Nuplazid, which is approved to treat Parkinson's disease psychosis, or PDP. Acadia assigned Nuplazid an annual wholesale price of $23,400, so if patient and provider demand for this drug lives up to expectations, then Nuplazid could easily turn into a blockbuster medication. | The company in question is Acadia Pharmaceuticals (NASDAQ: ACAD) , a biotech that has only just recently reached the commercial stage. In April, Acadia won approval for its first drug, Nuplazid, which is approved to treat Parkinson's disease psychosis, or PDP. Acadia assigned Nuplazid an annual wholesale price of $23,400, so if patient and provider demand for this drug lives up to expectations, then Nuplazid could easily turn into a blockbuster medication. |
36182.0 | 2016-09-03 00:00:00 UTC | Better Buy: ACADIA Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc. | ACAD | https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-2016-09-03 | nan | nan | Image source: Getty Images.
ACADIA Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are both cash-burning biotech stocks that offer huge upside if everything goes according to plan. However, shareholders in each company face a real risk of being wiped out if something goes awry . That's why it's essential for investors in stocks like these to do plenty of homework before they even consider making a purchase.
With that in mind, let's pit these two high-risk, high-reward companies against each other to see if we can determine which stock is the better buy.
The case for ACADIA Pharmaceuticals
ACADIA Pharmaceuticals' stock has been a rocket ship over the last five years thanks to investor optimism about its drug Nuplazid for Parkinson's disease psychosis (PDP), a disease that causes patients to experience delusions and hallucinations. Caring for patients with PDP is incredibly difficult because of the lack of treatment options. This leads many patients with PDP to be sent to nursing homes, greatly increasing the cost of their care.
However, the FDA approved Nuplazid on Aug. 29, and the drug promises to help ease that burden -- and therein lies the opportunity for investors.
Image source: ACADIA.
Roughly 40% of the 1 million Americans with Parkinson's disease will develop PDP, so Nuplazid has a large addressable market. Because management knows that Nuplazid is the only game in town, they have given it an aggressive wholesale price of $23,400 annually. If ACADIA can convince a large portion of patients and providers to use Nuplazid, the drug could easily turn into a blockbuster.
Of course, just because a drug finds its way to market doesn't mean it's an automatic success. ACADIA now has to convince payers, providers, and patients that Nuplazid's clinical benefits exceed its costs, which is not an easy thing to do.
ACADIA's market cap is approaching $4 billion, so there's a lot of optimism being priced in. If the company fails to gain traction, then shares would likely tumble, so there's no doubt that ACADIA's stock is quite risky today.
The case for Sarepta Therapeutics
Rare-disease-focused Sarepta Therapeutics has set its sights on Duchenne muscular dystrophy (DMD), a deadly muscle-wasting disease with no cure. Although there have been several recent attempts to bring drugs to market that help treat this awful disease, they have all failed to win over regulators, making Sarepta essentially the last company standing. If Sarepta can get the green light from the FDA on its DMD treatment, called eteplirsen, then it should have the market to itself, which could potentially be worth billions in future sales.
Of course, that's a huge "if," as Sarepta's recent regulatory history has been far from perfect. During eteplirsen's advisory committee meeting, there were a lot of negative comments about the methodology that was used to collect data during clinical trials. The FDA has also delayed its go/no-go decision date twice, most recently sending out a request for additional data from the drug's ongoing confirmatory study. We currently don't even have an updated Prescription Drug User Fee Act decision date for eteplirsen, so shareholders are in a holding pattern.
Despite all of that, there are reasons to be bullish on Sarepta today. The FDA is aware of the huge unmet medical need for DMD, and the agency knows that patients and providers are desperate for a treatment. If regulators approve the drug, then shares would likely skyrocket, especially since they are currently down more than 50% from their all-time high.
The better buy
While both of these companies offer substantial upside if everything goes according to plan, I think ACADIA is the smarter buy right now. Nuplazid has already cleared the most important regulatory hurdles, and it's not competing against any other drugs. That should ensure it has automatic demand , which should increase its chances of seeing market success.
Sarepta, on the other hand, still has its huge binary decision ahead of it. While my hunch is that the FDA will wind up giving eteplirsen the green light, it's impossible to handicap the odds. That means the company's stock will likely rise or fall dramatically once a decision is in hand, making Sarepta's stock about as high-risk as it gets. My fingers are crossed that this works out well for shareholders, but the investor in me knows that ACADIA is the better buy today.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldihas no position in any stocks mentioned. Like this article? Follow him on Twitter, where he goes by the handle@Longtermmindset, or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are both cash-burning biotech stocks that offer huge upside if everything goes according to plan. The case for ACADIA Pharmaceuticals ACADIA Pharmaceuticals' stock has been a rocket ship over the last five years thanks to investor optimism about its drug Nuplazid for Parkinson's disease psychosis (PDP), a disease that causes patients to experience delusions and hallucinations. Image source: ACADIA. | ACADIA Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are both cash-burning biotech stocks that offer huge upside if everything goes according to plan. The case for ACADIA Pharmaceuticals ACADIA Pharmaceuticals' stock has been a rocket ship over the last five years thanks to investor optimism about its drug Nuplazid for Parkinson's disease psychosis (PDP), a disease that causes patients to experience delusions and hallucinations. Image source: ACADIA. | ACADIA Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are both cash-burning biotech stocks that offer huge upside if everything goes according to plan. The case for ACADIA Pharmaceuticals ACADIA Pharmaceuticals' stock has been a rocket ship over the last five years thanks to investor optimism about its drug Nuplazid for Parkinson's disease psychosis (PDP), a disease that causes patients to experience delusions and hallucinations. Image source: ACADIA. | ACADIA Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are both cash-burning biotech stocks that offer huge upside if everything goes according to plan. My fingers are crossed that this works out well for shareholders, but the investor in me knows that ACADIA is the better buy today. The case for ACADIA Pharmaceuticals ACADIA Pharmaceuticals' stock has been a rocket ship over the last five years thanks to investor optimism about its drug Nuplazid for Parkinson's disease psychosis (PDP), a disease that causes patients to experience delusions and hallucinations. |
36183.0 | 2016-08-31 00:00:00 UTC | 3 Stocks That Could Make You Rich | ACAD | https://www.nasdaq.com/articles/3-stocks-could-make-you-rich-2016-08-31 | nan | nan | Most investors who want to become wealthy shouldn't be in a rush to do so. After all, the market's movements are impossible to predict, so it makes sense to construct a portfolio of stocks that wisely balances risk and reward. Doing so properly should allow you to grow your money when times are good and protect you from the downside when the next bear market rears its ugly head. Buying and holding shares of great companies, such as the three I'll describe below, is a proven way to grow your wealth over the long term.
The slow path to wealth
Investors who are after long-term growth but want downside protection might want to take a close look at CVS Health (NYSE: CVS) . CVS' services are likely to be in demand no matter what is going on in the economy, which should gives its stock downside protection.
You're likely familiar with the company's retail pharmacy empire, a network of more than 9,600 stores, mostly in the U.S. With more than 10,000 baby boomers retiring every day, the demand for pharmacy services is bound to steadily increase.
CVS Dividend data by YCharts .
CVS Health's stock is unlikely to double anytime soon, but if you're after steady growth and a shareholder-friendly management team, CVS Health is a great choice.
A little more upside, a bit more risk
Investors who are after a stock with more upside potential and are willing to accept a bit more risk might want to consider looking at American Tower (NYSE: AMT) .
American Tower is organized as a real estate investment trust, or REIT , and the company specializes in owning and operating cellular towers. American Tower builds or buys cellular towers around the world and then makes money by leasing out space on the towers to local wireless carriers. Wireless providers are happy to sign on as customers since leasing space saves them the headache and expense of finding and operating their own towers.
The massive global growth in smartphone sales has been a boon to American Tower's business. Wireless providers have scrambled to keep up with consumer demand for coverage and data, which drives demand for tower space. Since American Tower isn't competing for wireless customers directly, it's agnostic about which carriers uses which towers, giving it the advantage of being able to lease out space to multiple carriers on the same towers at the same time. That fact allowed the company to drive strong revenue and profit growth over the past decade.
Looking ahead, American Tower looks well positioned for continuing double-digit growth for years to come. With shares currently yielding 1.76% and only trading for about 21 times full-year adjusted funds from operations (AFFO) estimates -- the REIT equivalent of earnings -- this is a great stock for growth focused investors to consider owning.
A high-risk stock with strong appreciation potential
The final company on our list today is the spiciest of the bunch, but I think it offers the greatest shot at near-term upside potential.
Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. The drug is called Nuplazid and it was approved to treat Parkinson's disease psychosis, or PDP, a disease that causes delusions and hallucinations. Roughly 40% of the 1 million patients in the U.S. with Parkinson's suffer from PDP, and prior to Nuplazid's approval, there were no FDA-approved drugs on the market for this indication.
That sets the stage for strong growth if Nuplazid gains support from the medical community. In clinical trials, Nuplazid was effective at alleviating the symptoms of PDP. In addition, patients who used the drug did not have their motor control compromised, which is a common side effect of antipsychotics.
Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. With an annual wholesale price of $23,400 and no competition in sight, it's not hard to imagine the drug becoming a blockbuster. The numbers will get even more attractive if Nuplazid wins approval in international markets or expands into other indications like Alzheimer's disease psychosis or schizophrenia.
All in all, the growth ahead of Acadia could be extreme if Nuplazid can live up to its full potential. Commercial success is never guaranteed and the risks here are certainly high, but if you're looking for a stock that could appreciate rapidly from today's prices, Acadia is a great choice.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldi owns shares of American Tower.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.
The Motley Fool owns shares of and recommends American Tower. The Motley Fool recommends CVS Health. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Commercial success is never guaranteed and the risks here are certainly high, but if you're looking for a stock that could appreciate rapidly from today's prices, Acadia is a great choice. Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. | Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. All in all, the growth ahead of Acadia could be extreme if Nuplazid can live up to its full potential. | Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. All in all, the growth ahead of Acadia could be extreme if Nuplazid can live up to its full potential. | Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. All in all, the growth ahead of Acadia could be extreme if Nuplazid can live up to its full potential. |
36184.0 | 2016-08-28 00:00:00 UTC | 3 Stocks Up Over 1,000% in the Past 5 Years | ACAD | https://www.nasdaq.com/articles/3-stocks-over-1000-past-5-years-2016-08-28 | nan | nan | Past performance doesn't guarantee supersize gains (or losses) in the future, but investors who took the risk and socked these three darlings into their portfolios five years ago are undeniably smiling every time they open up their account statement. Shares in Medivation (NASDAQ: MDVN) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and LendingTree (NASDAQ: TREE) have all returned over 1,000% in the past five years. Is there still time to buy shares in these top performers?
No. 1: A megadeal takes this one out of contention
Pfizer, Inc .(NYSE: PFE) just won the high-stakes bidding war to buy Medivation Inc. last week, so unless a surprise bidder emerges, this one is off the table for consideration by new investors.
Pfizer is paying all cash for Medivation, so Medivation's performance from here is capped at the $81.50-per-share buyout price, but that doesn't mean Medivation can't help us spot the next top-performing biotech.
Medivation's success was due to the rapid adoption of Xtandi, a prostate cancer drug that came on the scene in 2012. After its launch, Xtandi quickly became the market share-leading drug used in post-chemotherapy patients, and after the Food and Drug Administration approved its use in 2014 for the pre-chemotherapy setting, sales took off. This year, industry watchers think Xtandi's sales could reach $2.8 billion, making it the sixth best-selling cancer drug on the market.
Even though Medivation splits Xtandi's profit with its partner, Astellas, Pfizer was still willing to pay more than 14 times the company's 2016 sales forecast to acquire it. Perhaps that tells us not to give up on companies making game-changing drugs that target big indications. After all, investors who sold Medivation early on missed an eye-popping 1,883% return over the past five years.
ACAD data by YCharts .
Acadia Pharmaceuticals markets Nuplazid, a newly approved treatment for hallucinations and delusions experienced by Parkinson's patients. Sadly, there's no cure for this progressive disease and that means that the market for Nuplazid is likely to increase.
An estimated 40% of the more than 4 million people with Parkinson's disease globally suffer from Parkinson's disease psychosis and Nuplazid is the first FDA-approved drug to specifically treat it. The big unmet need and lack of treatment options have fueled investor enthusiasm. However, there's no guarantee that this drug will be a top seller and that means that this is a risky stock.
Nuplazid became available at the end of May, so the jury's out on whether this drug will be a top seller. If it is, then Acadia Pharmaceuticals could still reward investors handsomely. If it isn't, then shares could tumble. That kind of uncertainty doesn't make it easy to sleep at night, but if you're a risk tolerant investor, then Acadia Pharmaceuticals' might still be worth buying.
TREE data by YCharts .
During that period, LendingTree's matchmaking of borrowers and lenders has resulted a quadrupling of revenue, including a 71% year-over-year jump in the second quarter. Importantly, as revenue has increased, so has LendingTree's profitability. Over the past 12 months, LendingTree has generated over $50 million in net income, which is far better than the trailing-12-month losses of over $50 million recorded back in 2012.
TREE Revenue (TTM) data by YCharts .
One of the biggest drivers of LendingTree's success has been rising demand for mortgages. Last quarter, record mortgage revenue of $56 million accounted for 59% of the company's sales.
The direction of interest rates and the ability of the economy to create higher-paying jobs will determine if mortgage demand can continue growing. So far, wages offer little evidence that loan demand is about to collapse. In July, average hourly wages improved to $25.69 from $25.03 a year ago.
The uptick in wages helped fuel a 84% year-over-year increase in total loan requests in Q2. Overall, borrowers made 3.6 million requests in the quarter.
Overall, LendingTree's business appears to be humming along, but we're not so far removed from the Great Recession to fail to remember that investors may not discover that loan demand has soured until it's too late. For that reason, LendingTree is an intriguing yet risky stock to buy, too.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Todd Campbell owns shares of Medivation.He owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him on Twitter where he goes by the handle @ebcapitalto see more articles like this.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares in Medivation (NASDAQ: MDVN) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and LendingTree (NASDAQ: TREE) have all returned over 1,000% in the past five years. ACAD data by YCharts . Acadia Pharmaceuticals markets Nuplazid, a newly approved treatment for hallucinations and delusions experienced by Parkinson's patients. | Shares in Medivation (NASDAQ: MDVN) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and LendingTree (NASDAQ: TREE) have all returned over 1,000% in the past five years. Acadia Pharmaceuticals markets Nuplazid, a newly approved treatment for hallucinations and delusions experienced by Parkinson's patients. ACAD data by YCharts . | Shares in Medivation (NASDAQ: MDVN) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and LendingTree (NASDAQ: TREE) have all returned over 1,000% in the past five years. ACAD data by YCharts . Acadia Pharmaceuticals markets Nuplazid, a newly approved treatment for hallucinations and delusions experienced by Parkinson's patients. | Shares in Medivation (NASDAQ: MDVN) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and LendingTree (NASDAQ: TREE) have all returned over 1,000% in the past five years. ACAD data by YCharts . Acadia Pharmaceuticals markets Nuplazid, a newly approved treatment for hallucinations and delusions experienced by Parkinson's patients. |
36185.0 | 2016-08-19 00:00:00 UTC | The 10 Best Small- and Mid-Cap Stocks to Buy Now | ACAD | https://www.nasdaq.com/articles/the-10-best-small-and-mid-cap-stocks-to-buy-now-2016-08-19 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Small- and mid-cap stocks are known for their high risk, sure. But they're also known as being excellent stocks to buy for their highflying potential, too.
That's because these smaller companies tend to be undercovered, and without that attention, they often tend to be undervalued for long periods of time. As a result, if you're looking for the best stocks to buy to outperform the market … well, it pays to go small.
Right now, the major U.S. blue-chip indices are trading at all-time highs. Yet the Russell 2000 small-cap index is 5% off its all-time highs. This further suggests that small- and mid-cap stocks are a value right now.
7 Heavy-Hitting Small-Caps That Will Wallop the Market
Today, we're going to look at 10 such stocks that are either underloved right now, or are just flying under the radar as they usually do. Consider these some of the best stocks to buy to outperform the market over the next few months.
Best Small- and Mid-Cap Stocks to Buy Now: Zagg (ZAGG)
Market Cap: $203 million
Zagg Inc (NASDAQ: ZAGG ) has not done much the last few years. However, this small cap's business is quietly getting better by the quarter.
This is a company whose revenue jumped 50% during its last quarter, and its gross margin expanded by 200 basis points. While M&A played a big role in Zagg's growth, what's more important is that Zagg controls more than half of the screen-protection market.
With telecom companies offering annual upgrades on smartphones, and trade-in values for used smartphones climbing, there is now tremendous value in the company's most important product. Furthermore, Zagg has a growing share of other key markets like headphones and battery cases.
Given Zagg's market share with these products, investors should expect no more than 10% organic growth long-term. However, at just 9 timesforward earnings, ZAGG stock still is very cheap for a company with 10% organic growth.
Best Small- and Mid-Cap Stocks to Buy Now: Fitbit (FIT)
Market Cap: $3 billion
Fitbit Inc (NYSE: FIT ) carries a $3.2 billion market capitalization, though that's after losing more than 50% of its value over the last year. Ironically, Fitbit earnings have been among the strongest in all of technology, consistently beating expectations and raising guidance in each quarter since going public.
The problem is, Fitbit has beaten analysts' expectations … just not the overly exuberant expectations of everyone else.
Thanks to its share losses, FIT now trades at just 10 times forward earnings. That is incredibly cheap for a company that's expected to grow 39% this year and 16% in 2017.
7 Best Dividend Stocks You Haven't Heard Of
With product refreshes ahead, and new smart wearables along with the potential for additional services and home products, FIT stock look poised to outperform the market.
Best Small- and Mid-Cap Stocks to Buy Now: Sodastream (SODA)
Market Cap: $600 million
Sodastream International Ltd (NASDAQ: SODA ) has nearly doubled over the last year in one of the quietest big moves on the market.
Maybe that's because shares still are down a whopping 60% from their all-time highs.
Sodastream is a company that will never grow to take on the big boys of soda, but after two years of margin and revenue losses, expectations are finally low enough for SODA to beat. While the company's earnings don't match its performance in 2013, or even 2014, they are growing relative to last year.
Given its large losses over the last few years, expect Sodastream's 10% and 6% revenue growth over the next two years to drive SODA higher, and allow it to outperform the broader market.
Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD)
Market Cap: $4.1 billion
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come.
Problem is that Acadia is going to have some growing pains.
The company is not going to be acquired nor will it find a massive U.S. partner with ownership interests.
It is NOT going to happen.
Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company. That transition can be brutal when a firm is having to worry about mass manufacturing, marketing, and its supply chain. Thankfully, Nuplazid is a drug that works without the side effects of commonly used drugs like Abilify or Seroquel, and is entering a market that is no stranger to producing drugs with several billion dollars in annual revenue.
The 7 Best Cheap Dividend Stocks to Buy Now
I expect the same for Nuplazid, but it will take Acadia a while to get there. Thus, ACAD stock looks very cheap around $33, and it will soar … you just have to be patient.
Best Small- and Mid-Cap Stocks to Buy Now: Five Below (FIVE)
Market Cap: $2.6 billion
Five Below Inc (NASDAQ: FIVE ) is a small retailer than sells all of its products for $5 or less. The company has large store space, which means comparable-sales growth is minimal and the majority of its growth comes from expansion.
While FIVE looks expensive at 29 times forward earnings, the company is expected to grow more than 20% for each of the next two years. That's impressive growth, and it's why UBS just upgraded the stock with a $55 price target.
However, I think FIVE could go much, much higher.
I think Five Below is on a similar trajectory to Dollar Tree, Inc. (NASDAQ: DLTR ). Still, regardless if FIVE stock trades to $55 or grows from a $2.5 billion company to become the next Dollar Tree, the point is that this dollar store has upside from here.
Best Small- and Mid-Cap Stocks to Buy Now: OpenText (OTEX)
Market Cap: $7.5 billion
Open Text Corp (USA) (NASDAQ: OTEX ) is a very quiet $7.5 billion tech company. You don't hear a lot about it, despite it being a cloud company that creates revenue with recurring services.
Unlike some of the more popular cloud services company, OTEX is highly efficient and grows by acquiring assets, optimizing those assets and combing the assets with its existing business. It has been a very lucrative business model, leading me to recently conclude that OTEX is "good as it gets for value investors."
9 Stocks to Buy That Will Sprint Past Everything Else
With expected growth of 15% this year, and the realization that next year's expected 3% growth is too conservative after M&A, OTEX stock at 14 times forward earnings is a great opportunity.
Best Small- and Mid-Cap Stocks to Buy Now: Yelp (YELP)
Market Cap: $3.1 billion
What Yelp Inc (NYSE: YELP ) has done in 2016 is very impressive, especially after two bad years in 2014 and 2015. The $3 billion review company has found itself a nice niche market, and despite heavy pressure from the likes of Alphabet Inc (NASDAQ: GOOG , NASDAQ: GOOGL ) and Facebook Inc (NASDAQ: FB ), Yelp continues to grow.
While Yelp did recently raise full-year revenue expectations to growth of 27% year-over-year, the most impressive metric for me has been advertising account and user growth. The company announced with Q2 earnings that local advertising accounts grew 32% and that the number of unique devices accessing local services increased 27% monthly.
Furthermore, Yelp's transactions business remains solid, with reservations reaching $6 billion after growing 50%. This is the business that allows users to book reservations on Yelp. Collectively, Yelp looks like a solid business, and looks to be trending higher with a 50% gain the last year.
Best Small- and Mid-Cap Stocks to Buy Now: Allegiant Travel (ALGT)
Market Cap: $2.3 billion
Allegiant Travel Company (NASDAQ: ALGT ) stock has fallen 40% over the last year, mostly due to weakness in the overall airline sector. Yet, the small $2 billion airline is an exception to the problems that larger companies like Delta Air Lines, Inc. (NYSE: DAL ) face.
Unlike Delta, Allegiant's revenue miles and capacity continues to rise. Moreover, Allegiant's revenue is expected to rise 6% this year and 10% next year. Despite its growth and clear superiority to competitors , ALGT stock trades at a very conservative multiple of just 10 times earnings.
10 Losers That Will Be 2017's Best Stocks to Buy
For a company that is disrupting the airline industry, that is too cheap of a multiple, and suggests ALGT is going higher.
Best Small- and Mid-Cap Stocks to Buy Now: Skechers (SKX)
Market Cap: $4 billion
Skechers USA Inc (NYSE: SKX ) has a lot of work to do. The company clearly faced pricing pressure during its second quarter after margins declined. Now, there is a lot of uncertainty whether margins will remain pressured, and whether Skechers is starting to reach a peak in its business.
These questions led me to downgrade the stock from "but" to "hold."
Still, while there are questions surrounding Skechers, the company is expected to grow by double digits, and it has double-digit margins. Furthermore, and perhaps most importantly, SKX stock trades at just 12x forward earnings. That's about half of Nike Inc's (NYSE: NKE ) multiple coupled with even faster growth.
In other words, if you like Nike, you must love Skechers. And because SKX is so cheap, it has a great shot to trade significantly higher long-term.
Best Small- and Mid-Cap Stocks to Buy Now: XPO Logistics (XPO)
Market Cap: $4 billion
XPO Logistics Inc (NYSE: XPO ) is a $4 billion company whose stock is down 12% over the last year, but up 35% the last year. The big recent gains were driven by XPO's first EPS-positive quarter in the Bradley Jacobs era, where the company blew past all expectations and gave a peak into what the future will look like.
It was truly a game-changing quarter for the company - one that will change sentiment. After all, there were many investors who doubted whether or not XPO would ever be profitable due to its large debt load and heavy spending.
The 10 Best Stocks of 2016
However, $170 million in free cash flow and $42.6 million in net income silences the critics. Now, XPO stock is set for an epic rally .
As of this writing, Brian Nichols was long ACAD, FIT, FIVE, OTEX, XPO and YELP.
The post The 10 Best Small- and Mid-Cap Stocks to Buy Now appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD) Market Cap: $4.1 billion Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come. Problem is that Acadia is going to have some growing pains. Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company. | Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD) Market Cap: $4.1 billion Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come. Problem is that Acadia is going to have some growing pains. Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company. | Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD) Market Cap: $4.1 billion Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come. Problem is that Acadia is going to have some growing pains. Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company. | Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD) Market Cap: $4.1 billion Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come. Problem is that Acadia is going to have some growing pains. Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company. |
36186.0 | 2016-08-18 00:00:00 UTC | Director takes a bigger stake in ACADIA Pharmaceuticals | ACAD | https://www.nasdaq.com/articles/director-takes-bigger-stake-acadia-pharmaceuticals-2016-08-18 | nan | nan | Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. The shares were purchased at $33.00 for a total of $42,999,990.00.
InvestorsKeyhole Trade Alert
IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. Support has been around $31.08 and resistance around $36.49. Look at the September 25/29 bull-put spread for a 25-cent credit. That's a 6.7% return and the stock has to fall 12.8% to cause a problem. [InvestorsKeyhole, Various news and data services]
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Originally published on InvestorsObserver.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. InvestorsKeyhole Trade Alert IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. InvestorsKeyhole Trade Alert IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. InvestorsKeyhole Trade Alert IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. InvestorsKeyhole Trade Alert IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. The shares were purchased at $33.00 for a total of $42,999,990.00. |
36187.0 | 2016-08-11 00:00:00 UTC | 5 Can't-Miss Quotes From ACADIA Pharmaceuticals Inc.'s Q2 Investor Call | ACAD | https://www.nasdaq.com/articles/5-cant-miss-quotes-acadia-pharmaceuticals-incs-q2-investor-call-2016-08-11 | nan | nan | As you can see, the company believes that pimavanserin (Nuplazid) could be useful in treating other diseases as well.
CEO Davis gave an update on future clinical work in this area:
What now?
There's no doubt that the growth opportunity in front of Nuplazid is huge, so if management can successfully execute on its commercialization plan then it wouldn't surprise me one bit to see the stock continue its winning ways from today's price. Any growth investors with a high tolerance for risk might want to put this stock on their radar.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | There's no doubt that the growth opportunity in front of Nuplazid is huge, so if management can successfully execute on its commercialization plan then it wouldn't surprise me one bit to see the stock continue its winning ways from today's price. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Any growth investors with a high tolerance for risk might want to put this stock on their radar. | There's no doubt that the growth opportunity in front of Nuplazid is huge, so if management can successfully execute on its commercialization plan then it wouldn't surprise me one bit to see the stock continue its winning ways from today's price. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As you can see, the company believes that pimavanserin (Nuplazid) could be useful in treating other diseases as well. CEO Davis gave an update on future clinical work in this area: What now? The Motley Fool has no position in any of the stocks mentioned. |
36188.0 | 2016-08-04 00:00:00 UTC | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 37.5% Follow-Through Indicator, 4.8% Sensitive | ACAD | https://www.nasdaq.com/articles/earnings-reaction-history-acadia-pharmaceuticals-inc-375-follow-through-indicator-48 | nan | nan | Expected Earnings Release: 08/04/2016, After-hours
Avg. Extended-Hours Dollar Volume: $1,620,961
ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 40%
Average next regular session additional gain: 1.4%
Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 66.7%
Average next regular session additional loss: 3.2%
Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,620,961 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,620,961 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,620,961 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $1,620,961 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. |
36189.0 | 2016-08-03 00:00:00 UTC | 5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More | ACAD | https://www.nasdaq.com/articles/5-drug-stocks-to-watch-for-earnings-on-aug-4%3A-bmrn-more-2016-08-03 | nan | nan | With Q2 earnings season drawing to a close, we have seen about 317 S&P 500 members (representing 73.5% of the index's total market capitalization) announce quarterly results as of Jul 29. Reported results show a 3.3% year-over-year decline in earnings while revenues declined 0.9%. Nevertheless, an impressive 72.9% of these companies managed to post an earnings beat, and 53.6% reported better-than-expected sales.
Within the Medical sector, several pharma and biotech companies are slated to report their earnings results this week. As per our Earnings Trends article, Medical is one of the six sectors expected to record positive earnings growth in this quarter.
Looking at the performance of the Medical sector, the Q2 scorecard shows that 63.5% stocks in the sector (total market capitalization of 71.9%) have reported results as of Jul 29, with a blended beat of 75.8% (the percentage of companies that have beaten both earnings and revenue estimates). The sector recorded a 5.4% improvement in earnings on revenue growth of 10.5%.
Let's take a look at five companies in the Medical sector that are scheduled to report results on Aug 4.
San Rafael, CA-based BioMarin Pharmaceutical Inc.BMRN is scheduled to report second-quarter 2016 results on Aug 4, after the market closes . BioMarin's track record has been decent with the company beating estimates in three of the last four quarters. However, the company has recorded an average negative surprise of 7.48% over the trailing four quarters. Nevertheless, the combination of BioMarin's Zacks Rank #3 (Hold) and +4.00% Earnings ESP makes us reasonably confident of an earnings beat this season. Investor focus will be on the company's key drugs, Vimizim and Kuvan. Continued penetration of Vimizim in additional markets and growth of new patients on Kuvan should continue to boost the company's top line. (Read More: BioMarin May Beat in Q2 Earnings: Stock to Gain? )
BIOMARIN PHARMA Price and EPS Surprise
BIOMARIN PHARMA Price and EPS Surprise | BIOMARIN PHARMA Quote
Large-cap biopharma company, Regeneron Pharmaceuticals, Inc.REGN , will be reporting results before the opening bell. On its second-quarter call, investor focus is expected to be on the company's key growth driver, Eylea, which should benefit from strong sales in the U.S. and abroad. Investor focus should also be on the performance of the company's PCSK9 inhibitor, Praluent. Regeneron's track record has been mixed with the company surpassing earnings estimates in two of the last four quarters and missing the same in the other two. The company has recorded an average negative earnings surprise of 0.06%. The combination of its Zacks Rank #3 and 0.00% ESP makes surprise prediction difficult for this quarter. (Read More: Regeneron Q2 Earnings: Can the Stock Surprise? )
REGENERON PHARM Price and EPS Surprise
REGENERON PHARM Price and EPS Surprise | REGENERON PHARM Quote
Teva Pharmaceutical Industries LimitedTEVA , known for its strong presence in the generics market, will be reporting second-quarter 2016, before the opening bell. Teva's performance has been impressive with the company reporting positive earnings surprises thrice in the last four quarters and posting in-line earnings in one. The average positive earnings surprise for the four preceding quarters is 4.56%. Meanwhile, the combination of Teva's Zacks Rank #2 (Buy) and +1.70% ESP makes us reasonably confident of an earnings beat this season. Teva's generics segment could, however, continue seeing weakness in the second quarter. (Read More: Teva: Stock Likely to Beat on Earnings in Q2 Again? )
TEVA PHARM ADR Price and EPS Surprise
TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote
San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes. ACADIA has a disappointing track record with the company missing expectations in three of the last four quarters and managing to beat once, bringing the average negative surprise to 15.41%. ACADIA currently has a Zacks Rank #4 (Sell) and an ESP of 0.00%. As it is, we caution against Sell-rated stocks (#4 or #5) going into an earnings announcement. On the second-quarter call, investor focus will remain on the sales ramp-up of ACADIA's newly launched product, Nuplazid. (Read More: ACADIA Q2 Earnings: What's in Store for the Stock? )
ACADIA PHARMA Price and EPS Surprise
ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote
Biopharma stock, Alnylam Pharmaceuticals, Inc.ALNY , is scheduled to report second-quarter results after the market closes. The Cambridge, MA-based company focuses on the development of novel therapeutics based on a biological pathway known as RNA (ribo nucleic acid) interference (RNAi). With no approved products in its portfolio, the company earns revenues primarily through collaborations. Alnylam has a disappointing track record so far. The company has missed estimates in three of the last four quarters and beat the same once, bringing the average negative surprise to 7.41%. Alnylam is a Zacks Rank #4 stock too with an ESP of 0.00%. Sell-rated stocks should never be considered going into an earnings announcement.
ALNYLAM PHARMA Price and EPS Surprise
ALNYLAM PHARMA Price and EPS Surprise | ALNYLAM PHARMA Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis Report
BIOMARIN PHARMA (BMRN): Free Stock Analysis Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | TEVA PHARM ADR Price and EPS Surprise TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes. ACADIA has a disappointing track record with the company missing expectations in three of the last four quarters and managing to beat once, bringing the average negative surprise to 15.41%. ACADIA currently has a Zacks Rank #4 (Sell) and an ESP of 0.00%. | TEVA PHARM ADR Price and EPS Surprise TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Biopharma stock, Alnylam Pharmaceuticals, Inc.ALNY , is scheduled to report second-quarter results after the market closes. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Biopharma stock, Alnylam Pharmaceuticals, Inc.ALNY , is scheduled to report second-quarter results after the market closes. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. TEVA PHARM ADR Price and EPS Surprise TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes. | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Biopharma stock, Alnylam Pharmaceuticals, Inc.ALNY , is scheduled to report second-quarter results after the market closes. TEVA PHARM ADR Price and EPS Surprise TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes. ACADIA has a disappointing track record with the company missing expectations in three of the last four quarters and managing to beat once, bringing the average negative surprise to 15.41%. |
36190.0 | 2016-08-02 00:00:00 UTC | ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock? | ACAD | https://www.nasdaq.com/articles/acadia-acad-q2-earnings-whats-store-stock-2016-08-02 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes . In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. Let's see how things are shaping up for this quarter.
Factors to Consider
ACADIA's second quarter revenues will include Nuplazid sales. The company launched Nuplazid (treatment of hallucinations and delusions associated with Parkinson's disease psychosis) in May 2016 in the U.S. Investors will remain focused on the sales ramp up of this product as well as the company's progress in educating healthcare providers on Nuplazid, ensuring patient access to the treatment and securing reimbursement. ACADIA has 132 neuroscience sales specialists promoting the product.
Another area of interest is the company's life cycle management plans for Nuplazid. ACADIA is exploring the potential to develop the drug for other neurological and psychiatric disorders with large unmet need.
Nuplazid is currently in a phase II proof-of-concept study for Alzheimer's disease (AD) psychosis with top line data expected in the fourth quarter. Meanwhile, ACADIA plans to initiate a phase II study on Nuplazid for AD agitation in the second half of the year. Another area of potential label expansion is schizophrenia.
Surprise History
ACADIA's earnings track record is disappointing with the company missing expectations in three of the last four quarters and surpassing in one quarter with an average negative surprise of 15.41%.
ACADIA PHARMA Price and EPS Surprise
ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote
Earnings Whispers?
Our proven model does not conclusively show that ACADIA is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to announce an earnings surprise. That is not the case here as you will see below.
Zacks ESP : The Earnings ESP for ACADIA is 0.00% since the Most Accurate estimate stands at a loss of 48 cents per share, in line with the Zacks Consensus Estimate.
Zacks Rank : ACADIA carries a Zacks Rank #4 (Sell). ACADIA's Zacks Rank #4 when combined with an ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
The Earnings ESP for Raptor Pharmaceuticals Corp. RPTP is +11.11% and it carries a Zacks Rank #3. The company will be reporting second-quarter results on Aug 4.
Bio-Techne Corp. TECH has an Earnings ESP of +1.14% and carries a Zacks Rank #3. It is expected to report fourth-quarter fiscal 2016 results on Aug 4.
The Earnings ESP for Acceleron Pharma, Inc. XLRN is +7.41% and it carries a Zacks Rank #3. The company will release second-quarter results on Aug 4.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIO-TECHNE CP (TECH): Free Stock Analysis Report
RAPTOR PHARMACT (RPTP): Free Stock Analysis Report
ACADIA PHARMA (ACAD): Free Stock Analysis Report
ACCELERON PHARM (XLRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, ACADIA plans to initiate a phase II study on Nuplazid for AD agitation in the second half of the year. ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes . In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Earnings Whispers? Click to get this free report BIO-TECHNE CP (TECH): Free Stock Analysis Report RAPTOR PHARMACT (RPTP): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes . | ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Earnings Whispers? Zacks ESP : The Earnings ESP for ACADIA is 0.00% since the Most Accurate estimate stands at a loss of 48 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report BIO-TECHNE CP (TECH): Free Stock Analysis Report RAPTOR PHARMACT (RPTP): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. | In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. Surprise History ACADIA's earnings track record is disappointing with the company missing expectations in three of the last four quarters and surpassing in one quarter with an average negative surprise of 15.41%. ACADIA Pharmaceuticals Inc.ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes . |
36191.0 | 2016-07-23 00:00:00 UTC | These 3 Biotechs Have Automatic Demand | ACAD | https://www.nasdaq.com/articles/these-3-biotechs-have-automatic-demand-2016-07-23 | nan | nan | It takes real skill to market a drug or medical device properly, and sales can greatly suffer if a company doesn't do it right. A marketing miscue can turn even the best drug or medical device into a flop.
In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes is joined by healthcare contributor Brian Feroldi to discuss why they think that Acadia Pharmaceuticals (NASDAQ: ACAD) , Portola Pharmaceuticals (NASDAQ: PTLA) , and Ophthotech (NASDAQ: OPHT) should see huge demand for their products right our of the gate. Plus, the team offers three questions that all investors should ask that can clue them in to a company's chance at market success.
A transcript follows the video.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
{%video%}
This podcast was recorded on Jul. 13, 2016.
Kristine Harjes : Pivoting the conversation a little bit to how investors can use this information, what does this all mean to an investor looking at a company and trying to decide whether or not they have a solid marketing effort and team?
Brian Feroldi : Right. I learned firsthand that just because you launch a drug or a medical device -- it could be great, it could be wonderful, but that doesn't mean it's going to sell well. There's truly a skill to marketing a device. It's something that's not always something that a company can get correct. I have three guide points that I look at when I'm investing to try to figure out ahead of time: OK, if this gets approved, what kind of chances does it have of seeing market success?
First question I ask is: Does the company that's launching the product have presence in the disease state already? Or, a partner that is in the disease state? For example, if Novo Nordisk , who is kind of the big dog in diabetes, if they launched a new diabetes drug, they would have, in my mind, no problem getting the word out and getting to doctors because they already have those relationships in place. But if you have a new company, or an established company that's trying to switch over to a brand-new disease state, that can be tricky. That's something that they might not get right the first time.
Harjes : This is [the case] a lot of the times that you see you company partnering with another company on their marketing efforts. If you know going into it, "I don't have any diabetes doctor relationships," then you can have a partnership where you'll forgo, maybe, a royalty on the sales for somebody else to take over for you and use their existing relationships and their marketing power.
Feroldi : Yeah, that's absolutely true. That's especially true for smaller companies. Employing sales reps is very expensive, and it makes a whole lot more sense to bring in a big partner with relationships already in place to help get the word out faster.
Harjes : Absolutely. What is the second thing you look for?
Feroldi : Sure. The second thing is: Is there an unmet medical need? Is this a disease state where there's no other approved drugs? One area that I look at are orphan drug makers, which can charge huge premiums, and you can bet that their patients are watching the FDA decision and biting their fingers to see if it's going to go their way. That's automatic built-in demand.
Another company I have my eye on recently is called Acadia Pharmaceuticals. They just launched a drug called Nuplazid, which is going to be used to treat Parkinson's disease psychosis. This is a disease that there's really no great treatment options for currently. Acadia chose to launch the drug themselves, and I don't see any competition, so I think they'll have quite an easy time marketing it.
Harjes : Acadia is a really interesting story. This is a pretty huge indication. Parkinson's disease psychosis occurs in about 20% of Parkinson's disease patients. So a lowball estimate would peg that at around 200,000 Americans currently suffering. Meanwhile, this is a drug with a $23,000 annual price tag. You multiply that out, and you get some really big numbers, but realistically you might be looking at around $4 billion annual peak sales. And they're not really up against any competition. Even though they are a pretty new company, a pretty small company, they should be able to very quickly build these relationships that we've talked so much about.
Feroldi : Yeah, that's the theory, right?
Harjes : Yep. We've got No. 1, for what investors should look for, is: Does the company have a presence in the market already? No. 2: Is it meeting an unmet medical need, or are there no other approved drugs? What is the third?
Feroldi : This is the best-case scenario of all. This is when another company is going to do all the work for you for free. These are what I refer to as off-balance-sheet sales forces.
Harjes : That does not sound like it should be a real thing. (laughs)
Feroldi : These are very, very rare. When a company like this comes along, I definitely put it on my watch list. This is a case where a drug comes out, and it works either in combination with some other existing drug, it makes that drug work better. I know you and Todd have talked a lot on the show about Portola Pharmaceuticals, and their factor Xa inhibitor antidote. You can bet that if that does hit the market, Johnson & Johnson , Pfizer , Bristol-Myers , they will be screaming from the rooftops about the drugs approval. Portola won't have to do anything.
Harjes : You know I love Portola Pharmaceuticals. I'll also add to that -- we've talked about them a ton, so I won't go too in the weeds here -- but these companies, the big guys, have already been handing Portola money to develop this factor Xa inhibitor antidote. You would think they're also going to be more than willing to hand out more money to get this drug off the ground.
Feroldi : Absolutely. Another one I think you talked about on the show is Ophthotech. Their drug Fovista works in combination with other drugs that are already on the market. Novartis ' Lucentis, Avastin. It really makes those drugs work better, so same story. If Ophthotech can get approval for Fovista, you can bet those big boys will be pushing it.
Harjes : For sure. Brian, is there anything else you wanted to get out there for listeners before we close the show? Maybe an example of what could go wrong in the marketing of a drug?
Feroldi : Sure. Doing this the right way is really tough. We've seen a couple of cases where companies tried to launch on their own, and they didn't have the relationships and place. It can be exceptionally hard to be a small company and try and take on an established market. One recent example is Keryx Biopharmaceuticals . Their drug is called Auryxia, which is used to increase serum phosphate levels in patients with chronic kidney disease. This drug was launched in 2014. It was going up directly against Sanofi 's Renvela. Doctors really were shy about prescribing it. And there really wasn't much Keryx could do to raise awareness for it. We just heard recently that they were going to be increasing their sales force by 50% in order to get the word out.
Harjes : That's definitely not a cheap decision.
Feroldi : Not at all.
Brian Feroldi has no position in any stocks mentioned. Kristine Harjes owns shares of Johnson and Johnson, Ophthotech, and Portola Pharmaceuticals. The Motley Fool owns shares of and recommends Johnson and Johnson. The Motley Fool recommends Novo Nordisk. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes is joined by healthcare contributor Brian Feroldi to discuss why they think that Acadia Pharmaceuticals (NASDAQ: ACAD) , Portola Pharmaceuticals (NASDAQ: PTLA) , and Ophthotech (NASDAQ: OPHT) should see huge demand for their products right our of the gate. Another company I have my eye on recently is called Acadia Pharmaceuticals. Acadia chose to launch the drug themselves, and I don't see any competition, so I think they'll have quite an easy time marketing it. | In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes is joined by healthcare contributor Brian Feroldi to discuss why they think that Acadia Pharmaceuticals (NASDAQ: ACAD) , Portola Pharmaceuticals (NASDAQ: PTLA) , and Ophthotech (NASDAQ: OPHT) should see huge demand for their products right our of the gate. Another company I have my eye on recently is called Acadia Pharmaceuticals. Acadia chose to launch the drug themselves, and I don't see any competition, so I think they'll have quite an easy time marketing it. | In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes is joined by healthcare contributor Brian Feroldi to discuss why they think that Acadia Pharmaceuticals (NASDAQ: ACAD) , Portola Pharmaceuticals (NASDAQ: PTLA) , and Ophthotech (NASDAQ: OPHT) should see huge demand for their products right our of the gate. Another company I have my eye on recently is called Acadia Pharmaceuticals. Acadia chose to launch the drug themselves, and I don't see any competition, so I think they'll have quite an easy time marketing it. | Acadia chose to launch the drug themselves, and I don't see any competition, so I think they'll have quite an easy time marketing it. In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes is joined by healthcare contributor Brian Feroldi to discuss why they think that Acadia Pharmaceuticals (NASDAQ: ACAD) , Portola Pharmaceuticals (NASDAQ: PTLA) , and Ophthotech (NASDAQ: OPHT) should see huge demand for their products right our of the gate. Another company I have my eye on recently is called Acadia Pharmaceuticals. |
36192.0 | 2016-07-19 00:00:00 UTC | Commit To Buy Acadia Pharmaceuticals At $18, Earn 11.4% Using Options | ACAD | https://www.nasdaq.com/articles/commit-buy-acadia-pharmaceuticals-18-earn-114-using-options-2016-07-19 | nan | nan | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but cautious about paying the going market price of $32.98/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $18 strike, which has a bid at the time of this writing of $2.05. Collecting that bid as the premium represents a 11.4% return against the $18 commitment, or a 7.6% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $18 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Acadia Pharmaceuticals Inc sees its shares decline 45.3% and the contract is exercised (resulting in a cost basis of $15.95 per share before broker commissions, subtracting the $2.05 from $18), the only upside to the put seller is from collecting that premium for the 7.6% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $32.98) to be 71%. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com.
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but cautious about paying the going market price of $32.98/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $32.98) to be 71%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $32.98) to be 71%. | Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares decline 45.3% and the contract is exercised (resulting in a cost basis of $15.95 per share before broker commissions, subtracting the $2.05 from $18), the only upside to the put seller is from collecting that premium for the 7.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) shares, but cautious about paying the going market price of $32.98/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com. |
36193.0 | 2016-07-18 00:00:00 UTC | This Could Be the Next Big Pharma Buyout | ACAD | https://www.nasdaq.com/articles/could-be-next-big-pharma-buyout-2016-07-18 | nan | nan | Remember the days when the mindset of Big Pharma was to just do deals? It didn't matter what you did -- you just had to do something.
According to the pundits at PricewaterhouseCoopers' Health Research Institute, 2016 was supposed to continue that trend. In fact, they projected this year to be "the year of pharma merger mania." Instead, after the Treasury Department played Whac-A-Mole with what would have been the biggest pharma deal of all time -- the $160 billion merger between Allergan and Pfizer -- the M&A frenzy vaporized almost overnight.
Still, the death of that deal doesn't spell the death of all M&A activity . In fact, two key phenomena that drove deal volumes to record levels in 2014 and 2015 haven't changed. First, ultra-low interest rates spell an abundance of cheap, easy-to-access debt. Second, many of the big-name pharmaceutical companies are sitting on hordes of cash and still need deals to refill their faltering pipelines.
But what companies fit into the M&A sweet spot right now? Currently, our Motley Fool contributors see three logical acquisition targets. All could demand significant premiums in a buyout scenario -- and, importantly, since you should never buy a company purely becuase you think it will be acquired, all three companies are attractive as stand-alone entities as well.
Poised for growth
Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP.
Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. Roughly 40% of the 1 million people in the U.S. who have Parkinson's disease suffer from PDP. With a wholesale price tag of $23,400 per year, it's not hard to believe that Nuplazid could turn into a blockbuster.
So why hasn't Big Pharma moved in on Acadia yet? It's possible that the industry is waiting to see how the drug performs on the market for a few quarters. These companies might also have reservations because during Nuplazid's late-stage trials, there was an uptick in the number of deaths among patients who used the drug compared with the control group. That fact might keep some providers from recommending the drug, which could suppress demand.
My hunch is that the healthcare community will still embrace Nuplazid with open arms because PDP places a huge burden on caregivers, but only time will tell. In the meantime, I think Acadia's stock could be an interesting opportunity for any investor with a high tolerance for risk.
Big Pharma ought to be lining up
Cory Renauer: One company I can see on the receiving end of a buyout offer is bluebird bio (NASDAQ: BLUE) . Its stock has been mercilessly hammered and is now more than 70% lower than where it stood a year ago. Its odds of success, however, are as strong as ever.
The company is developing unique cellular treatments for inherited disorders in three diseases, with Lenti-D for childhood cerebral adrenoleukodystrophy (CCALD) in the lead. This rare genetic disease threatens the lives of about 40 boys born in the U.S. each year, and it is treatable -- but only with extremely dangerous donor stem-cell transplants.
Bluebird's approach also involves stem-cell transplants, but with the patient's own cells. They're extracted and then "infected" with an effective copy of the necessary gene. By using the patient's own cells, this approach appears to eliminate lethal graft-vs.-host side effects common among donor transplants.
So far, results are outstanding in terms of safety, but the market interpreted efficacy results on par with donor transplants as a bad sign. It missed the fact that none of the patients treated with Bluebird's Lenti-D are showing signs of graft failure, or graft-vs.-host side effects.
Bluebird is also developing similar treatment that replaces a defective hemoglobin gene, called LentiGlobin, for treatment of two much larger indications. Beta-thalassemia affects about 288,000 people worldwide, and a staggering 25 million are thought to have sickle-cell disease. Unlike CCALD, these two conditions are often treatable with more conventional drugs, but long-term outcomes are generally poor.
Only the most severely affected patients with beta thalassemia and sickle-cell receive dangerous stem-cell transplants, but Bluebird's LentiGlobin has a chance to change the treatment paradigm, given its relative safety. With an enterprise value -- a theoretical acquisition price for a company that considers cash and debt -- of just $1.21 billion, Big Pharmas ought to be lining up to present buyout offers.
All that Jazz
Cheryl Swanson :Jazz Pharmaceuticals (NASDAQ: JAZZ) is no stranger to acquisition rumors, and I expect the stock to become a hot takeover target once M&A activity resumes in the biotech sector. The company is a very appetizing morsel for a Big Pharma shark, since the $8.6 billion market-cap guppy owns some unique formulations for rare diseases.
Jazz's lead drug is Xyrem, which has been found to be highly effective in treating major sleep disorders. However, the potential for misuse -- gamma hydroxybutyrate is more infamously known as the "date-rape drug" -- has created some strong barriers to competitor entry, with stringent requirements for medication distribution.
Jazz's pipeline is also starting to prove fruitful. Catalysts expected soon include the U.S. release of Defitelio for a rare liver disease, a filing for Vyxeos (a drug acquired from Celator Pharmaceuticals, Inc .), and phase 3 data for JZP-110 for excessive daytime sleepiness. All three events should occur before the end of the year.
Regardless of whether a suitor comes calling or not, Jazz should do very well in the next 12 months. A takeover attempt could lead to a nice bump for shareholders, but when you look at the fact that Jazz expects to grow earnings at a nearly 25% annualized rate over the next half-decade, it's hard not to see this stock as a highly intriguing buy.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldi has no position in any stocks mentioned. Cheryl Swanson owns shares of Allergan. Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Poised for growth Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP. Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. | Poised for growth Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP. Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. | Poised for growth Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP. Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. | Poised for growth Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP. Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. |
36194.0 | 2016-07-12 00:00:00 UTC | 3 Risky Biotech Stocks That Could Make You Rich | ACAD | https://www.nasdaq.com/articles/3-risky-biotech-stocks-could-make-you-rich-2016-07-12 | nan | nan | Image Source: Getty Images
If you're looking for stocks that offer unusual growth opportunities, clinical-stage biotechs are fertile ground. Even among this select group, though, there are only a handful of companies that can realistically transform an initial investment of say $10,000 into a small fortune.
The "trick," if you will, is to identify companies that are either developing, or have recently launched, franchise-level drugs that will allow them to build out a diverse product portfolio over time. The problem is that small companies with promising drugs -- experimental or otherwise -- tend to be bought out long before their full value is realized. What's left over are companies with drugs that tend to have substantial clinical or regulatory hurdles to clear, making them high-risk investing vehicles.
For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Here's why.
1. Acadia's flagship drug could be a megablockbuster
Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone. Total sales could rise markedly if Acadia is able to garner additional approvals overseas.
If that occurs, Nuplazid should easily provide enough free cash flows to greatly expand the biotech's clinical activities, and perhaps most importantly, enable it to make a splash on the M&A front. The obvious risk, though, is the ability of a young commercial operation like Acadia's to successfully handle a drug launch. After all, many companies simply decide to either sell themselves outright or sign a licensing agreement upon reaching this stage in their life cycle, admitting that bigger partners are better equipped to convince doctors to prescribe novel drugs such as Nuplazid.
2. Sales of Amarin's fish oil pill are ramping up
After a tumultuous couple of years that saw Amarin take on the FDA over a number of issues regarding its highly refined fish oil pill Vascepa, the drugmaker's efforts finally appear to be paying off. Vascepa's sales are forecast to grow by nearly 70% this quarter compared to a year ago, and by roughly another 50% next year. Even so, Amarin's shares are presently trading at a mere 2.3 times the company's 2017 projected revenue.
Amarin's shares are probably not garnering much of premium right now because of the pending interim data readout for Vascepa's large cardiovascular outcomes trial. It's scheduled for the third-quarter of this year, and it could prove to be a turning -- or breaking -- point in Amarin's story.
If this interim data analysis suggests that Vascepa does lower the risk of adverse cardiovascular events, the drug's sales should tick even higher than the present rosy forecast and put it solidly on the path toward becoming a blockbuster. Of course, a positive outcome is no guarantee, and a negative readout is equally likely, based on the body of published research on omega3 treatments so far.
3. Sarepta is waiting for the FDA's final decision
Sarepta's story is tied to the regulatory fate of its Duchenne muscular dystrophy (DMD) drug eteplirsen. Given that there isn't a single drug approved to treat this deadly muscle-wasting disease at the moment, eteplirsen would almost certainly rake in hundreds of millions in annual sales if the FDA approves it. Perhaps even more importantly, though, a regulatory approval for eteplirsen would essentially validate the biotech's broader exon-skipping platform for DMD that could treat upwards of 80% of this diverse patient population.
While it's hard to estimate even a rough peak sales figure given that Sarepta's internal thoughts on pricing eteplirsen are still a mystery, industry experts have suggested that the company's DMD platform as a whole could easily generate over $1 billion in annual sales. Such a steady and sizable revenue stream would provide Sarepta with the firepower to pursue additional value-creating opportunities down the road.
Last month, the FDA requested data from the company's ongoing confirmatory study of eteplirsen regarding the drug's ability to restore dystrophin production, implying that the agency would forgo a final approval decision until these data are considered. Although that development was definitely good news in light of the drug's negative advisory committee vote, Sarepta is arguably heading toward a make or break moment. If eteplirsen doesn't restore dystrophin levels to clinically meaninful levels, Sarepta's shares are going to have a tough time finding a bottom, as most of the company's value is tied to its DMD platform.
Are any of these speculative biotechs worth the risk?
There's no doubt that a single misstep for any of these companies could cause its shares to tank in the blink of an eye. That's why I personally wouldn't add these stocks to my portfolio right now. Having said that, investors who are more comfortable with all-or-nothing type plays may want to consider these three names ahead of their upcoming clinical, commercial, or regulatory catalysts. After all, the market arguably hasn't built in much of a premium for any of these three -- meaning that they may be primed to skyrocket on positive news.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Acadia's flagship drug could be a megablockbuster Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone. | For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Acadia's flagship drug could be a megablockbuster Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone. | For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Acadia's flagship drug could be a megablockbuster Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone. | For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Acadia's flagship drug could be a megablockbuster Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone. |
36195.0 | 2016-07-05 00:00:00 UTC | Acadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over the Next Year | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc-why-acad-stock-will-be-volatile-over-next-year-2016-07-05 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Acadia Pharmaceuticals Inc. ( ACAD ) has been the model of inconsistency and unpredictability over the last year.
ACAD is currently trading right in the middle of its 52-week range, between $16.64 and $51.99. It has risen 14% over the last three months, yet is still down 18% over the last year.
Why ACAD stock will be more volatile
Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch.
3 Consumer Stocks With Strong Dividends AND Growth
Acadia has never launched a drug before, but is targeting a very large Parkinson's disease psychosis, or PDP, market where efficient manufacturing of Nuplazid, sales and marketing, and maintaining a controlled balance of supply and demand will all be very crucial to a successful launch.
Furthermore, ACAD must now communicate openly and rely on pharmacy benefit managers, retail and specialty pharmacists, hospitals, and physicians to ensure a smooth launch and distribution of Nuplazid.
There are a lot of moving parts - so many that a massive drug launch is often difficult for experienced pharmaceutical companies, much less one that has never done it before. As a result, there are plenty of mishap opportunities for a company that could barely get its new drug application filed after Nuplazid proved successful in its clinical study.
The fact that ACAD has a fairly large market capitalization of $3.9 billion illustrates that expectations are sky high for Nuplazid. Moreover, ACAD may have other products in its pipeline, but all are deep in the pipeline. Therefore, Nuplazid might very well be responsible for 99% of ACAD's market capitalization, especially with off-label usage and label expansion all very big parts of the ACAD stock story going forward.
If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time commercial drug company, then the market will likely be harsh on ACAD stock. I'd view this as more likely than not.
Nuplazid Will Still Be Hugely Successful
ACAD stock may be in for a bumpy year, but ultimately, patient investors should be rewarded.
Fact is that Nuplazid is just as efficient at treating psychotic effects as any competing drug on the market. In fact, it is the only drug to ever be statistically significant in treating PDP. The only difference is that it lacks the inconvenient, and sometimes life-threatening side effects of those other drugs.
As a result, Nuplazid is a game changer, and just so happens to be FDA approved in an antipsychotic market that has more widespread off label usage than any other disease type. This suggests that ACAD will not only succeed in capturing a huge chunk of the one million people worldwide who suffer from the disease, but also the millions who are looking for a suitable solution to treat the conditions associated with schizophrenia, Alzheimer's disease, bipolar, depression, anxiety, etc.
These diseases are often treated with drugs like Abilify, Seroquel, Prozac, Paxil, Lexapro, etc., many of which are only FDA approved to treat one or two specific indications. That said, Nuplazid's efficacy and safety profile give it a great shot to capture much of this off-label market, in addition to capturing most of the PDP market.
When it is all said and done, there is no reason that Nuplazid cannot create $5 billion, even $7 billion in peak sales. That's what many of the other top antipsychotic drugs have earned at their peak, prior to patent expirations.
Perhaps the best news of all when talking about these very likely blockbuster sales figures is that ACAD gets to keep 100% of the profits. It does not have a commercial partner at this moment.
This Means Two Things
First, Acadia Pharmaceuticals instantly becomes one of the most attractive M&A targets in the biotechnology industry . Second, ACAD's valuation of $3.9 billion does not look all that bad.
Despite significant value depreciation in the biotechnology industry, it still trades at an average of 6x trailing-12-month sales. Theoretically, if ACAD stock can grow sales to $5 billion or more, it could easily become a $30 billion company or more.
Clearly, that's a lot of long-term upside.
The bottom line is that Acadia Pharmaceuticals looks expensive ahead of a very important drug launch, one that is likely to be challenging and full of unexpected issues in its infancy. However, ACAD will eventually find solutions for unexpected problems, and if not, they will find a commercial partner.
Tesaro Inc (TSRO): Is There More Upside for Tesaro Stock?
Regardless, Nuplazid is going to be a commercial success because PDP patients have no other options and because the drug actually works, with no significant side effects.
Therefore, ACAD stock may look expensive now ahead of the short-term unknowns, but long term, ACAD at $34.25 is a value investor's dream come true.
As of this writing, Brian Nichols owns shares of ACAD.
More From InvestorPlace
7 "Hidden" Value Stocks to Buy in a Hurry
7 A-Plus Stocks to Buy for the Rest of 2016
The post Acadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over the Next Year appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Why ACAD stock will be more volatile Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch. Furthermore, ACAD must now communicate openly and rely on pharmacy benefit managers, retail and specialty pharmacists, hospitals, and physicians to ensure a smooth launch and distribution of Nuplazid. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time commercial drug company, then the market will likely be harsh on ACAD stock. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) has been the model of inconsistency and unpredictability over the last year. Why ACAD stock will be more volatile Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch. 3 Consumer Stocks With Strong Dividends AND Growth Acadia has never launched a drug before, but is targeting a very large Parkinson's disease psychosis, or PDP, market where efficient manufacturing of Nuplazid, sales and marketing, and maintaining a controlled balance of supply and demand will all be very crucial to a successful launch. | Why ACAD stock will be more volatile Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch. 3 Consumer Stocks With Strong Dividends AND Growth Acadia has never launched a drug before, but is targeting a very large Parkinson's disease psychosis, or PDP, market where efficient manufacturing of Nuplazid, sales and marketing, and maintaining a controlled balance of supply and demand will all be very crucial to a successful launch. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time commercial drug company, then the market will likely be harsh on ACAD stock. | Why ACAD stock will be more volatile Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch. The fact that ACAD has a fairly large market capitalization of $3.9 billion illustrates that expectations are sky high for Nuplazid. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) has been the model of inconsistency and unpredictability over the last year. |
36196.0 | 2016-07-05 00:00:00 UTC | These 3 Biotech Stocks Are Ridiculously Cheap Now | ACAD | https://www.nasdaq.com/articles/these-3-biotech-stocks-are-ridiculously-cheap-now-2016-07-05 | nan | nan | GILD data by YCharts .
Putting the market's dire outlook aside, I think the biggest reason to buy this stock right now is the growing possibility that Gilead may use this latest biotech plunge to start acquiring either a handful of tuck-in acquisitions, or perhaps go after bigger game, in order to shore up its top line. It's no secret that Gilead has been poking around some mid-sized oncology companies lately, and the biotech does have over $8 billion in cash at the moment.
All told, my view is that Gilead's highly compressed PE ratio -- relative to its peers -- and the company's strong position from which to pursue deals make this stock a great buy for patient investors right now.
Trevena's stock has been getting pummeled, but that may soon change
Trevena's stock hasn't had a good 2016, to put it mildly:
TRVN data by YCharts .
However, this small-cap biotech is possibly setting up for a major rebound with two late-stage trial data readouts scheduled for early 2017. Specifically, Trevena will release top-line data from a pair of pivotal-stage trials for its acute pain medicine oliceridine in the first quarter of next year.
While I'm usually extremely cautious with clinical-stage biotechs like Trevena, this stock looks, to me, like it has the makings of a hidden gem. In a nutshell, oliceridine is targeting a market that was valued at over $11 billion in 2014, and there's a clear need for alternative meds to morphine in the acute pain setting.
What makes this stock a compelling buy, in my view, is oliceridine's impressive mid-stage studies, where it proved to be a more effective and safer pain medicine than morphine. That doesn't guarantee it will generate similar results in its larger, pivotal-stage trials, but there's a growing body of evidence that oliceridine may indeed be an effective treatment for acute pain. If Trevena does report positive top-line results next results, I wouldn't be surprised to see this stock double from current levels, and apparently the Street shares my sentiment, with a consensus 12-month price of $13.67.
Are any of these three stocks worth buying right now?
Gilead is probably the "safest" of these three picks because of its monstrous free cash flows and diverse product and clinical portfolios. So, I'd have to say yes, Gilead is worth picking up on the Brexit sell-off.
As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. That's not to say I don't think they're compelling buys at the moment, but investors shouldn't shrug off their substantial risk profiles, regardless of the upside potential.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. Putting the market's dire outlook aside, I think the biggest reason to buy this stock right now is the growing possibility that Gilead may use this latest biotech plunge to start acquiring either a handful of tuck-in acquisitions, or perhaps go after bigger game, in order to shore up its top line. All told, my view is that Gilead's highly compressed PE ratio -- relative to its peers -- and the company's strong position from which to pursue deals make this stock a great buy for patient investors right now. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. Specifically, Trevena will release top-line data from a pair of pivotal-stage trials for its acute pain medicine oliceridine in the first quarter of next year. | As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. All told, my view is that Gilead's highly compressed PE ratio -- relative to its peers -- and the company's strong position from which to pursue deals make this stock a great buy for patient investors right now. Trevena's stock has been getting pummeled, but that may soon change Trevena's stock hasn't had a good 2016, to put it mildly: TRVN data by YCharts . | As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. Trevena's stock has been getting pummeled, but that may soon change Trevena's stock hasn't had a good 2016, to put it mildly: TRVN data by YCharts . What makes this stock a compelling buy, in my view, is oliceridine's impressive mid-stage studies, where it proved to be a more effective and safer pain medicine than morphine. |
36197.0 | 2016-06-28 00:00:00 UTC | ACADIA Pharmaceuticals Inc.'s Shareholders Are Having a Crazy Year. Here's Why | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-incs-shareholders-are-having-crazy-year-heres-why-2016-06-28 | nan | nan | ACAD data by YCharts .
So what: What caused the plunge and the follow-on recovery? Here's a review of the key developments that have taken place this year:
In January, Acadia raised $300 million through a common share offering, selling just over 10 million shares for $29 each. That move caught the markets off guard , as the company's balance sheet contained more than $240 million in cash at the time of the announcement. Combine that with the general biotech sell-off, and shares cratered to start the year.
Shares jumped in March after an FDA advisory committee recommended that Nuplazid -- Acadia's experimental treatment for Parkinson's disease psychosis -- should be given the green light.
The FDA decided to follow the committee's recommendation and officially approve Nupalzid for sale on April 29.
Nuplazid was launched for sale on May 31 at an annual wholesale price of $23,400, which was a higher price than many analysts were expecting.
The rumor mill kicked into high gear, with reports swirling that pharma giant AstraZeneca (NYSE: AZN) was interested in buying Acadia outright . A report from the Daily Mail claimed that Acadia would not even consider selling for less than $60 per share, which represents almost 100% upside from today's share price.
Unfortunately, those rumors never turned into a publicly announced offer, so traders' enthusiasm for Acadia's stock started to wane in the days following the report. That brings us to where the stock sits today.
Now what: AstraZeneca is facing some big revenue challenges over the next few years (which is a big reason it has become one of the highest-yielding big pharma stocks out there), so it's not out of the question that a bid may ultimately surface for Acadia. After all, AstraZeneca does have a recent history of buying small biopharma companies, especially those close to launching interesting new drugs. Last year, the company spent $2.7 billion to buy out ZS Pharma to get its hands on the company's treatment for hyperkalemia. However, that move isn't looking so great in hindsight , so it's possible the management team is feeling a bit gun-shy now.
Even if a buyout offer doesn't surface, there are plenty of reasons to be bullish on Acadia's stock right now. The National Parkinson Foundation estimates that 1 million people in the U.S. alone suffer from Parkinson's disease, and roughly 40% of them develop psychosis. Because there are no other approved treatment options on the market, Acadia should have this indication all to itself, which is why some analysts believe peak sales of Nuplazid could eclipse $4 billion in time.
If Acadia can execute on that huge market opportunity -- which is a big "if" -- then today's market capitalization of roughly $3.5 billion might seem like a great entry point in retrospect. Investors with an above-average tolerance for risk might want to give this company's stock a closer look.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
Brian Feroldihas no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares jumped in March after an FDA advisory committee recommended that Nuplazid -- Acadia's experimental treatment for Parkinson's disease psychosis -- should be given the green light. The rumor mill kicked into high gear, with reports swirling that pharma giant AstraZeneca (NYSE: AZN) was interested in buying Acadia outright . Unfortunately, those rumors never turned into a publicly announced offer, so traders' enthusiasm for Acadia's stock started to wane in the days following the report. | Here's a review of the key developments that have taken place this year: In January, Acadia raised $300 million through a common share offering, selling just over 10 million shares for $29 each. Shares jumped in March after an FDA advisory committee recommended that Nuplazid -- Acadia's experimental treatment for Parkinson's disease psychosis -- should be given the green light. ACAD data by YCharts . | Here's a review of the key developments that have taken place this year: In January, Acadia raised $300 million through a common share offering, selling just over 10 million shares for $29 each. Now what: AstraZeneca is facing some big revenue challenges over the next few years (which is a big reason it has become one of the highest-yielding big pharma stocks out there), so it's not out of the question that a bid may ultimately surface for Acadia. ACAD data by YCharts . | A report from the Daily Mail claimed that Acadia would not even consider selling for less than $60 per share, which represents almost 100% upside from today's share price. Because there are no other approved treatment options on the market, Acadia should have this indication all to itself, which is why some analysts believe peak sales of Nuplazid could eclipse $4 billion in time. ACAD data by YCharts . |
36198.0 | 2016-06-15 00:00:00 UTC | Noteworthy ETF Inflows: XBI, ACAD, ANAC, MDVN | ACAD | https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-acad-anac-mdvn-2016-06-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $90.0 million dollar inflow -- that's a 4.7% increase week over week in outstanding units (from 34,950,000 to 36,600,000). Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $90.0 million dollar inflow -- that's a 4.7% increase week over week in outstanding units (from 34,950,000 to 36,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94. | Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $90.0 million dollar inflow -- that's a 4.7% increase week over week in outstanding units (from 34,950,000 to 36,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94. |
36199.0 | 2016-06-08 00:00:00 UTC | Acadia Pharmaceuticals Inc.: 7 Companies That Could Buy ACAD | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc-7-companies-could-buy-acad-2016-06-08 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company .
As explained in an article late last year, I believe that Acadia's recently approved drug, Nuplazid, to treat Parkinson's disease psychosis, a worldwide patient population that could very well exceed 1 million , has the potential to achieve peak worldwide sales upwards of $10 billion.
Because of its efficacy and safety profile, it has great off-label potential to treat patients who lack options, along with incredible mergers and acquisitions appeal within the space.
Big Pharma Could Battle for ACAD Stock
I have a feeling that Acadia Pharmaceuticals' management knows it has a gem with Nuplazid. Not only is it the first-ever approved drug to treat PDP, with a safety profile that is second to none, but the anti-psychotic market might have the highest off-label usage of any other treatment arena.
10 Great Stocks That Will Make a Splash This Summer
With Nuplazid's safety, efficacy, Breakthrough Therapy designation and Fast Track FDA accolades, management likely knows that it has some massive selling points to pharmacies, physicians and hospitals.
As a result, it might be the most attractive biotech to big pharma in the market right now.
AstraZeneca makes a lot of sense, probably why the company was mentioned in the Daily Mail's report. It owned one of the better selling anti-psychotic drugs of the last decade, in Seroquel, a drug that reached sales of nearly $6 billion back in 2011 before it lost patent protection. Therefore, AZN knows its way around the market, and has the infrastructure to launch Nuplazid with few hiccups.
However, AstraZeneca is not alone in having experience in this space. The Japanese-based company Otsuka Holdings Co., Ltd. ( OTSKF ) and Bristol-Myers Squibb Co ( BMY ) are more than qualified to launch Nuplazid, co-developing and marketing the successful drug Abilify, whose sales peaked at nearly $6.5 billion in 2013. However, Abilify, like Seroquel, has faced generic competition amid patent expiration.
That said, AstraZeneca, Otsuka and Bristol-Myers are the obvious choices, but if big pharma sees Nuplazid replicating or even surpassing the success of Seroquel and Abilify, then the list of potential suitors could span to any company with the cash to afford ACAD. This includes Pfizer Inc. ( PFE ), a comp any that just recently bought Anacor Pharmaceuticals Inc ( ANAC ) for $4.5 billion and is desperate for growth.
That, or Biogen Inc ( BIIB ) could take a swing at Acadia. Biogen wants to become a market leader outside of MS and it has clinical programs in the treatment of Alzheimer's and Parkinson's disease. By acquiring Acadia, Biogen could get a head start in developing the connection with physicians and hospitals in this arena, while most likely giving its stock a much-needed boost.
Under Armour: Everything You Need to Know Before Buying the Dip in UA
Furthermore, AbbVie Inc ( ABBV ) might be interested in ACAD stock. While it may be tricky following the acquisition of Pharmacyclics, AbbVie already has the sales team and marketing infrastructure in place due to Duopa. Finally, Gilead Sciences, Inc. ( GILD ) is a legitimate possibility with a boatload of cash and a desperate need to find its next big growth driver.
What Stops the Acadia Acquisition?
All things considered, I just named seven companies who can not only afford Acadia Pharmaceuticals, but also legitimately need what Nuplazid can offer. The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. I think that's the big disconnect right now.
Acadia Pharmaceuticals has a market capitalization over $5 billion, and most likely believes that Nuplazid can achieve the same success, or greater than Seroquel or Abilify. If so, it is worth far more than $5, even $10 billion, and it is hard to know whether big pharma will realize that value right now.
Regardless, if big pharma does not want to pay now, ACAD is prepared to market Nuplazid alone, and it will succeed. So ultimately, whether it is now or two years from now, big pharma will pay up, and ACAD stock owners will be rewarded.
It's just a question of when, not if.
As of this writing, Brian Nichols owns shares of Acadia Pharmaceuticals.
More From InvestorPlace
The 10 Best Healthcare Stocks to Buy Now
Your 2016 Retirement Spring Cleaning Checklist
The post Acadia Pharmaceuticals Inc.: 7 Companies That Could Buy ACAD appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That said, AstraZeneca, Otsuka and Bristol-Myers are the obvious choices, but if big pharma sees Nuplazid replicating or even surpassing the success of Seroquel and Abilify, then the list of potential suitors could span to any company with the cash to afford ACAD. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company . As explained in an article late last year, I believe that Acadia's recently approved drug, Nuplazid, to treat Parkinson's disease psychosis, a worldwide patient population that could very well exceed 1 million , has the potential to achieve peak worldwide sales upwards of $10 billion. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company . As explained in an article late last year, I believe that Acadia's recently approved drug, Nuplazid, to treat Parkinson's disease psychosis, a worldwide patient population that could very well exceed 1 million , has the potential to achieve peak worldwide sales upwards of $10 billion. Big Pharma Could Battle for ACAD Stock I have a feeling that Acadia Pharmaceuticals' management knows it has a gem with Nuplazid. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company . Big Pharma Could Battle for ACAD Stock I have a feeling that Acadia Pharmaceuticals' management knows it has a gem with Nuplazid. The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company . The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. As explained in an article late last year, I believe that Acadia's recently approved drug, Nuplazid, to treat Parkinson's disease psychosis, a worldwide patient population that could very well exceed 1 million , has the potential to achieve peak worldwide sales upwards of $10 billion. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.